## Neuregulin 1 and Susceptibility to Schizophrenia

American Journal of Human Genetics 71, 877-892 DOI: 10.1086/342734

**Citation Report** 

#	Article	IF	CITATIONS
1	The status of genetic investigations of schizophrenia. , 0, , 288-308.		0
2	Is Biology Destiny? Is It All in Our Genes?. Journal of Psychiatric Practice, 2002, 8, 337-343.	0.3	11
3	Iceland's genome fits another piece in schizophrenia puzzle. Targets, 2002, 1, 83-84.	0.3	0
4	Molecular and cellular evidence for an oligodendrocyte abnormality in schizophrenia. Neurochemical Research, 2002, 27, 1193-1200.	1.6	175
5	REVIEW: Prospects of genetic epidemiology in the 21st century. European Journal of Epidemiology, 2002, 18, 607-616.	2.5	12
6	Neuregulins and the neuromuscular system: 10 years of answers and questions. Journal of Neurocytology, 2003, 32, 619-647.	1.6	98
7	Neuregulin: An activity-dependent synaptic modulator at the neuromuscular junction. Journal of Neurocytology, 2003, 32, 649-664.	1.6	25
8	Pharmacogenomics of multigenic diseases: Sex-specific differences in disease and treatment outcome. AAPS PharmSci, 2003, 5, 49-61.	1.3	24
9	The NMDA Receptor Hypofunction Model of Psychosis. Annals of the New York Academy of Sciences, 2003, 1003, 119-130.	1.8	169
10	Converging Evidence of NMDA Receptor Hypofunction in the Pathophysiology of Schizophrenia. Annals of the New York Academy of Sciences, 2003, 1003, 318-327.	1.8	402
11	Glutamatergic Animal Models of Schizophrenia. Annals of the New York Academy of Sciences, 2003, 1003, 131-137.	1.8	131
12	Linkage and association studies of schizophrenia. Current Psychiatry Reports, 2003, 5, 121-127.	2.1	56
13	Ethical issues in psychiatric genetics research: points to consider. Psychopharmacology, 2003, 171, 27-35.	1.5	34
14	NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology, 2003, 169, 215-233.	1.5	477
15	Cis-acting variation in the expression of a high proportion of genes in human brain. Human Genetics, 2003, 113, 149-153.	1.8	213
16	Genetics of schizophrenia: current strategies. Clinical Neuroscience Research, 2003, 3, 5-16.	0.8	6
17	The neuroanatomy of schizophrenia: circuitry and neurotransmitter systems. Clinical Neuroscience Research, 2003, 3, 77-107.	0.8	41
18	The genetics of schizophrenia: glutamate not dopamine?. European Journal of Pharmacology, 2003, 480, 177-184.	1.7	85

TION RE

#	Article	IF	Citations
19	Pharmacogenomics of schizophrenia: Towards personalized psychiatry. Drug Development Research, 2003, 60, 71-74.	1.4	2
20	Pharmacogenomics and animal models of schizophrenia. Drug Development Research, 2003, 60, 95-103.	1.4	1
21	Toward schizophrenia genes: Genetics and transcriptome. Drug Development Research, 2003, 60, 111-118.	1.4	1
22	Opposing effects of low and high-dose clozapine on survival of transgenic amyotrophic lateral sclerosis mice. Journal of Neuroscience Research, 2003, 74, 605-613.	1.3	33
23	Multipoint and single point non-parametric linkage analysis with imperfect data. American Journal of Medical Genetics Part A, 2003, 121B, 89-94.	2.4	14
24	Evidence for shared susceptibility in bipolar disorder and schizophrenia. American Journal of Medical Genetics Part A, 2003, 123C, 59-64.	2.4	172
25	Synapse signalling complexes and networks: machines underlying cognition. BioEssays, 2003, 25, 1229-1235.	1.2	45
26	Schizophrenia: from phenomenology to neurobiology. Neuroscience and Biobehavioral Reviews, 2003, 27, 269-306.	2.9	232
27	Genome scan of Arab Israeli families maps a schizophrenia susceptibility gene to chromosome 6q23 and supports a locus at chromosome 10q24. Molecular Psychiatry, 2003, 8, 488-498.	4.1	101
28	Support for genetic variation in neuregulin 1 and susceptibility to schizophrenia. Molecular Psychiatry, 2003, 8, 485-487.	4.1	226
29	Genome-wide scan in a large complex pedigree with predominantly male schizophrenics from the island of Kosrae: evidence for linkage to chromosome 2q. Molecular Psychiatry, 2003, 8, 695-705.	4.1	54
30	Association study of neuregulin 1 gene with schizophrenia. Molecular Psychiatry, 2003, 8, 706-709.	4.1	230
31	Neuregulin 1 in schizophrenia: out of Iceland. Molecular Psychiatry, 2003, 8, 639-640.	4.1	36
32	Pharmacogenetics goes genomic. Nature Reviews Genetics, 2003, 4, 937-947.	7.7	301
33	LPA1 receptor-deficient mice have phenotypic changes observed in psychiatric disease. Molecular and Cellular Neurosciences, 2003, 24, 1170-1170.	1.0	2
34	The neurodevelopmental hypothesis of schizophrenia: a review of recent developments. Annals of Medicine, 2003, 35, 86-93.	1.5	168
35	Genebanks: A Comparison of Eight Proposed International Genetic Databases. Public Health Genomics, 2003, 6, 37-45.	0.6	65
36	Schizophrenia. New England Journal of Medicine, 2003, 349, 1738-1749.	13.9	599

#	ARTICLE	IF	Citations
37	LPA1 receptor-deficient mice have phenotypic changes observed in psychiatric disease. Molecular and Cellular Neurosciences, 2003, 24, 1170-1179.	1.0	116
38	Genes for schizophrenia? Recent findings and their pathophysiological implications. Lancet, The, 2003, 361, 417-419.	6.3	553
39	ErbB-4: mechanism of action and biology. Experimental Cell Research, 2003, 284, 66-77.	1.2	213
40	Neuregulins: functions, forms, and signaling strategies. Experimental Cell Research, 2003, 284, 14-30.	1.2	942
41	Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet, The, 2003, 362, 798-805.	6.3	861
42	Calcium signaling dysfunction in schizophrenia: a unifying approach. Brain Research Reviews, 2003, 43, 70-84.	9.1	139
43	Association of Neuregulin 1 with Schizophrenia Confirmed in a Scottish Population. American Journal of Human Genetics, 2003, 72, 83-87.	2.6	518
44	Polymorphisms at the G72/G30 Gene Locus, on 13q33, Are Associated with Bipolar Disorder in Two Independent Pedigree Series*. American Journal of Human Genetics, 2003, 72, 1131-1140.	2.6	253
45	Genomewide Scan for Hand Osteoarthritis: A Novel Mutation in Matrilin-3. American Journal of Human Genetics, 2003, 72, 1448-1459.	2.6	167
46	Genome Scan Meta-Analysis of Schizophrenia and Bipolar Disorder, Part II: Schizophrenia. American Journal of Human Genetics, 2003, 73, 34-48.	2.6	1,072
47	Genomewide Linkage Scan for Schizophrenia Susceptibility Loci among Ashkenazi Jewish Families Shows Evidence of Linkage on Chromosome 10q22. American Journal of Human Genetics, 2003, 73, 601-611.	2.6	99
48	The DTNBP1 (Dysbindin) Gene Contributes to Schizophrenia, Depending on Family History of the Disease. American Journal of Human Genetics, 2003, 73, 1438-1443.	2.6	180
49	A Systematic Genomewide Linkage Study in 353 Sib Pairs with Schizophrenia. American Journal of Human Genetics, 2003, 73, 1355-1367.	2.6	115
50	Genetics and genomics of behavioral and psychiatric disorders. Current Opinion in Genetics and Development, 2003, 13, 303-309.	1.5	65
51	Bringing Order to the Glutamate Chaos in Schizophrenia. Neuron, 2003, 40, 881-884.	3.8	380
52	The International HapMap Project. Nature, 2003, 426, 789-796.	13.7	5,735
53	Basic molecular genetics for epidemiologists. Journal of Epidemiology and Community Health, 2003, 57, 398-400.	2.0	12
54	Schizophrenia as a Complex Trait. Archives of General Psychiatry, 2003, 60, 1187.	13.8	1,976

#	Article	IF	Citations
55	deCODE genetics, Inc Pharmacogenomics, 2003, 4, 209-215.	0.6	59
56	A Genome-Wide Search for Genes Involved in Type 2 Diabetes in a Recently Genetically Isolated Population From the Netherlands. Diabetes, 2003, 52, 3001-3004.	0.3	26
57	Neural Development of the Neuregulin Receptor ErbB4 in the Cerebral Cortex and the Hippocampus: Preferential Expression by Interneurons Tangentially Migrating from the Ganglionic Eminences. Cerebral Cortex, 2003, 13, 252-264.	1.6	194
58	The right to health of the European Union citizens. A strategy for a social European construction. Journal of Epidemiology and Community Health, 2003, 57, 564-564.	2.0	0
59	Evidence for association of schizophrenia with genetic variation in the 8p21.3 gene, PPP3CC, encoding the calcineurin gamma subunit. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 8993-8998.	3.3	238
60	Recent advances in the genetics of schizophrenia. Human Molecular Genetics, 2003, 12, R125-R133.	1.4	135
61	DISC1 (Disrupted-In-Schizophrenia 1) is a centrosome-associated protein that interacts with MAP1A, MIPT3, ATF4/5 and NUDEL: regulation and loss of interaction with mutation. Human Molecular Genetics, 2003, 12, 1591-1608.	1.4	347
62	The Genetics of Adult-Onset Neuropsychiatric Disease: Complexities and Conundra?. Science, 2003, 302, 822-826.	6.0	160
63	Neuregulin 1-erbB2 signaling is required for the establishment of radial glia and their transformation into astrocytes in cerebral cortex. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 4251-4256.	3.3	185
64	Advanced glossary on genetic epidemiology. Journal of Epidemiology and Community Health, 2003, 57, 562-564.	2.0	6
66	Genetics of Schizophrenia and Affective Disorders. Pharmacopsychiatry, 2003, 36, 195-202.	1.7	31
67	Psychiatry in the Genomics Era. American Journal of Psychiatry, 2003, 160, 616-620.	4.0	71
68	Molecular genetics of schizophrenia: a review of the recent literature. Current Opinion in Psychiatry, 2003, 16, 157-170.	3.1	21
69	DISC1 (Disrupted in Schizophrenia-1) is expressed in limbic regions of the primate brain. NeuroReport, 2003, 14, 951-954.	0.6	32
70	The future of psychiatric genetics. Annals of Medicine, 2003, 35, 122-134.	1.5	11
71	DISC1 (Disrupted in Schizophrenia-1) is expressed in limbic regions of the primate brain. NeuroReport, 2003, 14, 951-954.	0.6	63
73	The Genetics of Schizophrenia: Chromosomal Deletions, Attentional Disturbances, and Spectrum Boundaries. American Journal of Psychiatry, 2003, 160, 1549-1553.	4.0	26
74	Chapter 25. SNPs: A human genetic tool for the new millennium. Annual Reports in Medicinal Chemistry, 2003, 38, 249-259.	0.5	0

	Сітатіо	n Report	
#	Article	IF	CITATIONS
75	Theory and Practice in Quantitative Genetics. Twin Research and Human Genetics, 2003, 6, 361-376.	1.5	337
76	Safety of Quetiapine During Pregnancy. American Journal of Psychiatry, 2003, 160, 588-a-589.	4.0	29
77	Clozapine and Tardive Dyskinesia. American Journal of Psychiatry, 2003, 160, 588-588.	4.0	32
78	Genetic Linkage in Bipolar Disorder. CNS Spectrums, 2003, 8, 891-904.	0.7	26
79	Genetik psychiatrischer StĶrugen. , 2003, , 69-105.		3
80	Schizophrenia: Neural Mechanisms for Novel Therapies. Molecular Medicine, 2003, 9, 3-9.	1.9	50
81	Inflammatory disorders of the central nervous system. Current Opinion in Neurology, 2003, 16, 347-350.	1.8	5
82	Linkage of Osteoporosis to Chromosome 20p12 and Association to BMP2. PLoS Biology, 2003, 1, e69.	2.6	222
83	Neuregulins. , 2003, , 15-31.		4
84	Ligand-Dependent Recruitment of the ErbB4 Signaling Complex into Neuronal Lipid Rafts. Journal of Neuroscience, 2003, 23, 3164-3175.	1.7	123
86	Glutamate Hypothesis of Schizophrenia and Approach for Possible Therapeutic Drugs. Current Medicinal Chemistry - Central Nervous System Agents, 2004, 4, 147-154.	0.6	31
87	Possible Contributions of Myelin and Oligodendrocyte Dysfunction to Schizophrenia. International Review of Neurobiology, 2004, 59, 381-424.	0.9	51
88	Mapping the Systematic Lupus Erythematosus Susceptibility Genes. , 2004, 102, 011-030.		5
90	Biomarker identification in neurologic diseases: improving diagnostics and therapeutics. Expert Review of Molecular Diagnostics, 2004, 4, 361-375.	1.5	6
91	Neuregulin 1 and schizophrenia. Annals of Medicine, 2004, 36, 62-71.	1.5	119
92	Search for cognitive trait components of schizophrenia reveals a locus for verbal learning and memory on 4q and for visual working memory on 2q. Human Molecular Genetics, 2004, 13, 1693-1702.	1.4	74
93	A case control and family based association study of the neuregulin1 gene and schizophrenia. Journal of Medical Genetics, 2004, 41, 31-34.	1.5	101
94	Generation and Characterization of Neuregulin-2-Deficient Mice. Molecular and Cellular Biology, 2004, 24, 8221-8226.	1.1	37

#	Article	IF	CITATIONS
95	An integrative genomics approach to the reconstruction of gene networks in segregating populations. Cytogenetic and Genome Research, 2004, 105, 363-374.	0.6	204
96	Psychiatric genetics: into the 21st century. International Review of Psychiatry, 2004, 16, 243-245.	1.4	3
97	Identification in 2 Independent Samples of a Novel Schizophrenia RiskHaplotype of the Dystrobrevin Binding Protein Gene (DTNBP1). Archives of General Psychiatry, 2004, 61, 336.	13.8	175
98	Mapping Genes for Common Diseases: The Case for Genetic (LD) Maps. Human Heredity, 2004, 58, 2-9.	0.4	34
99	Haplotype analysis and identification of genes for a complex trait: examples from schizophrenia. Annals of Medicine, 2004, 36, 322-331.	1.5	12
100	Schizophrenia, vitamin D, and brain development. International Review of Neurobiology, 2004, 59, 351-380.	0.9	62
101	Linkage of Calpain 10 to Type 2 Diabetes: The Biological Rationale. Diabetes, 2004, 53, S19-S25.	0.3	72
102	Allele-specific gene expression differences in humans. Human Molecular Genetics, 2004, 13, R255-R260.	1.4	94
103	Genetics of schizophrenia: implications for treatment. Expert Review of Neurotherapeutics, 2004, 4, 725-731.	1.4	5
104	NMDA Receptor Function, Neuroplasticity, and the Pathophysiology of Schizophrenia. International Review of Neurobiology, 2004, 59, 491-515.	0.9	115
105	S100B Serum Levels and Long-Term Improvement of Negative Symptoms in Patients with Schizophrenia. Neuropsychopharmacology, 2004, 29, 1004-1011.	2.8	106
106	Pathways to schizophrenia: the impact of environmental factors. International Journal of Neuropsychopharmacology, 2004, 7, S7-S13.	1.0	148
107	S100B in Schizophrenic Psychosis. International Review of Neurobiology, 2004, 59, 445-470.	0.9	78
108	Neurotrophic and neuroprotective effects of the neuregulin glial growth factor-2 on dopaminergic neurons in rat primary midbrain cultures. Journal of Neurochemistry, 2004, 91, 1358-1368.	2.1	54
109	The contribution of three strong candidate schizophrenia susceptibility genes in demographically distinct populations. Genes, Brain and Behavior, 2004, 3, 240-248.	1.1	101
110	Measuring the Relative Information in Allele-Sharing Linkage Studies. Biometrics, 2004, 60, 368-375.	0.8	12
111	The use of pedigree, sib-pair and association studies of common diseases for genetic mapping and epidemiology. Nature Genetics, 2004, 36, 1045-1051.	9.4	144
112	Are medical and nonmedical uses of large-scale genomic markers conflating genetics and 'race'?. Nature Genetics, 2004, 36, S43-S47.	9.4	71

#	Article	IF	CITATIONS
113	Neuregulin 1-erbB signaling and the molecular/cellular basis of schizophrenia. Nature Neuroscience, 2004, 7, 575-580.	7.1	361
114	Activity-dependent transcription regulation of PSD-95 by neuregulin-1 and Eos. Nature Neuroscience, 2004, 7, 1250-1258.	7.1	143
115	Receptor tyrosine kinase ErbB4 modulates neuroblast migration and placement in the adult forebrain. Nature Neuroscience, 2004, 7, 1319-1328.	7.1	233
116	The Icelandic Cancer Project – a population-wide approach to studying cancer. Nature Reviews Cancer, 2004, 4, 488-492.	12.8	15
117	Confirmation and refinement of an â€~at-risk' haplotype for schizophrenia suggests the EST cluster, Hs.97362, as a potential susceptibility gene at the Neuregulin-1 locus. Molecular Psychiatry, 2004, 9, 208-212.	4.1	131
118	Genome-wide scan in Portuguese Island families identifies 5q31–5q35 as a susceptibility locus for schizophrenia and psychosis. Molecular Psychiatry, 2004, 9, 213-218.	4.1	105
119	Examination of G72 and D-amino-acid oxidase as genetic risk factors for schizophrenia and bipolar affective disorder. Molecular Psychiatry, 2004, 9, 203-207.	4.1	293
120	Confirmation and fine mapping of the chromosome 1 alcohol dependence risk locus. Molecular Psychiatry, 2004, 9, 312-319.	4.1	22
121	Expression analysis of neuregulin-1 in the dorsolateral prefrontal cortex in schizophrenia. Molecular Psychiatry, 2004, 9, 299-307.	4.1	267
122	Polymorphisms within 5′ end of the Neuregulin 1 gene are genetically associated with schizophrenia in the Chinese population. Molecular Psychiatry, 2004, 9, 11-12.	4.1	103
123	The molecular genetics of schizophrenia: new findings promise new insights. Molecular Psychiatry, 2004, 9, 14-27.	4.1	293
124	No association with the neuregulin 1 haplotype to Japanese schizophrenia. Molecular Psychiatry, 2004, 9, 126-127.	4.1	96
125	Association of SNPs and haplotypes in GABAA receptor β2 gene with schizophrenia. Molecular Psychiatry, 2004, 9, 603-608.	4.1	72
126	Identification of a novel neuregulin 1 at-risk haplotype in Han schizophrenia Chinese patients, but no association with the Icelandic/Scottish risk haplotype. Molecular Psychiatry, 2004, 9, 698-704.	4.1	149
127	Molecular genetics of autism spectrum disorder. Molecular Psychiatry, 2004, 9, 819-832.	4.1	190
128	No evidence for linkage or association of neuregulin-1 (NRG1) with disease in the Irish study of high-density schizophrenia families (ISHDSF). Molecular Psychiatry, 2004, 9, 777-783.	4.1	95
129	A genome scan and follow-up study identify a bipolar disorder susceptibility locus on chromosome 1q42. Molecular Psychiatry, 2004, 9, 1083-1090.	4.1	92
130	Neuregulin 1: genetic support for schizophrenia subtypes. Molecular Psychiatry, 2004, 9, 1061-1063.	4.1	75

#	Article	IF	CITATIONS
131	No association between polymorphisms of methylenetetrahydrofolate reductase gene and schizophrenia in both Chinese and Scottish populations. Molecular Psychiatry, 2004, 9, 1063-1065.	4.1	30
132	Pharmacogenomics in drug development: societal and technical aspects. Pharmacogenomics Journal, 2004, 4, 226-232.	0.9	9
133	New Approaches to Gene Hunting in IBD. Inflammatory Bowel Diseases, 2004, 10, 312-317.	0.9	19
134	Bipolar Disorder and Schizophrenia: Convergent Molecular Data. NeuroMolecular Medicine, 2004, 5, 109-118.	1.8	106
136	Attention?Deficit Hyperactivity Disorder in the post?genomic era. European Child and Adolescent Psychiatry, 2004, 13, I50-70.	2.8	84
137	Linkage studies of schizophrenia. Neurotoxicity Research, 2004, 6, 17-34.	1.3	21
138	The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia. Psychopharmacology, 2004, 174, 32-8.	1.5	199
139	Approaches for adolescents with an affected family member with schizophrenia. Current Psychiatry Reports, 2004, 6, 296-302.	2.1	7
140	The genes for schizophrenia: Finally a breakthrough?. Current Psychiatry Reports, 2004, 6, 303-312.	2.1	40
141	The genes for schizophrenia: Finally a breakthrough?. Current Psychosis & Therapeutics Reports, 2004, 2, 57-66.	0.1	0
142	Interleukin-1β (IL-1β) gene and increased risk for the depressive symptom-dimension in schizophrenia spectrum disorders. , 2004, 124B, 10-14.		64
143	Ethnicity-independent genetic basis of functional psychoses: A genotype-to-phenotype approach. American Journal of Medical Genetics Part A, 2004, 124B, 101-112.	2.4	14
144	Linkage disequlibrium in theDTNBP1 (dysbindin) gene region and on chromosome 1p36 among psychotic patients from a genetic isolate in Israel: Findings from identity by descent haplotype sharing analysis. American Journal of Medical Genetics Part A, 2004, 128B, 65-70.	2.4	45
145	Neuregulin1 downregulates postsynaptic GABAa receptors at the hippocampal inhibitory synapse. Hippocampus, 2004, 14, 337-344.	0.9	82
146	Neuregulin-2 is developmentally regulated and targeted to dendrites of central neurons. Journal of Comparative Neurology, 2004, 472, 156-172.	0.9	63
147	Role of pharmacogenomics in drug development. Drug Development Research, 2004, 62, 86-96.	1.4	7
148	Complexities in psychiatric genetics. International Review of Psychiatry, 2004, 16, 284-293.	1.4	17
149	Population Genomics of Drug Response. Molecular Diagnosis and Therapy, 2004, 4, 73-82.	3.3	6

#	Article	IF	CITATIONS
150	Genomics and genealogy provide an Icelandic springboard into the human gene pool. Journal of Mental Health, 2004, 13, 21-27.	1.0	1
151	DNA pooling as a tool for largeâ€scale association studies in complex traits. Annals of Medicine, 2004, 36, 146-152.	1.5	68
152	Evidence of novel neuronal functions of dysbindin, a susceptibility gene for schizophrenia. Human Molecular Genetics, 2004, 13, 2699-2708.	1.4	334
153	Support for RGS4 as a susceptibility gene for schizophrenia. Biological Psychiatry, 2004, 55, 192-195.	0.7	132
154	Identification of PIK3C3 promoter variant associated with bipolar disorder and schizophrenia. Biological Psychiatry, 2004, 55, 981-988.	0.7	96
156	Reduced plastic brain responses in schizophrenia: a transcranial magnetic stimulation study*1. Schizophrenia Research, 2004, 71, 17-26.	1.1	107
157	Why genetic investigation of psychiatric disorders is so difficult. Current Opinion in Genetics and Development, 2004, 14, 280-286.	1.5	45
158	Multiple novel transcription initiation sites for NRG1. Gene, 2004, 342, 97-105.	1.0	139
159	A high proportion of polymorphisms in the promoters of brain expressed genes influences transcriptional activity. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2004, 1690, 238-249.	1.8	61
160	Behavioral characteristics of a nervous system-specific erbB4 knock-out mouse. Behavioural Brain Research, 2004, 153, 159-170.	1.2	142
161	DISC1 localizes to the centrosome by binding to kendrin. Biochemical and Biophysical Research Communications, 2004, 317, 1195-1199.	1.0	100
162	Genes, dopamine and cortical signal-to-noise ratio in schizophrenia. Trends in Neurosciences, 2004, 27, 683-690.	4.2	576
163	Short- and Long-Range Attraction of Cortical GABAergic Interneurons by Neuregulin-1. Neuron, 2004, 44, 251-261.	3.8	383
164	Neuregulin-1 (NRG-1) mRNA and protein in the adult human brain. Neuroscience, 2004, 127, 125-136.	1.1	143
165	Regulation of ErbB4 phosphorylation and cleavage by a novel histidine acid phosphatase. Neuroscience, 2004, 127, 91-100.	1.1	22
166	Case-control and family-based association studies between the neuregulin 1 (Arg38Gln) polymorphism and schizophrenia. Neuroscience Letters, 2004, 366, 158-161.	1.0	51
167	Lack of a genetic association between the frizzled-3 gene and schizophrenia in a British population. Neuroscience Letters, 2004, 366, 336-338.	1.0	23
168	Lipid rafts in neuregulin signaling at synapses. Life Sciences, 2004, 75, 2495-2504.	2.0	20

#	Article	IF	CITATIONS
169	Disrupted in Schizophrenia 1 and Nudel form a neurodevelopmentally regulated protein complex: implications for schizophrenia and other major neurological disorders. Molecular and Cellular Neurosciences, 2004, 25, 42-55.	1.0	216
170	Disrupted in Schizophrenia 1 (DISC1) is a multicompartmentalized protein that predominantly localizes to mitochondria. Molecular and Cellular Neurosciences, 2004, 26, 112-122.	1.0	137
171	Neuregulin-1Î <sup>2</sup> induces neurite extension and arborization in cultured hippocampal neurons. Molecular and Cellular Neurosciences, 2004, 27, 379-393.	1.0	109
172	Intrathecal therapy with trastuzumab may be beneficial in cases of refractory schizophrenia. Medical Hypotheses, 2004, 62, 542-545.	0.8	5
173	Genomewide Scan in Families with Schizophrenia from the Founder Population of Afrikaners Reveals Evidence for Linkage and Uniparental Disomy on Chromosome 1. American Journal of Human Genetics, 2004, 74, 403-417.	2.6	84
174	Genomewide Significant Linkage to Recurrent, Early-Onset Major Depressive Disorder on Chromosome 15q. American Journal of Human Genetics, 2004, 74, 1154-1167.	2.6	107
175	Common Variants in the 5′ Region of the Leptin Gene Are Associated with Body Mass Index in Men from the National Heart, Lung, and Blood Institute Family Heart Study. American Journal of Human Genetics, 2004, 75, 220-230.	2.6	86
176	Genomewide Linkage Scan for Myopia Susceptibility Loci among Ashkenazi Jewish Families Shows Evidence of Linkage on Chromosome 22q12. American Journal of Human Genetics, 2004, 75, 448-459.	2.6	123
177	Polymorphisms in the Trace Amine Receptor 4 (TRAR4) Gene on Chromosome 6q23.2 Are Associated with Susceptibility to Schizophrenia. American Journal of Human Genetics, 2004, 75, 624-638.	2.6	101
178	Strategies for Studying Complex Genetic Traits. , 2004, 14, 346-352.		2
179	Have schizophrenia genes been found?. Current Opinion in Psychiatry, 2004, 17, 107-113.	3.1	8
180	Association of EGF polymorphism with schizophrenia in Finnish men. NeuroReport, 2004, 15, 1215-1218.	0.6	36
181	Neuregulin genotype and medication response in Finnish patients with schizophrenia. NeuroReport, 2004, 15, 2517-2520.	0.6	44
182	Systematic screening for mutations in the human N-methyl-D-aspartate receptor 1 gene in schizophrenic patients from the German population. Psychiatric Genetics, 2004, 14, 233-234.	0.6	4
183	Genetic studies of neuropsychiatric disorders in Costa Rica: a model for the use of isolated populations. Psychiatric Genetics, 2004, 14, 13-23.	0.6	37
184	Allelic variations in gene expression. Current Opinion in Oncology, 2004, 16, 39-43.	1.1	50
186	Genotyping Accuracy for Whole-Genome Amplification of DNA from Buccal Epithelial Cells. Twin Research and Human Genetics, 2004, 7, 482-484.	1.5	6
105			

#	Article	IF	Citations
188	Workshop Abstracts. Personalized Medicine, 2005, 2, 145-185.	0.8	1
189	Dopamine-Glutamate Interaction and Antipsychotics Mechanism of Action: Implication for New Pharmacological Strategies in Psychosis. Current Pharmaceutical Design, 2005, 11, 3561-3594.	0.9	56
190	Shared Chromosomal Susceptibility Regions Between Autism and Other Mental Disorders. International Review of Neurobiology, 2005, 71, 419-443.	0.9	9
191	Operation of the Schizophrenia Susceptibility Gene, Neuregulin 1, Across Traditional Diagnostic Boundaries to Increase Risk for Bipolar Disorder. Archives of General Psychiatry, 2005, 62, 642.	13.8	232
193	Association of schizophrenia in African Americans to polymorphism in synapsin III gene. Psychiatric Genetics, 2005, 15, 127-132.	0.6	23
194	Neuregulin-1 immunoglobulin-like domain mutant mice: clozapine sensitivity and impaired latent inhibition. NeuroReport, 2005, 16, 271-275.	0.6	113
195	Neuregulin 1 gene and variations in perceptual aberration of schizotypal personality in adolescents. Psychological Medicine, 2005, 35, 1589-1598.	2.7	59
197	Down-regulation of Dickkopf 3, a regulator of the Wnt signalling pathway, in elderly schizophrenic subjects. Journal of Neurochemistry, 2005, 94, 520-530.	2.1	43
198	Genome-wide association studies for common diseases and complex traits. Nature Reviews Genetics, 2005, 6, 95-108.	7.7	2,717
199	Complex trait mapping in isolated populations: Are specific statistical methods required?. European Journal of Human Genetics, 2005, 13, 698-706.	1.4	28
200	Fine mapping of a schizophrenia susceptibility locus at chromosome 6q23: increased evidence for linkage and reduced linkage interval. European Journal of Human Genetics, 2005, 13, 763-771.	1.4	40
201	Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Molecular Psychiatry, 2005, 10, 40-68.	4.1	1,859
202	Phenotype of schizophrenia: a review and formulation. Molecular Psychiatry, 2005, 10, 27-39.	4.1	251
203	BDNF gene is a risk factor for schizophrenia in a Scottish population. Molecular Psychiatry, 2005, 10, 208-212.	4.1	242
204	Support for involvement of neuregulin 1 in schizophrenia pathophysiology. Molecular Psychiatry, 2005, 10, 366-374.	4.1	168
205	The neurodevelopmental model of schizophrenia: update 2005. Molecular Psychiatry, 2005, 10, 434-449.	4.1	864
206	Genetic tests of biologic systems in affective disorders. Molecular Psychiatry, 2005, 10, 719-740.	4.1	31
207	Excitement and confusion on chromosome 6q: the challenges of neuropsychiatric genetics in microcosm. Molecular Psychiatry, 2005, 10, 1062-1073.	4.1	28

#	Article	IF	CITATIONS
208	Genetic investigation of chromosome 5q GABAA receptor subunit genes in schizophrenia. Molecular Psychiatry, 2005, 10, 1074-1088.	4.1	112
209	Schizophrenia: genes at last?. Trends in Genetics, 2005, 21, 518-525.	2.9	278
210	Genetic association studies of complex traits: design and analysis issues. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2005, 573, 54-69.	0.4	234
211	Mood disorders and their treatment: alterations in the regulation of receptor-G protein coupling. Drug Development Research, 2005, 65, 147-155.	1.4	2
212	Linkage evidence of schizophrenia to loci near neuregulin 1 gene on chromosome 8p21 in Taiwanese families. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2005, 134B, 79-83.	1.1	33
213	Fine mapping of a region on chromosome 8p gives evidence for a QTL contributing to individual differences in an anxiety-related personality trait: TPQ harm avoidance. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2005, 132B, 104-108.	1.1	23
214	Dihydropyrimidinase-related protein 2 (DRP-2) gene and association to deficit and nondeficit schizophrenia. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2005, 136B, 8-11.	1.1	40
215	Neuregulin-1 polymorphism in late onset Alzheimer's disease families with psychoses. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2005, 139B, 28-32.	1.1	71
216	Fine mapping of a major locus on Chromosome 10 for exploratory and fear-like behavior in mice. Mammalian Genome, 2005, 16, 306-318.	1.0	22
217	N-Methyl-d-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives. Psychopharmacology, 2005, 179, 30-53.	1.5	211
218	Distinct Influences of Neonatal Epidermal Growth Factor Challenge on Adult Neurobehavioral Traits in Four Mouse Strains. Behavior Genetics, 2005, 35, 615-629.	1.4	41
219	Genetic models of schizophrenia and bipolar disorder. European Archives of Psychiatry and Clinical Neuroscience, 2005, 255, 159-166.	1.8	85
220	Association of Ala72Ser polymorphism with COMT enzyme activity and the risk of schizophrenia in Koreans. Human Genetics, 2005, 116, 319-328.	1.8	83
221	Meta-analysis in psychiatric genetics. Current Psychiatry Reports, 2005, 7, 143-152.	2.1	47
222	Schizophrenia: An Update and Review. Journal of Genetic Counseling, 2005, 14, 329-340.	0.9	60
225	Increased Expression in Dorsolateral Prefrontal Cortex of CAPON in Schizophrenia and Bipolar Disorder. PLoS Medicine, 2005, 2, e263.	3.9	93
226	Pharmacologic Implications of Neurobiological Models of Schizophrenia. Harvard Review of Psychiatry, 2005, 13, 352-359.	0.9	7
227	Bilateral Lesions of the Habenula Induce Attentional Disturbances in Rats. Neuropsychopharmacology, 2005, 30, 484-496.	2.8	75

#	Article	IF	CITATIONS
228	Understanding the Pathology of Schizophrenia: The Impact of High- Throughput Screening of the Genome and Proteome in Postmortem CNS. Current Psychiatry Reviews, 2005, 1, 1-9.	0.9	13
229	Application of Pharmacogenomic Approaches in the Study of Drug Response in Complex Diseases. Current Pharmacogenomics and Personalized Medicine: the International Journal for Expert Reviews in Pharmacogenomics, 2005, 3, 177-190.	0.3	0
230	Endogenous Neuregulin Restores Radial Glia in a (Ferret) Model of Cortical Dysplasia. Journal of Neuroscience, 2005, 25, 8498-8504.	1.7	23
231	Genes, Human Diseases and Genome Evolution in the Post-Genomic Era: Insights from Uric Acid Nephrolithiasis. Current Genomics, 2005, 6, 207-214.	0.7	0
232	Techniques for the Identification of Genes Involved in Psychiatric Disorders. Australian and New Zealand Journal of Psychiatry, 2005, 39, 542-549.	1.3	2
233	Relationship Between a High-Risk Haplotype in theDTNBP1(Dysbindin) Gene and Clinical Features of Schizophrenia. American Journal of Psychiatry, 2005, 162, 1824-1832.	4.0	148
234	Psychiatric Genetics: A Methodologic Critique. American Journal of Psychiatry, 2005, 162, 3-11.	4.0	137
235	Regulation of NMDA Receptors by Neuregulin Signaling in Prefrontal Cortex. Journal of Neuroscience, 2005, 25, 4974-4984.	1.7	191
236	Gene expression variation and expression quantitative trait mapping of human chromosome 21 genes. Human Molecular Genetics, 2005, 14, 3741-3749.	1.4	99
237	Association Between the Neuregulin 1 Gene and Schizophrenia: A Systematic Review. Schizophrenia Bulletin, 2005, 31, 613-617.	2.3	104
238	Discovering the Genetics of Complex Disorders Through Integration of Genomic Mapping and Transcriptional Profiling. Current Hypertension Reviews, 2005, 1, 21-34.	0.5	6
239	A 200-kb region of human chromosome 22q11.2 confers antipsychotic-responsive behavioral abnormalities in mice. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 19132-19137.	3.3	44
240	Evidence and Implications for Multiplicative Interactions among Loci Predisposing to Human Common Disease. Human Heredity, 2005, 59, 176-184.	0.4	4
241	Genomics and new targets for multiple sclerosis. Pharmacogenomics, 2005, 6, 151-161.	0.6	9
242	Neuregulin-11 <sup>±</sup> and $1^2$ isoform expression in cardiac microvascular endothelial cells and function in cardiac myocytes in vitro. Experimental Cell Research, 2005, 311, 135-146.	1.2	98
243	Genomewide Scan for Affective Disorder Susceptibility Loci in Families of a Northern Swedish Isolated Population. American Journal of Human Genetics, 2005, 76, 237-248.	2.6	51
244	Bipolar I Disorder and Schizophrenia: A 440–Single-Nucleotide Polymorphism Screen of 64 Candidate Genes among Ashkenazi Jewish Case-Parent Trios. American Journal of Human Genetics, 2005, 77, 918-936.	2.6	358
245	Looking Forward in Geriatric Anxiety and Depression: Implications of Basic Science for the Future. American Journal of Geriatric Psychiatry, 2005, 13, 1027-1040.	0.6	12

#	Article	IF	CITATIONS
246	Genetics and Epigenetics in Major Psychiatric Disorders. Molecular Diagnosis and Therapy, 2005, 5, 149-160.	3.3	134
247	Neurodevelopment, neuroplasticity, and new genes for schizophrenia. Progress in Brain Research, 2005, 147, 319-345.	0.9	115
248	The genetics of schizophrenia and bipolar disorder: dissecting psychosis. Journal of Medical Genetics, 2005, 42, 193-204.	1.5	479
249	Genes for Schizophrenia and Bipolar Disorder? Implications for Psychiatric Nosology. Schizophrenia Bulletin, 2005, 32, 9-16.	2.3	435
250	Genes contributing to risk for common forms of stroke. Trends in Molecular Medicine, 2005, 11, 217-224.	3.5	40
251	Genomic approaches to schizophrenia. Clinical Therapeutics, 2005, 27, S2-S7.	1.1	21
252	Relative efficiency of the linkage disequilibrium mapping approach in detecting candidate genes for schizophrenia in different European populations. Genomics, 2005, 86, 280-286.	1.3	9
253	COMT genetic variation confers risk for psychotic and affective disorders: a case control study. Behavioral and Brain Functions, 2005, 1, 19.	1.4	115
254	Developing therapeutics for schizophrenia and other psychotic disorders. NeuroRx, 2005, 2, 579-589.	6.0	22
255	Cortical Glutamatergic Markers in Schizophrenia. Neuropsychopharmacology, 2005, 30, 1521-1531.	2.8	61
256	Principles of Haplotype Mapping and Potential Applications to Attention-Deficit/Hyperactivity Disorder. Biological Psychiatry, 2005, 57, 1357-1366.	0.7	14
257	Evidence for a Relationship Between Genetic Variants at the Brain-Derived Neurotrophic Factor (BDNF) Locus and Major Depression. Biological Psychiatry, 2005, 58, 307-314.	0.7	284
258	Investigation of the apolipoprotein-L (APOL) gene family and schizophrenia using a novel DNA pooling strategy for public database SNPs. Schizophrenia Research, 2005, 76, 231-238.	1.1	12
259	Genetic and post-mortem mRNA analysis of the 14-3-3 genes that encode phosphoserine/threonine-binding regulatory proteins in schizophrenia and bipolar disorder. Schizophrenia Research, 2005, 78, 137-146.	1.1	45
260	Statistical tools for linkage analysis and genetic association studies. Expert Review of Molecular Diagnostics, 2005, 5, 781-796.	1.5	11
261	Clustering of metabolic comorbidity in schizophrenia: a genetic contribution?. Journal of Psychopharmacology, 2005, 19, 47-55.	2.0	107
262	Aktuelle Aspekte genetischer Forschung bei Schizophrenie. , 2006, , 69-79.		0
263	Deconstructing Schizophrenia: An Overview of the Use of Endophenotypes in Order to Understand a Complex Disorder. Schizophrenia Bulletin, 2006, 33, 21-32.	2.3	383

#	Article	IF	CITATIONS
264	Genomewide Linkage Scan of 409 European-Ancestry and African American Families with Schizophrenia: Suggestive Evidence of Linkage at 8p23.3-p21.2 and 11p13.1-q14.1 in the Combined Sample. American Journal of Human Genetics, 2006, 78, 315-333.	2.6	141
265	A Review of Disrupted-in-Schizophrenia-1 (disc1): Neurodevelopment, Cognition, and Mental Conditions. Biological Psychiatry, 2006, 59, 1189-1197.	0.7	171
266	Neuregulin 1 and Schizophrenia: Genetics, Gene Expression, and Neurobiology. Biological Psychiatry, 2006, 60, 132-140.	0.7	413
267	Toward Constructing an Endophenotype Strategy for Bipolar Disorders. Biological Psychiatry, 2006, 60, 93-105.	0.7	402
268	Critical Appraisal of DNA Microarrays in Psychiatric Genomics. Biological Psychiatry, 2006, 60, 163-176.	0.7	129
269	Evaluation of a Susceptibility Gene for Schizophrenia: Genotype Based Meta-Analysis of RGS4 Polymorphisms from Thirteen Independent Samples. Biological Psychiatry, 2006, 60, 152-162.	0.7	87
270	Genetic Mouse Models of Schizophrenia: From Hypothesis-Based To Susceptibility Gene-Based Models. Biological Psychiatry, 2006, 59, 1180-1188.	0.7	108
271	A Novel Missense Mutation in the Transmembrane Domain of Neuregulin 1 is Associated with Schizophrenia. Biological Psychiatry, 2006, 60, 548-553.	0.7	101
272	Schizophrenia-Relevant Behavioral Testing in Rodent Models: A Uniquely Human Disorder?. Biological Psychiatry, 2006, 59, 1198-1207.	0.7	309
274	Schizophrenia: Modeling a complex psychiatric disorder. Drug Discovery Today: Disease Models, 2006, 3, 319-325.	1.2	5
275	No significant association of the 5′ end of neuregulin 1 and schizophrenia in a large Danish sample. Schizophrenia Research, 2006, 83, 1-5.	1.1	22
276	Gene regulation by hypoxia and the neurodevelopmental origin of schizophrenia. Schizophrenia Research, 2006, 84, 253-271.	1.1	119
277	Schizophrenia susceptibility genes converge on interlinked pathways related to glutamatergic transmission and long-term potentiation, oxidative stress and oligodendrocyte viability. Schizophrenia Research, 2006, 86, 1-14.	1.1	112
278	Schizophrenia—A stem cell disorder. Experimental Neurology, 2006, 199, 26-27.	2.0	9
279	Effect of Y1 receptor deficiency on motor activity, exploration, and anxiety. Behavioural Brain Research, 2006, 167, 87-93.	1.2	83
280	Behavioural effects of chronic haloperidol and risperidone treatment in rats. Behavioural Brain Research, 2006, 171, 286-294.	1.2	57
281	Supportive evidence for neuregulin 1 as a susceptibility gene for schizophrenia in a Japanese population. Neuroscience Letters, 2006, 396, 117-120.	1.0	45
282	Recent progress in animal modeling of immune inflammatory processes in schizophrenia: Implication of specific cytokines. Neuroscience Research, 2006, 56, 2-13.	1.0	159

	Сітат	ion Report	
#	Article	IF	CITATIONS
283	Genetics of restless legs syndrome. Parkinsonism and Related Disorders, 2006, 12, 1-7.	1.1	14
284	The Neurobiology of Multiple Sclerosis: Genes, Inflammation, and Neurodegeneration. Neuron, 2006, 52, 61-76.	3.8	666
285	Neurobiology of Schizophrenia. Neuron, 2006, 52, 139-153.	3.8	617
286	Modeling Madness in Mice: One Piece at a Time. Neuron, 2006, 52, 179-196.	3.8	316
287	Synaptic plasticity impairment and hypofunction of NMDA receptors induced by glutathione deficit: Relevance to schizophrenia. Neuroscience, 2006, 137, 807-819.	1.1	157
288	Limited influence of olanzapine on adult forebrain neural precursors in vitro. Neuroscience, 2006, 140, 111-122.	1.1	15
289	Schizophrenia susceptibility genes: emergence of positional candidates and future directions. Trends in Pharmacological Sciences, 2006, 27, 226-233.	4.0	97
290	Genetic Association and Brain Morphology Studies and the Chromosome 8p22 Pericentriolar Material 1 (PCM1) Gene in Susceptibility to Schizophrenia. Archives of General Psychiatry, 2006, 63, 844.	13.8	82
291	Neuregulin 1 Transcripts Are Differentially Expressed in Schizophrenia and Regulated by 5′ SNPs Associated With the Disease. Focus (American Psychiatric Publishing), 2006, 4, 350-359.	0.4	4
292	Using Inbred Mouse Strains to Identify Genes for Complex Diseases. Frontiers in Bioscience - Landmark, 2006, 11, 1216.	3.0	10
294	The overlapping of the spectra: overlapping genes and genetic models. , 0, , 25-42.		0
296	Convergent Evidence for 2′,3′-Cyclic Nucleotide 3′-Phosphodiesterase as a Possible Susceptibility for Schizophrenia. Archives of General Psychiatry, 2006, 63, 18.	y Gene 13.8	115
297	An investigation of the dihydropyrimidinase-like 2 (DPYSL2) gene in schizophrenia: genetic association study and expression analysis. International Journal of Neuropsychopharmacology, 2006, 9, 705.	1.0	21
298	Sexually dimorphic changes in the exploratory and habituation profiles of heterozygous neuregulin-1 knockout mice. NeuroReport, 2006, 17, 79-83.	0.6	74
299	Translational and developmental perspective on N-methyl-D-aspartate synaptic deficits in schizophrenia. Development and Psychopathology, 2006, 18, .	1.4	13
300	Recurrence risks for schizophrenia in a Swedish National Cohort. Psychological Medicine, 2006, 36, 1417-1425.	2.7	154
301	Linkage disequilibrium analyses in the Costa Rican population suggests discrete gene loci for schizophrenia at 8p23.1 and 8q13.3. Psychiatric Genetics, 2006, 16, 159-168.	0.6	20
302	An update on the genetics of schizophrenia. Current Opinion in Psychiatry, 2006, 19, 158-164.	3.1	129

#	Article	IF	Citations
303	Schizophrenia and bipolar disorder: differences and overlaps. Current Opinion in Psychiatry, 2006, 19, 165-170.	3.1	127
304	Investigating cis-acting regulatory variation using assays of relative allelic expression. Psychiatric Genetics, 2006, 16, 173-177.	0.6	14
306	Psychosis pathways converge via D2High dopamine receptors. Synapse, 2006, 60, 319-346.	0.6	298
307	ErbB receptor signalling regulates dendrite formation in mouse cerebellar granule cellsin vivo. European Journal of Neuroscience, 2006, 23, 2225-2229.	1.2	26
308	Susceptibility genes for schizophrenia. Psychiatry and Clinical Neurosciences, 2006, 60, S4.	1.0	9
309	Association analyses of the neuregulin 1 gene with schizophrenia and manic psychosis in a Hispanic population. Acta Psychiatrica Scandinavica, 2006, 113, 314-321.	2.2	38
310	Schizophrenia: signals from the other side. Nature Medicine, 2006, 12, 734-735.	15.2	9
311	Altered neuregulin 1–erbB4 signaling contributes to NMDA> receptor hypofunction in schizophrenia. Nature Medicine, 2006, 12, 824-828.	15.2	528
312	Pathophysiologically based treatment interventions in schizophrenia. Nature Medicine, 2006, 12, 1016-1022.	15.2	307
313	A neuregulin 1 variant associated with abnormal cortical function and psychotic symptoms. Nature Neuroscience, 2006, 9, 1477-1478.	7.1	226
314	Human monogenic disorders — a source of novel drug targets. Nature Reviews Genetics, 2006, 7, 249-260.	7.7	81
315	The origin and specification of cortical interneurons. Nature Reviews Neuroscience, 2006, 7, 687-696.	4.9	834
316	Genetics of affective (mood) disorders. European Journal of Human Genetics, 2006, 14, 660-668.	1.4	230
317	Molecular genetic studies of schizophrenia. European Journal of Human Genetics, 2006, 14, 669-680.	1.4	154
318	Schizophrenia genetics: uncovering positional candidate genes. European Journal of Human Genetics, 2006, 14, 512-519.	1.4	85
319	A summary statistic approach to sequence variation in noncoding regions of six schizophrenia-associated gene loci. European Journal of Human Genetics, 2006, 14, 1037-1043.	1.4	10
320	Association study of the G-protein signaling 4 (RGS4) and proline dehydrogenase (PRODH) genes with schizophrenia: a meta-analysis. European Journal of Human Genetics, 2006, 14, 1130-1135.	1.4	35
321	Extreme population differences across Neuregulin 1 gene, with implications for association studies. Molecular Psychiatry, 2006, 11, 66-75.	4.1	83

	Сітатіо	n Report	
#	Article	IF	CITATIONS
322	Family-based association study of Epsin 4 and Schizophrenia. Molecular Psychiatry, 2006, 11, 395-399.	4.1	16
323	Identification of the semaphorin receptor PLXNA2 as a candidate for susceptibility to schizophrenia. Molecular Psychiatry, 2006, 11, 471-478.	4.1	135
324	Association of the NRG1 gene and schizophrenia: a meta-analysis. Molecular Psychiatry, 2006, 11, 539-546.	4.1	203
325	Evidence for association of DNA sequence variants in the phosphatidylinositol-4-phosphate 5-kinase Ilα gene (PIP5K2A) with schizophrenia. Molecular Psychiatry, 2006, 11, 837-846.	4.1	46
326	Further evidence for association between ErbB4 and schizophrenia and influence on cognitive intermediate phenotypes in healthy controls. Molecular Psychiatry, 2006, 11, 1062-1065.	4.1	90
327	Evidence implicating BRD1 with brain development and susceptibility to both schizophrenia and bipolar affective disorder. Molecular Psychiatry, 2006, 11, 1126-1138.	4.1	77
328	Two isoforms of GABAA receptor Î <sup>2</sup> 2 subunit with different electrophysiological properties: differential expression and genotypical correlations in schizophrenia. Molecular Psychiatry, 2006, 11, 1092-1105.	4.1	50
329	Analysis of GABRB2 association with schizophrenia in German population with DNA sequencing and one-label extension method for SNP genotyping. Clinical Biochemistry, 2006, 39, 210-218.	0.8	30
330	Genome scans and gene expression microarrays converge to identify gene regulatory loci relevant in schizophrenia. Human Genetics, 2006, 119, 558-570.	1.8	34
332	Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission. Neurotoxicity Research, 2006, 10, 131-148.	1.3	205
333	Genetic analysis of psychiatric disorders in humans. Genes, Brain and Behavior, 2006, 5, 25-33.	1.1	7
334	Axonal regulation of myelination by neuregulin 1. Current Opinion in Neurobiology, 2006, 16, 492-500.	2.0	381
335	Neuregulins: Versatile growth and differentiation factors in nervous system development and human disease. Brain Research Reviews, 2006, 51, 161-175.	9.1	133
336	ErbB receptors: new insights on mechanisms and biology. Trends in Cell Biology, 2006, 16, 649-656.	3.6	317
337	Regional vulnerability of mesencephalic dopaminergic neurons prone to degenerate in Parkinson's disease: A post-mortem study in human control subjects. Neurobiology of Disease, 2006, 23, 409-421.	2.1	21
338	The role of the phosphatidylinositide 3-kinase–protein kinase B pathway in schizophrenia. , 2006, 110, 117-134.		103
339	Major affective disorders and schizophrenia: a common molecular signature?. Human Mutation, 2006, 27, 833-853.	1.1	40
340	Linkage and association of schizophrenia with genetic variations in the locus of neuregulin 1 in Korean population. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2006, 141B, 281-286.	1.1	26

#	Article	IF	CITATIONS
341	Evidence that interaction between neuregulin 1 and its receptor erbB4 increases susceptibility to schizophrenia. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2006, 141B, 96-101.	1.1	162
342	Analysis of polymorphisms in AT-rich domains of neuregulin 1 gene in schizophrenia. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2006, 141B, 102-109.	1.1	33
343	Genetic association between schizophrenia and the DISC1 gene in the Scottish population. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2006, 141B, 155-159.	1.1	61
344	The involvement ofErbB4 with schizophrenia: Association and expression studies. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2006, 141B, 142-148.	1.1	226
345	Allele Quantification and DNA Pooling Methods. , 2007, 373, 63-74.		4
346	Variations in the Vesicular Monoamine Transporter 1 Gene (VMAT1/SLC18A1) are Associated with Bipolar I Disorder. Neuropsychopharmacology, 2006, 31, 2739-2747.	2.8	59
347	Schizophrenia: Do the Genetics and Neurobiology of Neuregulin Provide a Pathogenesis Model?. Harvard Review of Psychiatry, 2006, 14, 64-77.	0.9	8
348	Carving Chaos: Genetics and the Classification of Mood and Psychotic Syndromes. Harvard Review of Psychiatry, 2006, 14, 47-63.	0.9	88
349	Neuregulins. , 2006, , 1401-1406.		0
350	Reduced Aphâ€1b expression causes tissue―and substrateâ€specific changes in γâ€secretase activity in rats with a complex phenotype. FASEB Journal, 2006, 20, 175-177.	0.2	19
351	Haplotypes spanning SPEC2, PDZ-GEF2 and ACSL6 genes are associated with schizophrenia. Human Molecular Genetics, 2006, 15, 3329-3342.	1.4	46
352	New Alzheimer's disease locus on chromosome 8. Journal of Medical Genetics, 2006, 43, 931-935.	1.5	16
353	DNA copy-number analysis in bipolar disorder and schizophrenia reveals aberrations in genes involved in glutamate signaling. Human Molecular Genetics, 2006, 15, 743-749.	1.4	158
354	Convergent evidence that oligodendrocyte lineage transcription factor 2 (OLIG2) and interacting genes influence susceptibility to schizophrenia. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 12469-12474.	3.3	116
355	Schizophrenia Susceptibility Genes: Emergence of Positional Candidates and Future Directions. Focus (American Psychiatric Publishing), 2006, 4, 369-377.	0.4	0
356	The role of neuregulin-ErbB4 interactions on the proliferation and organization of cells in the subventricular zone. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 1930-1935.	3.3	158
357	Neuregulin 1 transcripts are differentially expressed in schizophrenia and regulated by 5' SNPs associated with the disease. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 6747-6752.	3.3	380
358	Meta-analysis shows strong positive association of the neuregulin 1 ( NRG1 ) gene with schizophrenia. Human Molecular Genetics, 2006, 15, 1995-2002.	1.4	260

#	Article	IF	CITATIONS
359	Schizophrenie und verwandte Störungen — Neurobiologie. , 2006, , 345-386.		3
360	Allelic Variation in RGS4 Impacts Functional and Structural Connectivity in the Human Brain. Journal of Neuroscience, 2007, 27, 1584-1593.	1.7	98
362	Defining Primary and Secondary Progenitor Disorders in the Brain: Proteomic Approaches for Analysis of Neural Progenitor Cells. Current Pharmaceutical Biotechnology, 2007, 8, 117-125.	0.9	1
363	Neuregulin 1 Genotype and Schizophrenia. Schizophrenia Bulletin, 2007, 34, 9-12.	2.3	74
364	Families with the risk allele of DISC1 reveal a link between schizophrenia and another component of the same molecular pathway, NDE1. Human Molecular Genetics, 2007, 16, 453-462.	1.4	74
365	Prefrontal Dopamine Signaling in Schizophrenia - The Corticocentric Model. Pharmacopsychiatry, 2007, 40, S45-S53.	1.7	12
366	Schizophrenia: more evidence for less glutamate. Expert Review of Neurotherapeutics, 2007, 7, 29-31.	1.4	13
367	Schizophrenia Susceptibility Genes: in Search of A Molecular Logic and Novel Drug Targets for A Devastating Disorder. International Review of Neurobiology, 2007, 78, 397-422.	0.9	14
368	Loss of erbB signaling in oligodendrocytes alters myelin and dopaminergic function, a potential mechanism for neuropsychiatric disorders. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 8131-8136.	3.3	279
369	The neuronal pathology of schizophrenia: molecules and mechanisms. Biochemical Society Transactions, 2007, 35, 433-436.	1.6	36
370	α7 nicotinic acetylcholine receptor mRNA expression and binding in postmortem human brain are associated with genetic variation in neuregulin 1. Human Molecular Genetics, 2007, 16, 2921-2932.	1.4	61
371	Neuregulin1 (NRG1) Signaling through Fyn Modulates NMDA Receptor Phosphorylation: Differential Synaptic Function in NRG1+/- Knock-Outs Compared with Wild-Type Mice. Journal of Neuroscience, 2007, 27, 4519-4529.	1.7	169
372	Complexin 1 knockout mice exhibit marked deficits in social behaviours but appear to be cognitively normal. Human Molecular Genetics, 2007, 16, 2288-2305.	1.4	49
373	When Puberty is Precocious. , 2007, , .		5
374	DISC1 Regulates the Transport of the NUDEL/LIS1/14-3-3Â Complex through Kinesin-1. Journal of Neuroscience, 2007, 27, 15-26.	1.7	214
375	Disturbed Structural Connectivity in Schizophrenia Primary Factor in Pathology or Epiphenomenon?. Schizophrenia Bulletin, 2007, 34, 72-92.	2.3	183
376	Insights from spatially mapped gene expression in the mouse brain. Human Molecular Genetics, 2007, 16, R209-R219.	1.4	40
377	Prioritization of Positional Candidate Genes Using Multiple Web-Based Software Tools. Twin Research and Human Genetics. 2007. 10. 861-870.	0.3	34

#	Article	IF	CITATIONS
378	Genetic analysis of the calcineurin pathway identifies members of the EGR gene family, specifically EGR3, as potential susceptibility candidates in schizophrenia. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 2815-2820.	3.3	153
379	Molecular Cloning of a Brain-specific, Developmentally Regulated Neuregulin 1 (NRG1) Isoform and Identification of a Functional Promoter Variant Associated with Schizophrenia. Journal of Biological Chemistry, 2007, 282, 24343-24351.	1.6	131
380	Gene Expression in the Etiology of Schizophrenia. Schizophrenia Bulletin, 2007, 34, 412-418.	2.3	42
383	Update on psychiatric genetics. Genetics in Medicine, 2007, 9, 332-340.	1.1	12
384	The genetics of bipolar affective disorder. Current Opinion in Psychiatry, 2007, 20, 8-12.	3.1	73
385	From the EGR gene family to common pathways in schizophrenia: single genes versus convergent pathways. Future Neurology, 2007, 2, 347-351.	0.9	0
386	Neuregulin-1 signaling in schizophrenia. Future Neurology, 2007, 2, 477-480.	0.9	0
387	Bridging pharmacology and neurodevelopment in schizophrenia. International Journal of Neuropsychopharmacology, 2007, 10, 713-6.	1.0	3
388	The Neuregulin-1 Receptor ErbB4 Controls Glutamatergic Synapse Maturation and Plasticity. Neuron, 2007, 54, 583-597.	3.8	319
389	Neuregulin-1 Enhances Depolarization-Induced GABA Release. Neuron, 2007, 54, 599-610.	3.8	279
390	NRG1 and Synaptic Function in the CNS. Neuron, 2007, 54, 495-497.	3.8	22
391	Phenotypic characterization of spatial cognition and social behavior in mice with â€~knockout' of the schizophrenia risk gene neuregulin 1. Neuroscience, 2007, 147, 18-27.	1.1	213
392	Developmental profile of neuregulin receptor ErbB4 in postnatal rat cerebral cortex and hippocampus. Neuroscience, 2007, 148, 126-139.	1.1	21
393	Heterozygous neuregulin 1 mice display greater baseline and Δ9-tetrahydrocannabinol-induced c-Fos expression. Neuroscience, 2007, 149, 861-870.	1.1	72
394	Regulation of ErbB-4 endocytosis by neuregulin in GABAergic hippocampal interneurons. Brain Research Bulletin, 2007, 73, 210-219.	1.4	28
395	No association between the ERBB3 gene and schizophrenia in a Japanese population. Neuroscience Research, 2007, 57, 574-578.	1.0	15
396	Risk factors for schizophrenia — All roads lead to dopamine. European Neuropsychopharmacology, 2007, 17, S101-S107.	0.3	100
397	Integrating genomics and neuromarkers for the era of brain-related personalized medicine. Personalized Medicine, 2007, 4, 201-215.	0.8	31

ARTICLE IF CITATIONS # Impact of Schizophrenia Candidate Genes on Schizotypy and Cognitive Endophenotypes at the 398 0.7 124 Population Level. Biological Psychiatry, 2007, 62, 784-792. Schizophrenia endophenotypes as treatment targets. Expert Opinion on Therapeutic Targets, 2007, 11, 399 1.5 1189-1206. Involvement of Neuropeptide Systems in Schizophrenia: Human Studies. International Review of 402 0.9 27 Neurobiology, 2007, 78, 327-376. Functional Genomics and Schizophrenia: Endophenotypes and Mutant Models. Psychiatric Clinics of North America, 2007, 30, 365-399. Glutamate and Schizophrenia: Phencyclidine, Nâ€Methylâ€dâ€Aspartate Receptors, and Dopamine–Glutamate 0 9 404 463 Interactions. International Review of Neurobiology, 2007, 78, 69-108. The role of white matter for the pathophysiology of schizophrenia. International Review of Psychiatry, 2007, 19, 459-468. 1.4 407 Phenotypic and genetic complexity of psychosis. British Journal of Psychiatry, 2007, 190, 200-203. 1.7 95 Potential genetic variants in schizophrenia: A Bayesian analysis. World Journal of Biological 408 1.3 26 Psychiatry, 2007, 8, 12-22. 409 The Genetic Deconstruction of Psychosis. Schizophrenia Bulletin, 2007, 33, 905-911. 2.3 242 Disease-associated intronic variants in the ErbB4 gene are related to altered ErbB4 splice-variant 1.4 expression in the brain in schizophrenia. Human Molecular Genetics, 2007, 16, 129-141. Adult neurogenesis and schizophrenia: A window on abnormal early brain development?. 411 1.1 88 Schizophrenia Research, 2007, 90, 1-14. The role of DTNBP1, NRG1, and AKT1 in the genetics of schizophrenia in Finland. Schizophrenia 1.1 Research, 2007, 91, 27-36. A Case-control association study between the GRID1 gene and schizophrenia in the Chinese Northern 413 1.1 67 Han population. Schizophrenia Ŕesearch, 2007, 93, 385-390. Interactions among genes in the ErbB-Neuregulin signalling network are associated with increased 414 1.4 susceptibility to schizophrenia. Behavioral and Brain Functions, 2007, 3, 31. Haplotype Analysis and a Novel Allele-Sharing Method Refines a Chromosome 4p Locus Linked to 415 0.7 23 Bipolar Affective Disorder. Biological Psychiatry, 2007, 61, 797-805. Cortical white-matter microstructure in schizophrenia. British Journal of Psychiatry, 2007, 191, 113-119. Major psychiatric disorders in adult life., 2007, , 454-468. 419 0

CITATION REPORT

Psychosis Secondary to Alzheimer's Disease. , 0, , 455-471.

#	Article	IF	CITATIONS
423	Association study of polymorphisms in the glutamate transporter genesSLC1A1,SLC1A3, andSLC1A6 with schizophrenia. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2007, 144B, 271-278.	1.1	44
424	Positive association of schizophrenia toJARID2 gene. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2007, 144B, 45-51.	1.1	32
425	Familyâ€based association study of neuregulinâ€1 gene and psychosis in a Spanish sample. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2007, 144B, 954-957.	1.1	23
426	Prediction of psychosis onset in Alzheimer disease: The role of depression symptom severity and the HTR2A T102C polymorphism. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2007, 144B, 1054-1062.	1.1	26
427	Chasing genes for mood disorders and schizophrenia in genetically isolated populations. Human Mutation, 2007, 28, 1156-1170.	1.1	18
428	Genetic susceptibility for breast cancer: How many more genes to be found?. Critical Reviews in Oncology/Hematology, 2007, 63, 125-149.	2.0	104
429	Susceptibility genes for schizophrenia: Characterisation of mutant mouse models at the level of phenotypic behaviour. Neuroscience and Biobehavioral Reviews, 2007, 31, 60-78.	2.9	140
430	Genetic correlates of brain aging on MRI and cognitive test measures: a genome-wide association and linkage analysis in the Framingham study. BMC Medical Genetics, 2007, 8, S15.	2.1	179
431	The NRG1 exon 11 missense variant is not associated with autism in the Central Valley of Costa Rica. BMC Psychiatry, 2007, 7, 21.	1.1	5
432	Post-pubertal emergence of alterations in locomotor activity in stop null mice. Synapse, 2007, 61, 689-697.	0.6	16
433	An organelle proteomic method to study neurotransmissionâ€related proteins, applied to a neurodevelopmental model of schizophrenia. Proteomics, 2007, 7, 3569-3579.	1.3	40
434	New order for thought disorders. Nature, 2007, 448, 263-265.	13.7	29
435	Time for growth. Nature, 2007, 448, 265-266.	13.7	11
436	Association of Neuregulin 1 with schizophrenia and bipolar disorder in a second cohort from the Scottish population. Molecular Psychiatry, 2007, 12, 94-104.	4.1	112
437	Genome-wide scan supports the existence of a susceptibility locus for schizophrenia and bipolar disorder on chromosome 15q26. Molecular Psychiatry, 2007, 12, 87-93.	4.1	45
438	Neuregulin 1 (8p12) and childhood-onset schizophrenia: susceptibility haplotypes for diagnosis and brain developmental trajectories. Molecular Psychiatry, 2007, 12, 195-205.	4.1	105
439	Interleukin 3 and schizophrenia: the impact of sex and family history. Molecular Psychiatry, 2007, 12, 273-282.	4.1	49
440	New genes associated with schizophrenia in neurite formation: a review of cell culture experiments. Molecular Psychiatry, 2007, 12, 620-629.	4.1	64

#	Article	IF	CITATIONS
441	Allelic variation in GAD1 (GAD67) is associated with schizophrenia and influences cortical function and gene expression. Molecular Psychiatry, 2007, 12, 854-869.	4.1	248
442	Neuregulin1-induced cell migration is impaired in schizophrenia: association with neuregulin1 and catechol-o-methyltransferase gene polymorphisms. Molecular Psychiatry, 2007, 12, 946-957.	4.1	69
443	Significant correlation in linkage signals from genome-wide scans of schizophrenia and schizotypy. Molecular Psychiatry, 2007, 12, 958-965.	4.1	77
444	Association analysis of the chromosome 4p15–p16 candidate region for bipolar disorder and schizophrenia. Molecular Psychiatry, 2007, 12, 1011-1025.	4.1	39
445	Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Molecular Psychiatry, 2007, 12, 707-747.	4.1	331
446	Neuronal migration in the adult brain: are we there yet?. Nature Reviews Neuroscience, 2007, 8, 141-151.	4.9	165
447	NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders. Nature Reviews Neuroscience, 2007, 8, 413-426.	4.9	1,025
448	Can neuroscience be integrated into the DSM-V?. Nature Reviews Neuroscience, 2007, 8, 725-732.	4.9	471
449	Synapses, Schizophrenia, and Civilization: What Made <i>Homo</i> Sapient?. Zygon, 2007, 42, 767-778.	0.2	0
450	Altered motor activity, exploration and anxiety in heterozygous neuregulin 1 mutant mice: implications for understanding schizophrenia. Genes, Brain and Behavior, 2007, 6, 677-687.	1.1	157
451	Early brain development disruption from NMDA receptor hypofunction: Relevance to schizophrenia. Brain Research Reviews, 2007, 53, 260-270.	9.1	105
452	The role of cortical inhibition in the pathophysiology and treatment of schizophrenia. Brain Research Reviews, 2007, 56, 427-442.	9.1	96
453	Translational research in the pharmaceutical industry: from theory to reality. Drug Discovery Today, 2007, 12, 419-425.	3.2	20
454	Neuregulin-1 genotype moderates the association between job strain and early atherosclerosis in young men. Annals of Behavioral Medicine, 2007, 33, 148-155.	1.7	29
455	Are some genetic risk factors common to schizophrenia, bipolar disorder and depression? evidence fromDISC1, GRIK4 andNRG1. Neurotoxicity Research, 2007, 11, 73-83.	1.3	91
456	Comorbidity implications in brain disease: Neuronal substrates of symptom profiles. Neurotoxicity Research, 2007, 12, 1-15.	1.3	11
457	Heterozygous neuregulin 1 mice are more sensitive to the behavioural effects of Δ9-tetrahydrocannabinol. Psychopharmacology, 2007, 192, 325-336.	1.5	161
458	Association study of polymorphisms in post-synaptic density protein 95 (PSD-95) with schizophrenia. Journal of Neural Transmission, 2007, 114, 423-426.	1.4	16

#	Article	IF	CITATIONS
459	Evidence for statistical epistasis between catechol-O-methyltransferase (COMT) and polymorphisms in RGS4, G72 (DAOA), GRM3, and DISC1: influence on risk of schizophrenia. Human Genetics, 2007, 120, 889-906.	1.8	130
460	Interleukin-1 beta gene polymorphism and its interactions with neuregulin-1 gene polymorphism are associated with schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2007, 258, 10-15.	1.8	53
461	Unravelling the genome: a review of molecular genetic research in schizophrenia. Irish Journal of Medical Science, 2007, 176, 5-9.	0.8	7
462	Neurological soft signs as candidate endophenotypes for schizophrenia: A shooting star or a Northern star?. Neuroscience and Biobehavioral Reviews, 2008, 32, 957-971.	2.9	174
463	The Role of NRG3 in Mammary Development. Journal of Mammary Gland Biology and Neoplasia, 2008, 13, 195-203.	1.0	14
464	The epidermal growth factor receptor family: Biology driving targeted therapeutics. Cellular and Molecular Life Sciences, 2008, 65, 1566-1584.	2.4	593
465	Understanding BACE1: essential protease for amyloid-β production in Alzheimer's disease. Cellular and Molecular Life Sciences, 2008, 65, 3265-3289.	2.4	71
466	Genomic structural variation and schizophrenia. Current Psychiatry Reports, 2008, 10, 171-177.	2.1	13
467	Association and interaction analyses of NRG1 and ERBB4 genes with schizophrenia in a Japanese population. Journal of Human Genetics, 2008, 53, 929-935.	1.1	33
468	Failure to confirm an association between Epsin 4 and schizophrenia in a Japanese population. Journal of Neural Transmission, 2008, 115, 1347-1354.	1.4	1
469	Impact of neuregulin-1 on the pathophysiology of schizophrenia in human post-mortem studies. European Archives of Psychiatry and Clinical Neuroscience, 2008, 258, 35-39.	1.8	20
470	Age-related changes in the expression of schizophrenia susceptibility genes in the human prefrontal cortex. Brain Structure and Function, 2008, 213, 255-271.	1.2	50
471	Association study in the 5q31-32 linkage region for schizophrenia using pooled DNA genotyping. BMC Psychiatry, 2008, 8, 11.	1.1	26
472	Biomarker discovery in psychiatric disorders. Electrophoresis, 2008, 29, 2884-2890.	1.3	33
473	Genomeâ€wide linkage scan, fine mapping, and haplotype analysis in a large, inbred, Arab Israeli pedigree suggest a schizophrenia susceptibility locus on chromosome 20p13. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2008, 147B, 209-215.	1.1	15
474	Upâ€regulation of <i>ADM</i> and <i>SEPX1</i> in the lymphoblastoid cells of patients in monozygotic twins discordant for schizophrenia. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2008, 147B, 557-564.	1.1	25
475	No association between the protein tyrosine phosphatase, receptorâ€ŧype, Z Polypeptide 1 ( <i>PTPRZ1</i> ) gene and schizophrenia in the Japanese population. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2008, 147B, 1013-1018.	1.1	4
477	Association analysis of schizophrenia on 18 genes involved in neuronal migration: <i>MDGA1</i> as a new susceptibility gene. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2008, 147B, 1089-1100.	1.1	101

#	Article	IF	CITATIONS
478	The neuregulin 1 promoter polymorphism rs6994992 is not associated with chronic schizophrenia or neurocognition. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2008, 147B, 1298-1300.	1.1	25
479	<i>FBXL21</i> association with schizophrenia in irish family and case–control samples. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2008, 147B, 1231-1237.	1.1	10
480	Neurogenetics in theAnnals: Dealing with complexity. Annals of Neurology, 2008, 63, A11-A14.	2.8	4
481	Genomewide association for schizophrenia in the CATIE study: results of stage 1. Molecular Psychiatry, 2008, 13, 570-584.	4.1	332
482	The genetics of bipolar disorder: genome â€~hot regions,' genes, new potential candidates and future directions. Molecular Psychiatry, 2008, 13, 742-771.	4.1	175
483	Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nature Reviews Neuroscience, 2008, 9, 437-452.	4.9	899
484	Neuroimaging and molecular genetics of schizophrenia: pathophysiological advances and therapeutic potential. British Journal of Pharmacology, 2008, 153, S120-4.	2.7	31
485	Psychiatric genetics: progress amid controversy. Nature Reviews Genetics, 2008, 9, 527-540.	7.7	481
486	The genetics of multiple sclerosis: SNPs to pathways to pathogenesis. Nature Reviews Genetics, 2008, 9, 516-526.	7.7	294
487	Identification of a chromosome 8p locus for early-onset coronary heart disease in a French Canadian population. European Journal of Human Genetics, 2008, 16, 105-114.	1.4	17
488	Molecular dissection of NRG1-ERBB4 signaling implicates PTPRZ1 as a potential schizophrenia susceptibility gene. Molecular Psychiatry, 2008, 13, 162-172.	4.1	73
489	The effects of a neuregulin 1 variant on white matter density and integrity. Molecular Psychiatry, 2008, 13, 1054-1059.	4.1	190
490	Serious obstetric complications interact with hypoxia-regulated/vascular-expression genes to influence schizophrenia risk. Molecular Psychiatry, 2008, 13, 873-877.	4.1	172
491	Genomic imprinting in the development and evolution of psychotic spectrum conditions. Biological Reviews, 2008, 83, 441-493.	4.7	74
492	A protein interaction based model for schizophrenia study. BMC Bioinformatics, 2008, 9, S23.	1.2	13
493	Agrin and neuregulin, expanding roles and implications for therapeutics. Biotechnology Advances, 2008, 26, 187-201.	6.0	10
494	Association of schizophrenia with DTNBP1 but not with DAO, DAOA, NRG1 and RGS4 nor their genetic interaction. Journal of Psychiatric Research, 2008, 42, 278-288.	1.5	80
495	Neuregulin-1 haplotype HAPICE is associated with lower hippocampal volumes in schizophrenic patients and in non-affected family members. Journal of Psychiatric Research, 2008, 43, 1-6.	1.5	44

#	Article	IF	CITATIONS
496	Emerging Opportunities for Antipsychotic Drug Discovery in the Postgenomic Era. Journal of Medicinal Chemistry, 2008, 51, 1077-1107.	2.9	51
497	Increased levels of serotonin2A receptors and serotonin transporter in the CNS of neuregulin 1 hypomorphic/mutant mice. Schizophrenia Research, 2008, 99, 341-349.	1.1	40
498	153 – The TGM2 gene is associated with schizophrenia in a British population. Schizophrenia Research, 2008, 98, 96.	1.1	0
499	154 – Association between Neuregulin-1 and P300 wave deficits (an endophenotype for psychosis). Schizophrenia Research, 2008, 98, 96.	1.1	Ο
501	Differential RNA expression between schizophrenic patients and controls of the dystrobrevin binding protein 1 and neuregulin 1 genes in immortalized lymphocytes. Schizophrenia Research, 2008, 100, 281-290.	1.1	25
502	Elevated neuregulin-1 and ErbB4 protein in the prefrontal cortex of schizophrenic patients. Schizophrenia Research, 2008, 100, 270-280.	1.1	170
503	Failure to replicate the association between NRG1 and schizophrenia using Japanese large sample. Schizophrenia Research, 2008, 101, 1-8.	1.1	30
504	Neuregulin-1 and the P300 waveform—A preliminary association study using a psychosis endophenotype. Schizophrenia Research, 2008, 103, 178-185.	1.1	40
505	The hippocampus in families with schizophrenia in relation to obstetric complications. Schizophrenia Research, 2008, 104, 71-78.	1.1	34
506	Interaction between interleukin 3 and dystrobrevin-binding protein 1 in schizophrenia. Schizophrenia Research, 2008, 106, 208-217.	1.1	19
507	Basic helix–loop–helix transcription factor NEUROG1 and schizophrenia: Effects on illness susceptibility, MRI brain morphometry and cognitive abilitiesâ~†. Schizophrenia Research, 2008, 106, 192-199.	1.1	17
508	The dice are rolling for schizophrenia genetics. Psychological Medicine, 2008, 38, 1693-1696.	2.7	14
509	Deficiency of Aph1B/C-Î <sup>3</sup> -secretase disturbs Nrg1 cleavage and sensorimotor gating that can be reversed with antipsychotic treatment. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 9775-9780.	3.3	77
510	Evidence of Missense Mutations on the Neuregulin 1 Gene Affecting Function of Prepulse Inhibition. Biological Psychiatry, 2008, 63, 17-23.	0.7	74
511	MEGF10 Association with Schizophrenia. Biological Psychiatry, 2008, 63, 441-448.	0.7	16
512	Shared Gene Expression Alterations in Schizophrenia and Bipolar Disorder. Biological Psychiatry, 2008, 64, 89-97.	0.7	166
513	Support for Neuregulin 1 as a Susceptibility Gene for Bipolar Disorder and Schizophrenia. Biological Psychiatry, 2008, 64, 419-427.	0.7	104
514	Association of a Nonsynonymous Variant of DAOA with Visuospatial Ability in a Bipolar Family Sample. Biological Psychiatry, 2008, 64, 438-442.	0.7	19

#	Article	IF	CITATIONS
515	Decreased Neurotrophic Response to Birth Hypoxia in the Etiology of Schizophrenia. Biological Psychiatry, 2008, 64, 797-802.	0.7	75
516	Neuregulin 3 Genetic Variations and Susceptibility to Schizophrenia in a Chinese Population. Biological Psychiatry, 2008, 64, 1093-1096.	0.7	39
517	Structural And Functional Organization Of The Synapse. , 2008, , .		8
519	Centralized Biorepositories for Genetic and Genomic Research. JAMA - Journal of the American Medical Association, 2008, 299, 1359.	3.8	58
520	Mechanisms of Neuregulin Action. Novartis Foundation Symposium, 2008, 289, 74-86.	1.2	50
521	Interaction Between Physical Activity and Genetic Factors in Complex Metabolic Disease. , 2007, , 155-173.		0
522	Specific developmental reductions in subventricular zone ErbB1 and ErbB4 mRNA in the human brain. International Journal of Developmental Neuroscience, 2008, 26, 791-803.	0.7	16
523	Aspects of Piaget's cognitive developmental psychology and neurobiology of psychotic disorders – An integrative model. Medical Hypotheses, 2008, 71, 426-433.	0.8	12
524	Explorative study on the expression of neuregulin-1 gene in peripheral blood of schizophrenia. Neuroscience Letters, 2008, 438, 1-5.	1.0	46
525	Neuregulin-1/ErbB Signaling Serves Distinct Functions in Myelination of the Peripheral and Central Nervous System. Neuron, 2008, 59, 581-595.	3.8	321
526	Disruption to social dyadic interactions but not emotional/anxiety-related behaviour in mice with heterozygous â€~knockout' of the schizophrenia risk gene neuregulin-1. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 462-466.	2.5	87
527	Calcineurin A gamma and B gene expressions in the whole blood in Japanese patients with schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 1000-1004.	2.5	4
528	Molecular Properties and Cell Biology of the NMDA Receptor. , 2008, , 317-367.		4
529	Developing New Drugs for Schizophrenia: From Animals to the Clinic. , 2008, , 199-261.		18
530	Association of 5′ end neuregulin-1 ( NRG1 ) gene variation with subcortical medial frontal microstructure in humans. NeuroImage, 2008, 40, 712-718.	2.1	86
531	The effects of neuregulin1 on brain function in controls and patients with schizophrenia and bipolar disorder. NeuroImage, 2008, 42, 817-826.	2.1	66
532	Genetic variation in the schizophrenia-risk gene neuregulin1 correlates with differences in frontal brain activation in a working memory task in healthy individuals. NeuroImage, 2008, 42, 1569-1576.	2.1	46
533	Content versus delivery: Challenges and options in the treatment of schizophrenia. European Neuropsychopharmacology, 2008, 18, v-vi.	0.3	0

#	Article	IF	CITATIONS
534	Schizophrenia: From developmental deviance to dopamine dysregulation. European Neuropsychopharmacology, 2008, 18, S129-S134.	0.3	119
535	A roadmap to disentangle the molecular etiology of schizophrenia. European Psychiatry, 2008, 23, 224-232.	0.1	7
536	Genetic variation in the schizophrenia-risk gene neuregulin1 correlates with personality traits in healthy individuals. European Psychiatry, 2008, 23, 344-349.	0.1	17
537	Regulation of pituitary adenylyl cyclase-activating polypeptide (PACAP, ADCYAP1: adenylyl) Tj ETQq1 1 0.784314 Targets, 2008, 12, 1097-1108.	rgBT /Ove 1.5	erlock 10 T 11
538	Cerebrospinal fluid: identification of diagnostic markers for schizophrenia. Expert Review of Molecular Diagnostics, 2008, 8, 209-216.	1.5	23
539	Association between Polymorphisms in the Vesicular Monoamine Transporter 1 Gene <i>(VMAT1/SLC18A1)</i> on Chromosome 8p and Schizophrenia. Neuropsychobiology, 2008, 57, 55-60.	0.9	36
540	Neuregulin-1 regulates LTP at CA1 hippocampal synapses through activation of dopamine D4 receptors. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 15587-15592.	3.3	126
541	Schizophrenia: the polygene princess and the pea. Psychological Medicine, 2008, 38, 1687-1691.	2.7	10
542	Presynaptic Type III Neuregulin1-ErbB signaling targets α7 nicotinic acetylcholine receptors to axons. Journal of Cell Biology, 2008, 181, 511-521.	2.3	57
543	Developmental disruptions in neural connectivity in the pathophysiology of schizophrenia. Development and Psychopathology, 2008, 20, 1297-1327.	1.4	125
544	Type III Neuregulin-1 Is Required for Normal Sensorimotor Gating, Memory-Related Behaviors, and Corticostriatal Circuit Components. Journal of Neuroscience, 2008, 28, 6872-6883.	1.7	183
545	Copy variations in schizophrenia and bipolar disorder. Cytogenetic and Genome Research, 2008, 123, 27-35.	0.6	9
546	Genes and Neuroimaging: Advances in Psychiatric Research. Neurodegenerative Diseases, 2008, 5, 277-285.	0.8	15
547	ErbB4-Neuregulin Signaling Modulates Synapse Development and Dendritic Arborization through Distinct Mechanisms. Journal of Biological Chemistry, 2008, 283, 32944-32956.	1.6	97
548	Insolubility of Disrupted-in-Schizophrenia 1 Disrupts Oligomer-Dependent Interactions with Nuclear Distribution Element 1 and Is Associated with Sporadic Mental Disease. Journal of Neuroscience, 2008, 28, 3839-3845.	1.7	127
549	Identification of YWHAE, a gene encoding 14-3-3epsilon, as a possible susceptibility gene for schizophrenia. Human Molecular Genetics, 2008, 17, 3212-3222.	1.4	97
550	Genome-Wide Association for Methamphetamine Dependence. Archives of General Psychiatry, 2008, 65, 345.	13.8	130
551	The Evolution of Drug Development in Schizophrenia: Past Issues and Future Opportunities. Neuropsychopharmacology, 2008, 33, 2061-2079.	2.8	183

#	Article	IF	CITATIONS
552	Cis- and trans- loci influence expression of the schizophrenia susceptibility gene DTNBP1. Human Molecular Genetics, 2008, 17, 1169-1174.	1.4	18
553	Systems Biology and Complex Neurobehavioral Traits. Pharmacopsychiatry, 2008, 41, S32-S36.	1.7	14
554	Role of glutamate in schizophrenia: integrating excitatory avenues of research. Expert Review of Neurotherapeutics, 2008, 8, 1389-1406.	1.4	45
555	Mice Lacking the Immediate Early Gene Egr3 Respond to the Anti-Aggressive Effects of Clozapine Yet are Relatively Resistant to its Sedating Effects. Neuropsychopharmacology, 2008, 33, 1266-1275.	2.8	56
556	Drug discovery based on genetic and metabolic findings in schizophrenia. Expert Review of Clinical Pharmacology, 2008, 1, 773-789.	1.3	8
557	ErbB4 and its Isoforms: Patentable Drug Targets?. Recent Patents on DNA & Gene Sequences, 2008, 2, 27-33.	0.7	9
558	Alteration of BACE1-dependent NRG1/ErbB4 signaling and schizophrenia-like phenotypes in <i>BACE1</i> -null mice. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 5585-5590.	3.3	264
560	Behavioral profile of a heterozygous mutant mouse model for EGF-like domain neuregulin 1 Behavioral Neuroscience, 2008, 122, 748-759.	0.6	55
561	Cognitive Impairment in Schizophrenia: a Review of Developmental and Genetic Models, and Pro-cognitive Profile of the Optimised D3 > D2 Antagonist, S33138. Therapie, 2008, 63, 187-229.	0.6	44
562	Chronic antipsychotic drug administration alters the expression of neuregulin 1β, ErbB2, ErbB3, and ErbB4 in the rat prefrontal cortex and hippocampus. International Journal of Neuropsychopharmacology, 2008, 11, 553-61.	1.0	36
563	Trafficking and Targeting of NMDA Receptors. Frontiers in Neuroscience, 2008, , 149-200.	0.0	11
564	Schizophrenia genetics: the search for a hard lead. Current Opinion in Psychiatry, 2008, 21, 157-160.	3.1	26
565	Genes and structural brain imaging in schizophrenia. Current Opinion in Psychiatry, 2008, 21, 161-167.	3.1	59
566	Genetic epidemiology. , 2008, , 80-94.		0
568	Genomic Approaches to Complex Disease. , 2009, , 33-46.		0
569	Genetic vulnerability. , 0, , 31-46.		0
570	Neurobiologicalendophenotypes of psychosis and schizophrenia. , 2009, , 61-80.		7
571	Apoptotic Engulfment Pathway and Schizophrenia. PLoS ONE, 2009, 4, e6875.	1.1	35

#	Article	IF	CITATIONS
572	Linking white and grey matter in schizophrenia: Oligodendrocyte and neuron pathology in the prefrontal cortex. Frontiers in Neuroanatomy, 2009, 3, 9.	0.9	67
573	Neuregulin Î <sup>2</sup> 1 enhances peak glutamate-induced intracellular calcium levels through endoplasmic reticulum calcium release in cultured hippocampal neuronsThis article is one of a selection of papers published in a special issue celebrating the 125th anniversary of the Faculty of Medicine at the University of Manitoba Canadian Journal of Physiology and Pharmacology. 2009. 87. 883-891.	0.7	9
574	New findings from genetic association studies of schizophrenia. Journal of Human Genetics, 2009, 54, 9-14.	1.1	29
575	Elucidating the genetic architecture of familial schizophrenia using rare copy number variant and linkage scans. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 16746-16751.	3.3	133
576	NR1 knockdown mice as a representative model of the glutamate hypothesis of schizophrenia. Progress in Brain Research, 2009, 179, 51-58.	0.9	38
578	Whole Genome Association Study in a Homogenous Population in Shandong Peninsula of China Reveals JARID2 as a Susceptibility Gene for Schizophrenia. Journal of Biomedicine and Biotechnology, 2009, 2009, 1-7.	3.0	32
579	The effect of COMT, BDNF, 5-HTT, NRG1 and DTNBP1 genes on hippocampal and lateral ventricular volume in psychosis. Psychological Medicine, 2009, 39, 1783-1797.	2.7	68
580	Neuregulin-1 Modulates Hippocampal Gamma Oscillations: Implications for Schizophrenia. Cerebral Cortex, 2009, 19, 612-618.	1.6	148
581	Analysis of a Promoter Polymorphism in the SMDF Neuregulin 1 Isoform in Schizophrenia. Neuropsychobiology, 2009, 59, 205-212.	0.9	6
582	NMDA Receptor Phosphorylation at a Site Affected in Schizophrenia Controls Synaptic and Behavioral Plasticity. Journal of Neuroscience, 2009, 29, 11965-11972.	1.7	40
583	A Schizophrenia Gene Locus on Chromosome 17q21 in a New Set of Families of Mexican and Central American Ancestry: Evidence From the NIMH Genetics of Schizophrenia in Latino Populations Study. American Journal of Psychiatry, 2009, 166, 442-449.	4.0	31
584	Neuregulin links dopaminergic and glutamatergic neurotransmission to control hippocampal synaptic plasticity. Communicative and Integrative Biology, 2009, 2, 261-264.	0.6	21
585	Gene models of schizophrenia: DISC1 mouse models. Progress in Brain Research, 2009, 179, 75-86.	0.9	66
586	Novel Therapies for Schizophrenia: Understanding the Glutamatergic Synapse and Potential Targets for Altering N-methyl-D-aspartate Neurotransmission. Recent Patents on CNS Drug Discovery, 2009, 4, 220-238.	0.9	12
587	A family-based association study of DNA sequence variants in GRM7 with schizophrenia in an Indonesian population. International Journal of Neuropsychopharmacology, 2009, 12, 1283.	1.0	28
588	Neurotrophins Induce Neuregulin Release through Protein Kinase CδActivation. Journal of Biological Chemistry, 2009, 284, 26251-26260.	1.6	33
589	Genome-wide comparisons of variation in linkage disequilibrium. Genome Research, 2009, 19, 1849-1860.	2.4	58
590	Neuropsychiatric Disease and <i>Toxoplasma gondii</i> Infection. NeuroImmunoModulation, 2009, 16, 122-133.	0.9	162

#	Article	IF	CITATIONS
591	Impaired maturation of dendritic spines without disorganization of cortical cell layers in mice lacking NRG1/ErbB signaling in the central nervous system. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 4507-4512.	3.3	178
592	Disrupted-in-schizophrenia 1 and neuregulin 1 are required for the specification of oligodendrocytes and neurones in the zebrafish brain. Human Molecular Genetics, 2009, 18, 391-404.	1.4	84
593	Transcriptional Interaction of an Estrogen Receptor Splice Variant and ErbB4 Suggests Convergence in Gene Susceptibility Pathways in Schizophrenia. Journal of Biological Chemistry, 2009, 284, 18824-18832.	1.6	30
594	Genetics of bipolar disorder: successful start to a long journey. Trends in Genetics, 2009, 25, 99-105.	2.9	142
595	ErbB receptors and the development of the nervous system. Experimental Cell Research, 2009, 315, 611-618.	1.2	117
596	Differential distribution of neuregulin in human brain and spinal fluid. Brain Research, 2009, 1258, 1-11.	1.1	47
597	Neuregulin 1 transgenic mice display reduced mismatch negativity, contextual fear conditioning and social interactions. Brain Research, 2009, 1294, 116-127.	1.1	111
598	Familyâ€based association study of Neuregulin 1 with psychotic bipolar disorder. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2009, 150B, 693-702.	1.1	31
599	Linkage analysis of schizophrenia controlling for population substructure. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2009, 150B, 827-835.	1.1	12
600	Identification of neuroglycan C and interacting partners as potential susceptibility genes for schizophrenia in a Southern Chinese population. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2010, 153B, 103-113.	1.1	20
601	<i>NRG1</i> gene in recurrent major depression: No association in a largeâ€scale case–control association study. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2010, 153B, 141-147.	1.1	2
602	Association study of <i>NRG1</i> , <i>DTNBP1</i> , <i>RGS4</i> , <i>G72</i> /i>/ <i>G30</i> , and <i>PIP5K2A</i> with schizophrenia and symptom severity in a Hungarian sample. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2010, 153B, 792-801.	1.1	37
603	A novel method for haplotype clustering and visualization. Genetic Epidemiology, 2010, 34, 34-41.	0.6	6
604	Genetic variation in the schizophreniaâ€risk gene neuregulin 1 correlates with brain activation and impaired speech production in a verbal fluency task in healthy individuals. Human Brain Mapping, 2009, 30, 3406-3416.	1.9	50
605	Genetic variation in neuregulin1 is associated with differences in prefrontal engagement in children. Human Brain Mapping, 2009, 30, 3934-3943.	1.9	12
606	Selective populations of hippocampal interneurons express ErbB4 and their number and distribution is altered in ErbB4 knockout mice. Hippocampus, 2010, 20, 724-744.	0.9	119
607	Genome-wide association studies in ADHD. Human Genetics, 2009, 126, 13-50.	1.8	374
608	Modularity in philosophy, the neurosciences, and psychiatry. Poiesis & Praxis, 2009, 6, 93-108.	0.3	1

#	Article	IF	CITATIONS
609	Neuregulin 1 and age of onset in the major psychoses. Journal of Neural Transmission, 2009, 116, 479-486.	1.4	7
610	Neuregulin 1 ICE-single nucleotide polymorphism in first episode schizophrenia correlates with cerebral activation in fronto-temporal areas. European Archives of Psychiatry and Clinical Neuroscience, 2009, 259, 72-79.	1.8	29
611	Cannabis and psychosis/schizophrenia: human studies. European Archives of Psychiatry and Clinical Neuroscience, 2009, 259, 413-431.	1.8	221
612	Clozapine-Induced ERK1 and ERK2 Signaling in Prefrontal Cortex Is Mediated by the EGF Receptor. Journal of Molecular Neuroscience, 2009, 39, 185-198.	1.1	24
613	Development and application of genotyping technologies. Science in China Series C: Life Sciences, 2009, 52, 17-23.	1.3	8
614	Deficient NRG1-ERBB signaling alters social approach: relevance to genetic mouse models of schizophrenia. Journal of Neurodevelopmental Disorders, 2009, 1, 302-312.	1.5	32
616	Role of cannabis and endocannabinoids in the genesis of schizophrenia. Psychopharmacology, 2009, 206, 531-549.	1.5	123
617	Behavioral abnormalities in synapsin II knockout mice implicate a causal factor in schizophrenia. Synapse, 2009, 63, 662-672.	0.6	44
618	Glutamatergic deficits and parvalbumin-containing inhibitory neurons in the prefrontal cortex in schizophrenia. BMC Psychiatry, 2009, 9, 71.	1.1	114
619	Meta-analysis of 32 genome-wide linkage studies of schizophrenia. Molecular Psychiatry, 2009, 14, 774-785.	4.1	235
620	The relationship of anterior thalamic radiation integrity to psychosis risk associated neuregulin-1 variants. Molecular Psychiatry, 2009, 14, 237-238.	4.1	44
621	A 5′ promoter region SNP in NRG1 is associated with schizophrenia risk and type III isoform expression. Molecular Psychiatry, 2009, 14, 741-743.	4.1	40
622	Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study. Molecular Psychiatry, 2009, 14, 804-819.	4.1	139
623	Association of childhood trauma exposure and GABRA2 polymorphisms with risk of posttraumatic stress disorder in adults. Molecular Psychiatry, 2009, 14, 234-235.	4.1	76
624	Genomewide linkage scan of schizophrenia in a large multicenter pedigree sample using single nucleotide polymorphisms. Molecular Psychiatry, 2009, 14, 786-795.	4.1	61
625	Computational analysis of human genome polymorphism. Molecular Biology, 2009, 43, 260-268.	0.4	4
626	Neurobehavioral abnormalities in the dysbindinâ€1 mutant, sandy, on a C57BL/6J genetic background. Genes, Brain and Behavior, 2009, 8, 390-397.	1.1	106
627	From age correction to genomeâ€wide association. Acta Psychiatrica Scandinavica, 2009, 120, 355-362.	2.2	9

	CITATION RE	CITATION REPORT	
#	Article	IF	CITATIONS
628	The effects of αâ€secretase ADAM10 on the proteolysis of neuregulinâ€1. FEBS Journal, 2009, 276, 1568-1580.	2.2	29
629	Proteomic analysis reveals novel binding partners of dysbindin, a schizophreniaâ€related protein. Journal of Neurochemistry, 2009, 110, 1567-1574.	2.1	26
630	The pure parsimony haplotyping problem: overview and computational advances. International Transactions in Operational Research, 2009, 16, 561-584.	1.8	18
631	Survey of Schizophrenia and Bipolar Disorder Candidate Genes using Chromatin Immunoprecipitation and Tiled Microarrays (ChIP-chip). Journal of Neurogenetics, 2009, 23, 341-352.	0.6	14
632	Fine Mapping on Chromosome 10q22-q23 Implicates Neuregulin 3 in Schizophrenia. American Journal of Human Genetics, 2009, 84, 21-34.	2.6	81
633	Human Puberty: Physiology, Progression, and Genetic Regulation of Variation in Onset. , 2009, , 2113-2134.		1
634	<i>DTNBP1, NRG1, DAOA</i> , <i>DAO</i> and <i>GRM3</i> Polymorphisms and Schizophrenia: An Association Study. Neuropsychobiology, 2009, 59, 142-150.	0.9	33
636	Neonatal infection with neurotropic influenza A virus affects working memory and expression of type III Nrg1 in adult mice. Brain, Behavior, and Immunity, 2009, 23, 733-741.	2.0	29
637	Genetic influences on hippocampal structure and function in recombinant inbred mice. Behavioural Brain Research, 2009, 196, 78-83.	1.2	3
638	Mice mutant for genes associated with schizophrenia: Common phenotype or distinct endophenotypes?. Behavioural Brain Research, 2009, 204, 258-273.	1.2	54
639	Animal models of gene–environment interactions in schizophrenia. Behavioural Brain Research, 2009, 204, 274-281.	1.2	88
640	Prepulse inhibition and genetic mouse models of schizophrenia. Behavioural Brain Research, 2009, 204, 282-294.	1.2	184
641	Modeling cognitive endophenotypes of schizophrenia in mice. Trends in Neurosciences, 2009, 32, 347-358.	4.2	133
642	Neurodevelopmental mechanisms of schizophrenia: understanding disturbed postnatal brain maturation through neuregulin-1–ErbB4 and DISC1. Trends in Neurosciences, 2009, 32, 485-495.	4.2	293
643	DISC1 Regulates New Neuron Development in the Adult Brain via Modulation of AKT-mTOR Signaling through KIAA1212. Neuron, 2009, 63, 761-773.	3.8	301
644	In situ hybridization reveals developmental regulation of ErbB1-4 mRNA expression in mouse midbrain: Implication of ErbB receptors for dopaminergic neurons. Neuroscience, 2009, 161, 95-110.	1.1	83
645	Association study of polymorphisms in the group III metabotropic glutamate receptor genes, GRM4 and GRM7, with schizophrenia. Psychiatry Research, 2009, 167, 88-96.	1.7	42
646	Phenotype of spontaneous orofacial dyskinesia in neuregulin-1 †knockout' mice. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009, 33, 330-333.	2.5	7

#	Article	IF	CITATIONS
647	Expression of ErbB4 in substantia nigra dopamine neurons of monkeys and humans. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009, 33, 701-706.	2.5	31
648	Genetic association analysis of NRG1 with methamphetamine-induced psychosis in a Japanese population. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009, 33, 903-905.	2.5	11
649	Levels of neuregulin 1 and 3 proteins in Brodmann's area 46 from subjects with schizophrenia and bipolar disorder. Neuroscience Letters, 2009, 466, 27-29.	1.0	11
650	A Neuregulin 1 Variant Is Associated with Increased Lateral Ventricle Volume in Patients with First-Episode Schizophrenia. Biological Psychiatry, 2009, 65, 535-540.	0.7	54
651	Mixture Model Clustering of Phenotype Features Reveals Evidence for Association of DTNBP1 to a Specific Subtype of Schizophrenia. Biological Psychiatry, 2009, 66, 990-996.	0.7	41
652	Linkage analysis of schizophrenia in African-American families. Schizophrenia Research, 2009, 109, 70-79.	1.1	12
653	A two-method meta-analysis of Neuregulin 1(NRG1) association and heterogeneity in schizophrenia. Schizophrenia Research, 2009, 111, 109-114.	1.1	43
654	Upregulation of NRG-1 and VAMP-1 in human brain aggregates exposed to clozapine. Schizophrenia Research, 2009, 113, 273-276.	1.1	25
655	Zebrafish: a model system to examine the neurodevelopmental basis of schizophrenia. Progress in Brain Research, 2009, 179, 97-106.	0.9	45
656	Shared genetics of bipolar disorder and schizophrenia. Nature Reviews Neurology, 2009, 5, 299-300.	4.9	41
657	Schizophrenia: From the brain to peripheral markers. A consensus paper of the WFSBP task force on biological markers. World Journal of Biological Psychiatry, 2009, 10, 127-155.	1.3	64
658	D1 receptor antagonist-induced long-term depression in the medial prefrontal cortex of rat, in vivo: an animal model of psychiatric hypofrontality. Journal of Psychopharmacology, 2009, 23, 672-685.	2.0	13
659	Dissecting the Molecular Causes of Schizophrenia. Nucleic Acids and Molecular Biology, 2009, , 51-79.	0.2	1
660	The β-Secretase Enzyme BACE in Health and Alzheimer's Disease: Regulation, Cell Biology, Function, and Therapeutic Potential. Journal of Neuroscience, 2009, 29, 12787-12794.	1.7	498
661	Signals of recent positive selection in a worldwide sample of human populations. Genome Research, 2009, 19, 826-837.	2.4	658
662	Mutant models for genes associated with schizophrenia. Biochemical Society Transactions, 2009, 37, 308-312.	1.6	51
663	Positive and Negative Symptoms in Schizophrenia: The NMDA Receptor Hypofunction Hypothesis, Neuregulin/ErbB4 and Synapse Regression. Australian and New Zealand Journal of Psychiatry, 2009, 43, 711-721.	1.3	41
664	Neuregulin-1 signaling in schizophrenia: †Jack of all trades' or master of some?. Expert Review of Neurotherapeutics, 2009, 9, 1-3.	1.4	16
#	Article	IF	CITATIONS
-----	---	------	-----------
665	Genetic risk for white matter abnormalities in bipolar disorder. International Review of Psychiatry, 2009, 21, 387-393.	1.4	33
666	Can the role of genetic factors in schizophrenia be enlightened by studies of candidate gene mutant mice behaviour?. World Journal of Biological Psychiatry, 2009, 10, 778-797.	1.3	8
667	Glutamatergic Approaches to the Conceptualization and Treatment of Schizophrenia. , 2009, , 39-89.		6
668	Kalirin regulates cortical spine morphogenesis and disease-related behavioral phenotypes. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 13058-13063.	3.3	150
669	Support for NRG1 as a Susceptibility Factor for Schizophrenia in a Northern Swedish Isolated Population. Archives of General Psychiatry, 2009, 66, 828.	13.8	32
670	Behavioural characterization of neuregulin 1 type I overexpressing transgenic mice. NeuroReport, 2009, 20, 1523-1528.	0.6	77
671	Recent diffusion tensor imaging findings in early stages of schizophrenia. Current Opinion in Psychiatry, 2009, 22, 168-176.	3.1	92
672	An association study of the neuregulin 1 gene, bipolar affective disorder and psychosis. Psychiatric Genetics, 2009, 19, 113-116.	0.6	56
673	Update on key previously proposed candidate genes for schizophrenia. Current Opinion in Psychiatry, 2009, 22, 147-153.	3.1	38
674	The Role of Genes Involved in Neuroplasticity and Neurogenesis in the Observation of a Gene-Environment Interaction (GxE) in Schizophrenia. Current Molecular Medicine, 2009, 9, 506-518.	0.6	59
675	Genetic Mapping of Pharmacogenetic Regulatory Variation. Current Pharmaceutical Design, 2009, 15, 3773-3781.	0.9	4
676	Neuregulin 1 hypomorphic mutant mice: enhanced baseline locomotor activity but normal psychotropic drug-induced hyperlocomotion and prepulse inhibition regulation. International Journal of Neuropsychopharmacology, 2009, 12, 1383.	1.0	88
677	Primate-Accelerated Evolutionary Genes: Novel Routes to Drug Discovery in Psychiatric Disorders. Current Medicinal Chemistry, 2010, 17, 1300-1316.	1.2	9
678	Molecular Biomarkers in Schizophrenia – Implications for Clinical Practice. Current Psychiatry Reviews, 2010, 6, 114-121.	0.9	0
679	Genetic Studies of Schizophrenia and Bipolar Disorder. Focus (American Psychiatric Publishing), 2010, 8, 323-338.	0.4	2
681	No Association Between Neuregulin 1 and Psychotic Symptoms in Alzheimer's Disease Patients. Journal of Alzheimer's Disease, 2010, 20, 561-567.	1.2	16
682	A follow-up study: acute behavioural effects of î"9-THC in female heterozygous Neuregulin 1 transmembrane domain mutant mice. Psychopharmacology, 2010, 211, 277-289.	1.5	62
683	Mice with genetically altered glutamate receptors as models of schizophrenia: A comprehensive review. Neuroscience and Biobehavioral Reviews, 2010, 34, 285-294.	2.9	61

#	Article	IF	Citations
684	Gene expression of NMDA receptor subunits in the cerebellum of elderly patients with schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2010, 260, 101-111.	1.8	41
685	Neuregulin-1 genotypes and eye movements in schizophrenia. European Archives of Psychiatry and Clinical Neuroscience, 2010, 260, 77-85.	1.8	9
686	WRN mutations in Werner syndrome patients: genomic rearrangements, unusual intronic mutations and ethnic-specific alterations. Human Genetics, 2010, 128, 103-111.	1.8	87
687	Influence of Neuregulin1 Genotype on Neural Substrate of Perceptual Matching in Children. Behavior Genetics, 2010, 40, 157-166.	1.4	5
688	Measurement and comparison of serum neuregulin 1 immunoreactivity in control subjects and patients with schizophrenia: an influence of its genetic polymorphism. Journal of Neural Transmission, 2010, 117, 887-895.	1.4	47
689	New animal models of progressive neurodegeneration: tools for identifying targets in predictive diagnostics and presymptomatic treatment. EPMA Journal, 2010, 1, 217-227.	3.3	9
690	Î <sup>3</sup> -secretases: from cell biology to therapeutic strategies. Lancet Neurology, The, 2010, 9, 215-226.	4.9	162
691	Post-weaning social isolation increases activity in a novel environment but decreases defensive burying and subchronic MK-801 enhances the activity but not the burying effect in rats. Pharmacology Biochemistry and Behavior, 2010, 95, 72-79.	1.3	30
692	Disruption of thermal nociceptive behaviour in mice mutant for the schizophrenia-associated genes NRG1, COMT and DISC1. Brain Research, 2010, 1348, 114-119.	1.1	24
693	<i>EGR3</i> as a potential susceptibility gene for schizophrenia in Korea. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2010, 153B, 1355-1360.	1.1	36
694	The involvement of the NMDA receptor d-serine/glycine site in the pathophysiology and treatment of schizophrenia. Neuroscience and Biobehavioral Reviews, 2010, 34, 351-372.	2.9	111
695	Pharmacology of epigenetics in brain disorders. British Journal of Pharmacology, 2010, 159, 285-303.	2.7	55
696	Molecular and cellular characterization of Neuregulinâ€a type IV isoforms. Journal of Neurochemistry, 2010, 113, 1163-1176.	2.1	19
697	Control of cortical GABA circuitry development by Nrg1 and ErbB4 signalling. Nature, 2010, 464, 1376-1380.	13.7	423
698	From maps to mechanisms through neuroimaging of schizophrenia. Nature, 2010, 468, 194-202.	13.7	286
699	Schizophreniaâ€related endophenotypes in heterozygous neuregulinâ€1 â€ <sup>-</sup> knockout' mice. European Journa of Neuroscience, 2010, 31, 349-358.	al 1.2	68
700	Cytokine hypothesis of schizophrenia pathogenesis: Evidence from human studies and animal models. Psychiatry and Clinical Neurosciences, 2010, 64, 217-230.	1.0	177
701	Genetic investigations in the CATIE sample. , 0, , 237-254.		0

#	Article	IF	CITATIONS
702	The genetics of latent inhibition: studies of inbred and mutant mice. , 0, , 225-251.		2
703	Neue Ergebnisse in der genetischen Forschung bei schizophrenen Psychosen. , 2010, , 133-141.		0
704	Schizophrenia and related disorders. , 2010, , 391-426.		1
705	Dysbindin Regulates the Transcriptional Level of Myristoylated Alanine-Rich Protein Kinase C Substrate via the Interaction with NF-YB in Mice Brain. PLoS ONE, 2010, 5, e8773.	1.1	15
706	White Matter Integrity, Creativity, and Psychopathology: Disentangling Constructs with Diffusion Tensor Imaging. PLoS ONE, 2010, 5, e9818.	1.1	161
707	Molecular Cloning and Characterization of the Human ErbB4 Gene: Identification of Novel Splice Isoforms in the Developing and Adult Brain. PLoS ONE, 2010, 5, e12924.	1.1	15
708	Modeling the Positive Symptoms of Schizophrenia in Genetically Modified Mice: Pharmacology and Methodology Aspects. Schizophrenia Bulletin, 2010, 36, 246-270.	2.3	317
709	Positron Emission Tomography in Schizophrenia: A New Perspective. Journal of Nuclear Medicine, 2010, 51, 511-520.	2.8	55
711	Prepulse Inhibition of the Startle Reflex: A Window on the Brain in Schizophrenia. Current Topics in Behavioral Neurosciences, 2010, 4, 349-371.	0.8	96
712	Neurodevelopmental Animal Models of Schizophrenia: Role in Novel Drug Discovery and Development. Clinical Schizophrenia and Related Psychoses, 2010, 4, 124-137.	1.4	52
713	Nrg1 Reverse Signaling in Cortical Pyramidal Neurons. Journal of Neuroscience, 2010, 30, 15005-15006.	1.7	6
714	Nucleocytoplasmic Shuttling of Dysbindin-1, a Schizophrenia-related Protein, Regulates Synapsin I Expression. Journal of Biological Chemistry, 2010, 285, 38630-38640.	1.6	24
715	Common genetic variation in Neuregulin 3 ( <i>NRG3</i> ) influences risk for schizophrenia and impacts <i>NRG3</i> expression in human brain. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 15619-15624.	3.3	118
716	What have the genomics ever done for the psychoses?. Psychological Medicine, 2010, 40, 529-540.	2.7	46
717	Neuregulin 1 regulates pyramidal neuron activity via ErbB4 in parvalbumin-positive interneurons. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 1211-1216.	3.3	281
718	Intramembranous Valine Linked to Schizophrenia Is Required for Neuregulin 1 Regulation of the Morphological Development of Cortical Neurons. Journal of Neuroscience, 2010, 30, 9199-9208.	1.7	64
719	ErbB4 in parvalbumin-positive interneurons is critical for neuregulin 1 regulation of long-term potentiation. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 21818-21823.	3.3	221
720	Disrupted-in-Schizophrenia-1 expression is regulated by β-site amyloid precursor protein cleaving enzyme-1–neuregulin cascade. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 5622-5627.	3.3	97

ARTICLE IF CITATIONS # Gene expression of neuregulin-1 isoforms in different brain regions of elderly schizophrenia patients. 721 1.3 40 World Journal of Biological Psychiatry, 2010, 11, 243-250. Genetic variation influences glutamate concentrations in brains of patients with multiple sclerosis. 722 3.7 123 Brain, 2010, 133, 2603-2611 Executive Function, Neural Circuitry, and Genetic Mechanisms in Schizophrenia. 723 2.8 198 Neuropsychopharmacology, 2010, 35, 258-277. Expressions of Neuregulin 1<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>l<sup>2</sup></mml:mi></mml:math>and ErbB4 in 724 Prefrontal Cortex and Hippocampus of a Rat Schizophrenia Model Induced by Chronic MK-801 Administration, Journal of Biomedicine and Biotechnology, 2010, 2010, 1-7 Biological Validation of Increased Schizophrenia Risk With NRG1, ERBB4, and AKT1 Epistasis via 725 13.8 113 Functional Neuroimaging in Healthy Controls. Archives of General Psychiatry, 2010, 67, 991. Functional and Dysfunctional Synaptic Plasticity in Prefrontal Cortex: Roles in Psychiatric Disorders. Biological Psychiatry, 2010, 67, 199-207. Cognitive and Sensorimotor Gating Impairments in Transgenic Mice Overexpressing the Schizophrenia 727 0.7 125 Susceptibility Gene Tcf4 in the Brain. Biological Psychiatry, 2010, 68, 33-40. Heritability of DTI and MTR in nine-year-old children. NeuroImage, 2010, 53, 1085-1092. 2.1 730 66 Aumento de los valores de las proteÃnas neurregulina 1 y ErbB4 en la corteza prefrontal de pacientes 732 0.0 0 esquizofrénicos. Psiquiatria Biologica, 2010, 17, 54-62. Geneties of Schizophrenia and Bipolar Affective Disorder., 2010, , 759-776. Association analysis of Neuregulin 1 candidate regions in schizophrenia and bipolar disorder. 734 1.0 41 Neuroscience Letters, 2010, 478, 9-13. Support for the involvement of the ERBB4 gene in schizophrenia: A genetic association analysis. 1.0 Neuroscience Letters, 2010, 481, 120-125 Candidate genes and their interactions with other genetic/environmental risk factors in the etiology 736 1.4 18 of schizophrenia. Brain Research Bulletin, 2010, 83, 86-92. Advancing a functional genomics for schizophrenia: Psychopathological and cognitive phenotypes in mutants with gene disruption. Brain Research Bulletin, 2010, 83, 162-176. 1.4 Disturbed synaptic connectivity in schizophrenia: Convergence of genetic risk factors during 738 1.4 46 neurodevelopment. Brain Research Bulletin, 2010, 83, 140-146. Neuregulin 1–erbB4 pathway in schizophrenia: From genes to an interactome. Brain Research Bulletin, 1.4 2010, 83, 132-139. The neuregulin signaling pathway and schizophrenia: From genes to synapses and neural circuits. 740 1.4 146 Brain Research Bulletin, 2010, 83, 122-131. Neuregulin-1, the fetal endothelium, and brain damage in preterm newborns. Brain, Behavior, and 741 19 Immunity, 2010, 24, 784-791.

#	Article	IF	CITATIONS
742	Combined effect of neonatal immune activation and mutant DISC1 on phenotypic changes in adulthood. Behavioural Brain Research, 2010, 206, 32-37.	1.2	126
743	Genetic findings in schizophrenia patients related to alterations in the intracellular Ca-homeostasis. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 1375-1380.	2.5	21
744	Neuropeptide S attenuates neuropathological, neurochemical and behavioral changes induced by the NMDA receptor antagonist MK-801. Neuropharmacology, 2010, 58, 166-172.	2.0	35
745	Sensorimotor gating in neurotensin-1 receptor null mice. Neuropharmacology, 2010, 58, 173-178.	2.0	16
746	Cognition in transmembrane domain neuregulin 1 mutant mice. Neuroscience, 2010, 170, 800-807.	1.1	86
747	Signaling pathways in schizophrenia: emerging targets and therapeutic strategies. Trends in Pharmacological Sciences, 2010, 31, 381-390.	4.0	159
748	NRG1 and BDNF genes in schizophrenia: An association study in an Italian case-control sample. Psychiatry Research, 2010, 176, 82-84.	1.7	24
749	Nrg1/ErbB signaling networks in Schwann cell development and myelination. Seminars in Cell and Developmental Biology, 2010, 21, 922-928.	2.3	207
750	The effect of Neuregulin 1 on neural correlates of episodic memory encoding and retrieval. NeuroImage, 2010, 53, 985-991.	2.1	33
751	COMT genotype and its role on hippocampal–prefrontal regions in declarative memory. NeuroImage, 2010, 53, 978-984.	2.1	34
752	Roles of channels and receptors in the growth cone during PNS axonal regeneration. Experimental Neurology, 2010, 223, 38-44.	2.0	38
753	Additive effect of NRG1 and DISC1 genes on lateral ventricle enlargement in first episode schizophrenia. NeuroImage, 2010, 53, 1016-1022.	2.1	41
754	Imaging genetics of structural brain connectivity and neural integrity markers. NeuroImage, 2010, 53, 848-856.	2.1	19
755	Handbook of Genomics and the Family. Issues in Clinical Child Psychology, 2010, , .	0.2	5
756	Chemical Genetics Identifies Small-Molecule Modulators of Neuritogenesis Involving Neuregulin-1/ErbB4 Signaling. ACS Chemical Neuroscience, 2010, 1, 325-342.	1.7	5
757	Animal Models of Schizophrenia. Current Topics in Behavioral Neurosciences, 2010, 4, 391-433.	0.8	75
758	Behavioral Neurobiology of Schizophrenia and Its Treatment. Current Topics in Behavioral Neurosciences, 2010, , .	0.8	8
759	Transgenic and Mutant Tools to Model Brain Disorders. Neuromethods, 2010, , .	0.2	4

#	Article	IF	CITATIONS
760	The Neurodevelopmental Implications of PI3K Signaling. Current Topics in Microbiology and Immunology, 2010, 346, 245-265.	0.7	55
761	DISC1 in Schizophrenia: Genetic Mouse Models and Human Genomic Imaging. Schizophrenia Bulletin, 2011, 37, 14-20.	2.3	89
762	Plasticidad sináptica funcional y disfuncional en la corteza prefrontal: papel en los trastornos psiquiátricos. Psiquiatria Biologica, 2011, 18, 18-27.	0.0	3
763	Analyzing Schizophrenia by DNA Microarrays. Biological Psychiatry, 2011, 69, 157-162.	0.7	58
764	The Influence of Schizophrenia-Related Neuregulin-1 Polymorphisms on Sensorimotor Gating in Healthy Males. Biological Psychiatry, 2011, 69, 479-486.	0.7	58
765	Gating in Schizophrenia: From Genes to Cognition (to Real World Function?). Biological Psychiatry, 2011, 69, 395-396.	0.7	12
766	Convergence of Two Independent Mental Disease Genes on the Protein Level: Recruitment of Dysbindin to Cell-Invasive Disrupted-In-Schizophrenia 1 Aggresomes. Biological Psychiatry, 2011, 70, 604-610.	0.7	72
767	Schizophrenia: Treatment Targets Beyond Monoamine Systems. Annual Review of Pharmacology and Toxicology, 2011, 51, 189-209.	4.2	56
768	Expression of mutant human DISC1 in mice supports abnormalities in differentiation of oligodendrocytes. Schizophrenia Research, 2011, 130, 238-249.	1.1	37
769	Lack of association to a NRG1 missense polymorphism in schizophrenia or bipolar disorder in a Costa Rican population. Schizophrenia Research, 2011, 131, 52-57.	1.1	18
770	Phosphoinositide 3-kinase in Health and Disease. Current Topics in Microbiology and Immunology, 2011,	0.7	1
771	Neurogenesis in the Adult Brain II. , 2011, , .		3
772	TRP Channels and Psychiatric Disorders. Advances in Experimental Medicine and Biology, 2011, 704, 987-1009.	0.8	23
773	Translational Neuroscience of Schizophrenia: Seeking a Meeting of Minds Between Mouse and Man. Science Translational Medicine, 2011, 3, 102mr3.	5.8	18
775	Psychiatric Genetics and the Generation of Mutant Animal Models. Neuromethods, 2011, , 189-209.	0.2	0
776	Modeling Schizophrenia in Neuregulin 1 and ErbB4 Mutant Mice. Neuromethods, 2011, , 261-277.	0.2	Ο
777	Neuregulin signaling, cortical circuitry development and schizophrenia. Current Opinion in Genetics and Development, 2011, 21, 262-270.	1.5	80
778	Sex-specific neuroendocrine and behavioral phenotypes in hypomorphic Type II Neuregulin 1 rats. Behavioural Brain Research, 2011, 224, 223-232.	1.2	20

#	Article	IF	CITATIONS
779	The contribution of GABAergic dysfunction to neurodevelopmental disorders. Trends in Molecular Medicine, 2011, 17, 452-462.	3.5	130
780	The ERBB4 intracellular domain (4ICD) regulates NRG1-induced gene expression in hippocampal neurons. Neuroscience Research, 2011, 70, 155-163.	1.0	17
781	Zic2 hypomorphic mutant mice as a schizophrenia model and ZIC2 mutations identified in schizophrenia patients. Neuroscience Research, 2011, 71, e58.	1.0	0
782	Neuregulin-1β for the treatment of systolic heart failure. Journal of Molecular and Cellular Cardiology, 2011, 51, 501-505.	0.9	41
783	Linking oligodendrocyte and myelin dysfunction to neurocircuitry abnormalities in schizophrenia. Progress in Neurobiology, 2011, 93, 13-24.	2.8	263
784	Discovery and development of integrative biological markers for schizophrenia. Progress in Neurobiology, 2011, 95, 686-702.	2.8	28
785	Schizophrenia: susceptibility genes, dendritic-spine pathology and gray matter loss. Progress in Neurobiology, 2011, 95, 275-300.	2.8	113
786	Reciprocal signalling between NR2 subunits of the NMDA receptor and neuregulin1 and their role in schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 896-904.	2.5	36
787	Antipsychotic treatment and neuregulin 1–ErbB4 signalling in schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 924-930.	2.5	34
788	Biodistribution and brain permeability of the extracellular domain of neuregulin-1-β1. Neuropharmacology, 2011, 61, 1413-1418.	2.0	28
789	Behavioral analysis of NR2C knockout mouse reveals deficit in acquisition of conditioned fear and working memory. Neurobiology of Learning and Memory, 2011, 95, 404-414.	1.0	71
790	Concise Review: The Promise of Human Induced Pluripotent Stem Cell-Based Studies of Schizophrenia. Stem Cells, 2011, 29, 1915-1922.	1.4	73
791	Do transmembrane domain neuregulin 1 mutant mice exhibit a reliable sensorimotor gating deficit?. Behavioural Brain Research, 2011, 223, 336-341.	1.2	51
792	The role of the cerebellum in schizophrenia: from cognition to molecular pathways. Clinics, 2011, 66, 71-77.	0.6	91
794	Expression of ErbB4 in the neurons of Alzheimer's disease brain and APP/PS1 mice, a model of Alzheimer's disease. Anatomy and Cell Biology, 2011, 44, 116.	0.5	45
795	Type III Nrg1 Back Signaling Enhances Functional TRPV1 along Sensory Axons Contributing to Basal and Inflammatory Thermal Pain Sensation. PLoS ONE, 2011, 6, e25108.	1.1	12
796	Pallidal Hyperdopaminergic Innervation Underlying D2 Receptor-Dependent Behavioral Deficits in the Schizophrenia Animal Model Established by EGF. PLoS ONE, 2011, 6, e25831.	1.1	33
797	No NRG1 V266L in Chinese patients with schizophrenia. Psychiatric Genetics, 2011, 21, 47-49.	0.6	2

	CHANON	<b>LPORT</b>	
#	Article	IF	CITATIONS
798	Neuregulin1 as Novel Therapy for Heart Failure. Current Pharmaceutical Design, 2011, 17, 1808-1817.	0.9	20
799	The Role of Microbial Agents in the Etiology of Schizophrenia: An Infectious Hypothesis for Psychosis?. Current Immunology Reviews, 2011, 7, 57-63.	1.2	0
800	Genetic Animal Models of Schizophrenia Related with the Hypothesis of Abnormal Neurodevelopment. Biological and Pharmaceutical Bulletin, 2011, 34, 1358-1363.	0.6	20
803	Animal Model for Schizophrenia That Reflects Gene-Environment Interactions. Biological and Pharmaceutical Bulletin, 2011, 34, 1364-1368.	0.6	32
804	Animal models of schizophrenia. British Journal of Pharmacology, 2011, 164, 1162-1194.	2.7	613
805	Schizophrenia susceptibility pathway neuregulin 1–ErbB4 suppresses Src upregulation of NMDA receptors. Nature Medicine, 2011, 17, 470-478.	15.2	157
806	Transient exposure of neonatal mice to neuregulin-1 results in hyperdopaminergic states in adulthood: implication in neurodevelopmental hypothesis for schizophrenia. Molecular Psychiatry, 2011, 16, 307-320.	4.1	99
807	Neuregulin 3 (NRG3) as a susceptibility gene in a schizophrenia subtype with florid delusions and relatively spared cognition. Molecular Psychiatry, 2011, 16, 860-866.	4.1	65
808	Disruption of the neuregulin 1 gene in the rat alters HPA axis activity and behavioral responses to environmental stimuli. Physiology and Behavior, 2011, 104, 205-214.	1.0	36
809	Genetic variants in the ErbB4 gene are associated with white matter integrity. Psychiatry Research - Neuroimaging, 2011, 191, 133-137.	0.9	37
810	Analysis of the antibodies anti-Toxoplasma gondii by ELISA based on two diagnostic antigens: rSAG1 and rBAG1. Acta Parasitologica, 2011, 56, .	0.4	4
811	Clozapine and N-Methyl-d-Aspartate have positive modulatory actions on their respective discriminative stimulus properties in C57BL/6 mice. European Journal of Pharmacology, 2011, 650, 579-585.	1.7	2
812	Potential role of Neuregulin 1 and TNF-alpha (â^'308) polymorphism in schizophrenia patients visiting hospitals in Lahore, Pakistan. Molecular Biology Reports, 2011, 38, 4709-4714.	1.0	24
813	mGlu2/3 Agonists – a New Approach to the Treatment of Schizophrenia: Results of a Randomized Double-Blind Trial. Neuroscience and Behavioral Physiology, 2011, 41, 559-566.	0.2	1
814	Neurocognitive-genetic and neuroimaging-genetic research paradigms in schizophrenia and bipolar disorder. Journal of Neural Transmission, 2011, 118, 1621-1639.	1.4	26
815	An Update on the Epidemiology of Schizophrenia with a Special Reference to Clinically Important Risk Factors. International Journal of Mental Health and Addiction, 2011, 9, 39-59.	4.4	7
816	Linkage and association on 8p21.2-p21.1 in schizophrenia. , 2011, 156, 188-197.		26
817	A phenotypeâ€based genetic association study reveals the contribution of neuregulin1 gene variants to age of onset and positive symptom severity in schizophrenia. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2011, 156, 340-345.	1.1	15

		15	0
Ŧ	ARTICLE	IF	CITATIONS
818	Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2011, 156, 929-940.	1.1	14
819	Neuroplasticity signaling pathways linked to the pathophysiology of schizophrenia. Neuroscience and Biobehavioral Reviews, 2011, 35, 848-870.	2.9	147
820	The schizophrenia susceptibility gene neuregulin 1 modulates tolerance to the effects of cannabinoids. International Journal of Neuropsychopharmacology, 2011, 14, 631-643.	1.0	66
821	Neuregulin Receptor ErbB4 Functions as a Transcriptional Cofactor for the Expression of Surfactant Protein B in the Fetal Lung. American Journal of Respiratory Cell and Molecular Biology, 2011, 45, 761-767.	1.4	25
822	Disrupted Activity in the Hippocampal–Accumbens Circuit of Type III Neuregulin 1 Mutant Mice. Neuropsychopharmacology, 2011, 36, 488-496.	2.8	23
823	Analysis of 94 Candidate Genes and 12 Endophenotypes for Schizophrenia From the Consortium on the Genetics of Schizophrenia. American Journal of Psychiatry, 2011, 168, 930-946.	4.0	241
824	Therapeutic Interventions Targeting Beta Amyloid Pathogenesis in an Aging Dog Model. Current Neuropharmacology, 2011, 9, 651-661.	1.4	17
825	Susceptibility Genes for Schizophrenia: Mutant Models, Endophenotypes and Psychobiology. Current Topics in Behavioral Neurosciences, 2011, 12, 209-250.	0.8	5
826	Dysbindin-1 and NRG-1 gene expression in immortalized lymphocytes from patients with schizophrenia. Journal of Human Genetics, 2011, 56, 478-483.	1.1	27
827	Neuregulin 1 Promotes Excitatory Synapse Development and Function in GABAergic Interneurons. Journal of Neuroscience, 2011, 31, 15-25.	1.7	199
828	Diminished Cerebral Inhibition in Neonates Associated With Risk Factors for Schizophrenia: Parental Psychosis, Maternal Depression, and Nicotine Use. Schizophrenia Bulletin, 2011, 37, 1200-1208.	2.3	37
829	Specific Regulation of NRG1 Isoform Expression by Neuronal Activity. Journal of Neuroscience, 2011, 31, 8491-8501.	1.7	143
830	White Matter Abnormalities and Animal Models Examining a Putative Role of Altered White Matter in Schizophrenia. Schizophrenia Research and Treatment, 2011, 2011, 1-16.	0.7	16
831	Function of <i>ERBB4</i> is determined by alternative splicing. Cell Cycle, 2011, 10, 2647-2657.	1.3	95
832	Neuregulin-1 Signals from the Periphery Regulate AMPA Receptor Sensitivity and Expression in GABAergic Interneurons in Developing Neocortex. Journal of Neuroscience, 2011, 31, 5699-5709.	1.7	63
833	Progress in defining the biological causes of schizophrenia. Expert Reviews in Molecular Medicine, 2011, 13, e25.	1.6	29
834	Cleavage of Neuregulin-1 by BACE1 or ADAM10 Protein Produces Differential Effects on Myelination. Journal of Biological Chemistry, 2011, 286, 23967-23974.	1.6	101
835	Do COMT, BDNF and NRG1 polymorphisms influence P50 sensory gating in psychosis?. Psychological Medicine, 2011, 41, 263-276.	2.7	34

#	Article	IF	CITATIONS
836	Zic2 hypomorphic mutant mice as a schizophrenia model and ZIC2 mutations identified in schizophrenia patients. Scientific Reports, 2011, 1, 16.	1.6	19
837	The Relationship Among Neuregulin 1-Stimulated Phosphorylation of AKT, Psychosis Proneness, and Habituation of Arousal in Nonclinical Individuals. Schizophrenia Bulletin, 2011, 37, 141-147.	2.3	14
839	Increased expression of receptor phosphotyrosine phosphatase-î²/ζ is associated with molecular, cellular, behavioral and cognitive schizophrenia phenotypes. Translational Psychiatry, 2011, 1, e8-e8.	2.4	37
840	Behavioral and Molecular Biomarkers in Translational Animal Models for Neuropsychiatric Disorders. International Review of Neurobiology, 2011, 101, 203-238.	0.9	28
841	Molecular Genetic Models Related to Schizophrenia and Psychotic Illness: Heuristics and Challenges. Current Topics in Behavioral Neurosciences, 2011, 7, 87-119.	0.8	12
842	Genetics and Function of Neocortical GABAergic Interneurons in Neurodevelopmental Disorders. Neural Plasticity, 2011, 2011, 1-25.	1.0	181
843	Contribution of nonprimate animal models in understanding the etiology of schizophrenia. Journal of Psychiatry and Neuroscience, 2011, 36, E5-E29.	1.4	14
844	α1,6-Fucosyltransferase-deficient Mice Exhibit Multiple Behavioral Abnormalities Associated with a Schizophrenia-like Phenotype. Journal of Biological Chemistry, 2011, 286, 18434-18443.	1.6	70
845	Schizophrenia-Related Neuregulin-1 Single-Nucleotide Polymorphisms Lead to Deficient Smooth Eye Pursuit in a Large Sample of Young Men. Schizophrenia Bulletin, 2011, 37, 822-831.	2.3	16
846	Genome-Wide Copy Number Analysis Uncovers a New HSCR Gene: NRG3. PLoS Genetics, 2012, 8, e1002687.	1.5	51
847	Therapeutic Implications for Striatal-Enriched Protein Tyrosine Phosphatase (STEP) in Neuropsychiatric Disorders. Pharmacological Reviews, 2012, 64, 65-87.	7.1	152
848	Presenilins and Â-Secretase: Structure, Function, and Role in Alzheimer Disease. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a006304-a006304.	2.9	375
849	Can genetics inform the management of cognitive deficits in schizophrenia?. Journal of Psychopharmacology, 2012, 26, 334-348.	2.0	9
850	Transgenic Overexpression of the Type I Isoform of Neuregulin 1 Affects Working Memory and Hippocampal Oscillations but not Long-term Potentiation. Cerebral Cortex, 2012, 22, 1520-1529.	1.6	68
851	Genetic Architecture of Declarative Memory. Neuroscientist, 2012, 18, 516-532.	2.6	13
852	Glutamatergic Animal Models of Schizophrenia. Current Pharmaceutical Design, 2012, 18, 1593-1604.	0.9	33
853	Aggregated proteins in schizophrenia and other chronic mental diseases. Prion, 2012, 6, 134-141.	0.9	47
854	PI3Kδturns schizophrenic. Science-Business EXchange, 2012, 5, 718-718.	0.0	0

#	Article	IF	CITATIONS
855	The association of white matter volume in psychotic disorders with genotypic variation in NRG1, MOG and CNP: a voxel-based analysis in affected individuals and their unaffected relatives. Translational Psychiatry, 2012, 2, e167-e167.	2.4	53
856	The tyrosine phosphatase STEP: implications in schizophrenia and the molecular mechanism underlying antipsychotic medications. Translational Psychiatry, 2012, 2, e137-e137.	2.4	68
857	Genetic association of theEGR2gene with bipolar disorder in Korea. Experimental and Molecular Medicine, 2012, 44, 121.	3.2	10
858	Schizophrenia-associated HapICE haplotype is associated with increased NRG1 type III expression and high nucleotide diversity. Translational Psychiatry, 2012, 2, e104-e104.	2.4	70
859	The Importance of the NRG-1/ErbB4 Pathway for Synaptic Plasticity and Behaviors Associated with Psychiatric Disorders. Journal of Neuroscience, 2012, 32, 2988-2997.	1.7	157
860	Alzheimer's Therapeutics: Translation of Preclinical Science to Clinical Drug Development. Neuropsychopharmacology, 2012, 37, 261-277.	2.8	43
861	Is Neuregulin 1 Involved in Determining Cerebral Volumes in Schizophrenia Preliminary Results Showing a Decrease in Superior Temporal Gyrus Volume. Neuropsychobiology, 2012, 65, 119-125.	0.9	26
862	Effects of Antipsychotics on Dentate Gyrus Stem Cell Proliferation and Survival in Animal Models: A Critical Update. Neural Plasticity, 2012, 2012, 1-12.	1.0	12
863	The Yin and Yang of Cannabis-induced Psychosis: the Actions of Δ 9-Tetrahydrocannabinol and Cannabidiol in Rodent Models of Schizophrenia. Current Pharmaceutical Design, 2012, 18, 5113-5130.	0.9	42
864	Genetic Data Supporting the NMDA Clutamate Receptor Hypothesis for Schizophrenia. Current Pharmaceutical Design, 2012, 18, 1580-1592.	0.9	39
865	Current Progress in the Genetic Research of Schizophrenia: Relevance for Drug Discovery?. Current Pharmaceutical Biotechnology, 2012, 13, 1614-1621.	0.9	4
866	Clozapine induction of ERK1/2 cell signalling via the EGF receptor in mouse prefrontal cortex and striatum is distinct from other antipsychotic drugs. International Journal of Neuropsychopharmacology, 2012, 15, 1149-1160.	1.0	27
867	The Integration of the Glutamatergic and the White Matter Hypotheses of Schizophrenias Etiology. Current Neuropharmacology, 2012, 10, 2-11.	1.4	6
868	Molecular Genetics of the Psychosis Phenotype. Canadian Journal of Psychiatry, 2012, 57, 1-8.	0.9	0
869	Molecular Genetics of the Psychosis Phenotype. Canadian Journal of Psychiatry, 2012, 57, 446-453.	0.9	8
870	The genetics of bipolar disorder. , 0, , 196-211.		0
871	Glutamate Neurocircuitry: Theoretical Underpinnings in Schizophrenia. Frontiers in Pharmacology, 2012, 3, 195.	1.6	142
872	Using human induced pluripotent stem cells for modeling schizophrenia, a psychiatric disorder. Drug Discovery Today: Disease Models, 2012, 9, e179-e184.	1.2	1

#	Article	IF	CITATIONS
873	Essential Roles of Heparinâ€Binding Epidermal Growth Factorâ€Like Growth Factor in the Brain. CNS Neuroscience and Therapeutics, 2012, 18, 803-810.	1.9	49
874	Genetics of schizophrenia from a clinicial perspective. International Review of Psychiatry, 2012, 24, 393-404.	1.4	10
875	Reversal of Impaired Hippocampal Long-Term Potentiation and Contextual Fear Memory Deficits in Angelman Syndrome Model Mice by ErbB Inhibitors. Biological Psychiatry, 2012, 72, 182-190.	0.7	83
876	Effects of Amyloid-β Plaque Proximity on the Axon Initial Segment of Pyramidal Cells. Journal of Alzheimer's Disease, 2012, 29, 841-852.	1.2	27
877	The Long and the Short of it: Gene and Environment Interactions During Early Cortical Development and Consequences for Long-Term Neurological Disease. Frontiers in Psychiatry, 2012, 3, 50.	1.3	50
878	Evaluating the links between schizophrenia and sleep and circadian rhythm disruption. Journal of Neural Transmission, 2012, 119, 1061-1075.	1.4	92
879	The involvement of Type II Neuregulin-1 in rat visuospatial learning and memory. Neuroscience Letters, 2012, 531, 131-135.	1.0	8
880	Bipolar disorder. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2012, 106, 251-263.	1.0	12
881	Neuregulin repellent signaling via ErbB4 restricts GABAergic interneurons to migratory paths from ganglionic eminence to cortical destinations. Neural Development, 2012, 7, 10.	1.1	59
882	Mouse models of genetic effects on cognition: Relevance to schizophrenia. Neuropharmacology, 2012, 62, 1204-1220.	2.0	102
883	Avoiding mouse traps in schizophrenia genetics: lessons and promises from current and emerging mouse models. Neuroscience, 2012, 211, 136-164.	1.1	37
884	Processing of Neuregulin-1 by Neuropsin Regulates GABAergic Neuron to Control Neural Plasticity of the Mouse Hippocampus. Journal of Neuroscience, 2012, 32, 12657-12672.	1.7	59
885	The response of neuregulin 1 mutant mice to acute restraint stress. Neuroscience Letters, 2012, 515, 82-86.	1.0	22
886	Phenotypic effects of repeated psychosocial stress during adolescence in mice mutant for the schizophrenia risk gene neuregulin-1: A putative model of gene × environment interaction. Brain, Behavior, and Immunity, 2012, 26, 660-671.	2.0	76
887	Cognition in female transmembrane domain neuregulin 1 mutant mice. Behavioural Brain Research, 2012, 226, 218-223.	1.2	49
888	Missense substitutions associated with behavioural disturbances in Alzheimer's disease (AD). Brain Research Bulletin, 2012, 88, 394-405.	1.4	6
889	Comprehensive behavioral analysis of ENU-induced Disc1-Q31L and -L100P mutant mice. BMC Research Notes, 2012, 5, 108.	0.6	37
890	Convergent functional genomics of schizophrenia: from comprehensive understanding to genetic risk prediction. Molecular Psychiatry, 2012, 17, 887-905.	4.1	355

#	Article	IF	CITATIONS
891	Neurons on the Move: Migration and Lamination of Cortical Interneurons. NeuroSignals, 2012, 20, 168-189.	0.5	67
892	Tumour necrosis factor - alpha mediated mechanisms of cognitive dysfunction. Translational Neuroscience, 2012, 3, .	0.7	40
893	Investigation of the Possible Role of TRP Channels in Schizophrenia. Methods in Pharmacology and Toxicology, 2012, , 141-151.	0.1	0
894	Animal Models of Schizophrenia. Progress in Molecular Biology and Translational Science, 2012, 105, 411-444.	0.9	10
895	Interaction networks of lithium and valproate molecular targets reveal a striking enrichment of apoptosis functional clusters and neurotrophin signaling. Pharmacogenomics Journal, 2012, 12, 328-341.	0.9	36
896	Neuregulin-1 genotype is associated with structural differences in the normal human brain. NeuroImage, 2012, 59, 2057-2061.	2.1	30
897	Brain connectivity in psychiatric imaging genetics. NeuroImage, 2012, 62, 2250-2260.	2.1	62
898	Neonatal domoic acid treatment produces alterations to prepulse inhibition and latent inhibition in adult rats. Pharmacology Biochemistry and Behavior, 2012, 103, 338-344.	1.3	20
899	Copy number variations in neurodevelopmental disorders. Progress in Neurobiology, 2012, 99, 81-91.	2.8	150
900	Adolescent neuregulin 1 heterozygous mice display enhanced behavioural sensitivity to methamphetamine. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2012, 39, 376-381.	2.5	10
900 901	Adolescent neuregulin 1 heterozygous mice display enhanced behavioural sensitivity to methamphetamine. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2012, 39, 376-381. Association between schizophrenia and genetic variation in DCC: A case–control study. Schizophrenia Research, 2012, 137, 26-31.	2.5	<b>10</b> 53
900 901 902	Adolescent neuregulin 1 heterozygous mice display enhanced behavioural sensitivity to         methamphetamine. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2012, 39, 376-381.         Association between schizophrenia and genetic variation in DCC: A case–control study. Schizophrenia Research, 2012, 137, 26-31.         Reliable Biomarkers and Predictors of Schizophrenia and its Treatment. Psychiatric Clinics of North America, 2012, 35, 645-659.	2.5 1.1 0.7	10 53 29
900 901 902 903	Adolescent neuregulin 1 heterozygous mice display enhanced behavioural sensitivity to methamphetamine. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2012, 39, 376-381.Association between schizophrenia and genetic variation in DCC: A case–control study. Schizophrenia Research, 2012, 137, 26-31.Reliable Biomarkers and Predictors of Schizophrenia and its Treatment. Psychiatric Clinics of North America, 2012, 35, 645-659.Reduced Levels of Serotonin 2A Receptors Underlie Resistance of Egr3-Deficient Mice to Locomotor Suppression by Clozapine. Neuropsychopharmacology, 2012, 37, 2285-2298.	2.5 1.1 0.7 2.8	10 53 29 37
900 901 902 903 904	Adolescent neuregulin 1 heterozygous mice display enhanced behavioural sensitivity to methamphetamine. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2012, 39, 376-381.Association between schizophrenia and genetic variation in DCC: A case–control study. Schizophrenia Research, 2012, 137, 26-31.Reliable Biomarkers and Predictors of Schizophrenia and its Treatment. Psychiatric Clinics of North America, 2012, 35, 645-659.Reduced Levels of Serotonin 2A Receptors Underlie Resistance of Egr3-Deficient Mice to Locomotor Suppression by Clozapine. Neuropsychopharmacology, 2012, 37, 2285-2298.Functional Diversity of Actin Cytoskeleton in Neurons and its Regulation by Tropomyosin. International Review of Cell and Molecular Biology, 2012, 298, 33-94.	2.5 1.1 0.7 2.8 1.6	10 53 29 37 25
900 901 902 903 904	Adolescent neuregulin 1 heterozygous mice display enhanced behavioural sensitivity to methamphetamine. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2012, 39, 376-381.Association between schizophrenia and genetic variation in DCC: A case–control study. Schizophrenia Research, 2012, 137, 26-31.Reliable Biomarkers and Predictors of Schizophrenia and its Treatment. Psychiatric Clinics of North America, 2012, 35, 645-659.Reduced Levels of Serotonin 2A Receptors Underlie Resistance of Egr3-Deficient Mice to Locomotor Suppression by Clozapine. Neuropsychopharmacology, 2012, 37, 2285-2298.Functional Diversity of Actin Cytoskeleton in Neurons and its Regulation by Tropomyosin. International Review of Cell and Molecular Biology, 2012, 298, 33-94.Statistical epistasis and progressive brain change in schizophrenia: an approach for examining the relationships between multiple genes. Molecular Psychiatry, 2012, 17, 1093-1102.	2.5 1.1 0.7 2.8 1.6 4.1	10         53         29         37         25         23
<ul> <li>900</li> <li>901</li> <li>902</li> <li>903</li> <li>904</li> <li>905</li> <li>906</li> </ul>	Adolescent neuregulin 1 heterozygous mice display enhanced behavioural sensitivity to         methamphetamine. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2012, 39, 376-381.         Association between schizophrenia and genetic variation in DCC: A case–control study. Schizophrenia         Reliable Biomarkers and Predictors of Schizophrenia and its Treatment. Psychiatric Clinics of North         America, 2012, 35, 645-659.         Reduced Levels of Serotonin 2A Receptors Underlie Resistance of Egr3-Deficient Mice to Locomotor         Suppression by Clozapine. Neuropsychopharmacology, 2012, 37, 2285-2298.         Functional Diversity of Actin Cytoskeleton in Neurons and its Regulation by Tropomyosin.         International Review of Cell and Molecular Biology, 2012, 298, 33-94.         Statistical epistasis and progressive brain change in schizophrenia: an approach for examining the relationships between multiple genes. Molecular Psychiatry, 2012, 17, 1093-1102.         Discovery of common variants associated with low TSH levels and thyroid cancer risk. Nature Genetics, 2012, 44, 319-322.	2.5 1.1 0.7 2.8 1.6 4.1 9.4	<ol> <li>10</li> <li>53</li> <li>29</li> <li>37</li> <li>25</li> <li>23</li> <li>208</li> </ol>
<ul> <li>900</li> <li>901</li> <li>902</li> <li>903</li> <li>903</li> <li>903</li> <li>903</li> <li>903</li> <li>904</li> <li>905</li> <li>905</li> <li>905</li> <li>907</li> </ul>	Adolescent neuregulin 1 heterozygous mice display enhanced behavioural sensitivity to methamphetamine. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2012, 39, 376-381.Association between schizophrenia and genetic variation in DCC: A caseâ€" control study. Schizophrenia Research, 2012, 137, 26-31.Reliable Biomarkers and Predictors of Schizophrenia and its Treatment. Psychiatric Clinics of North America, 2012, 35, 645-659.Reduced Levels of Serotonin 2A Receptors Underlie Resistance of Egr3-Deficient Mice to Locomotor Suppression by Clozapine. Neuropsychopharmacology, 2012, 37, 2285-2298.Functional Diversity of Actin Cytoskeleton in Neurons and its Regulation by Tropomyosin. International Review of Cell and Molecular Biology, 2012, 298, 33-94.Statistical epistasis and progressive brain change in schizophrenia: an approach for examining the relationships between multiple genes. Molecular Psychiatry, 2012, 17, 1093-1102.Discovery of common variants associated with low TSH levels and thyroid cancer risk. Nature Cenetics, 2012, 44, 319-322.Mutant Mouse Models in Evaluating Novel Approaches to Antipsychotic Treatment. Handbook of Experimental Pharmacology, 2012, , 113-145.	2.5 1.1 0.7 2.8 1.6 4.1 9.4 0.9	10         53         29         37         25         23         208         8

#	Article	IF	CITATIONS
909	Fronto-temporal-mesolimbic gene expression and heritable differences in amphetamine-disrupted sensorimotor gating in rats. Psychopharmacology, 2012, 224, 349-362.	1.5	21
910	Hypothesis review: are clathrin-mediated endocytosis and clathrin-dependent membrane and protein trafficking core pathophysiological processes in schizophrenia and bipolar disorder?. Molecular Psychiatry, 2012, 17, 669-681.	4.1	78
911	Human genetics of schizophrenia. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2012, 106, 37-52.	1.0	4
912	Genome-Wide Association Study of Treatment Refractory Schizophrenia in Han Chinese. PLoS ONE, 2012, 7, e33598.	1.1	55
913	Distinct Neurobehavioural Effects of Cannabidiol in Transmembrane Domain Neuregulin 1 Mutant Mice. PLoS ONE, 2012, 7, e34129.	1.1	80
914	Comprehensive Analysis of NRG1 Common and Rare Variants in Hirschsprung Patients. PLoS ONE, 2012, 7, e36524.	1.1	36
915	Identification of Sialyltransferase 8B as a Generalized Susceptibility Gene for Psychotic and Mood Disorders on Chromosome 15q25-26. PLoS ONE, 2012, 7, e38172.	1.1	60
916	The Membrane-Bound Aspartyl Protease BACE1: Molecular and Functional Properties in Alzheimer's Disease and Beyond. Frontiers in Physiology, 2012, 3, 8.	1.3	69
917	Neuregulin1-ErbB Signaling in Doxorubicin-Induced Cardiotoxicity. , 2012, , .		0
918	Clinical applications of schizophrenia genetics: genetic diagnosis, risk, and counseling in the molecular era. The Application of Clinical Genetics, 2012, 5, 1.	1.4	35
919	The genetics of schizophrenia. , 0, , 230-261.		1
920	Association between a Missense Polymorphism (rs3924999, Arg253Gln) of Neuregulin 1 and Schizophrenia in Korean Population. Experimental Neurobiology, 2012, 21, 158-163.	0.7	2
921	Neuregulin and dopamine modulation of hippocampal gamma oscillations is dependent on dopamine D4 receptors. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 13118-13123.	3.3	82
922	Finding a druggable target for schizophrenia. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 11902-11903.	3.3	11
923	Modeling psychiatric disorders at the cellular and network levels. Molecular Psychiatry, 2012, 17, 1239-1253.	4.1	108
924	Neuregulin 1-ErbB4-PI3K signaling in schizophrenia and phosphoinositide 3-kinase-p110δ inhibition as a potential therapeutic strategy. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 12165-12170.	3.3	127
925	Synaptic Dysfunction in Schizophrenia. Advances in Experimental Medicine and Biology, 2012, 970, 493-516.	0.8	67
926	Association study of neuregulin 1 gene polymorphisms with auditory p300 in schizophrenia. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2012, 159B, 422-428.	1.1	17

#	Article	IF	CITATIONS
927	Advancing schizophrenia drug discovery: optimizing rodent models to bridge the translational gap. Nature Reviews Drug Discovery, 2012, 11, 560-579.	21.5	154
928	Schizophrenia Genetics: Putting All the Pieces Together. Current Neurology and Neuroscience Reports, 2012, 12, 261-266.	2.0	37
929	Physiological functions of the amyloid precursor protein secretases ADAM10, BACE1, and Presenilin. Experimental Brain Research, 2012, 217, 331-341.	0.7	52
930	Annual Research Review: Impact of advances in genetics in understanding developmental psychopathology. Journal of Child Psychology and Psychiatry and Allied Disciplines, 2012, 53, 510-518.	3.1	32
931	A critical role for NMDA receptors in parvalbumin interneurons for gamma rhythm induction and behavior. Molecular Psychiatry, 2012, 17, 537-548.	4.1	551
932	Control of interneuron dendritic growth through NRG1/erbB4-mediated kalirin-7 disinhibition. Molecular Psychiatry, 2012, 17, 99-107.	4.1	49
933	Genetic susceptibility to periodontitis. Periodontology 2000, 2012, 58, 37-68.	6.3	218
934	Neuregulin-1/ErbB4 signaling controls the migration of oligodendrocyte precursor cells during development. Experimental Neurology, 2012, 235, 610-620.	2.0	42
935	Family-based association study of early growth response gene 3 with child bipolar I disorder. Journal of Affective Disorders, 2012, 138, 387-396.	2.0	17
936	Targeting glutamate system for novel antipsychotic approaches: Relevance for residual psychotic symptoms and treatment resistant schizophrenia. European Journal of Pharmacology, 2012, 682, 1-11.	1.7	60
937	Genetic association analysis of ERBB4 polymorphisms with the risk of schizophrenia and SPEM abnormality in a Korean population. Brain Research, 2012, 1466, 146-151.	1.1	12
938	Mitochondria, oligodendrocytes and inflammation in bipolar disorder: Evidence from transcriptome studies points to intriguing parallels with multiple sclerosis. Neurobiology of Disease, 2012, 45, 37-47.	2.1	130
939	Glutamate signaling in the pathophysiology and therapy of schizophrenia. Pharmacology Biochemistry and Behavior, 2012, 100, 665-677.	1.3	132
940	A Model of Neuregulin Control of NMDA Receptors on Synaptic Spines. Bulletin of Mathematical Biology, 2012, 74, 717-735.	0.9	5
941	Lack of Associations of Neuregulin 1 Variations with Schizophrenia and Smooth Pursuit Eye Movement Abnormality in a Korean Population. Journal of Molecular Neuroscience, 2012, 46, 476-482.	1.1	10
942	Association study of the KCNJ3 gene as a susceptibility candidate for schizophrenia in the Chinese population. Human Genetics, 2012, 131, 443-451.	1.8	48
943	Perinatal phencyclidine administration decreases the density of cortical interneurons and increases the expression of neuregulin-1. Psychopharmacology, 2013, 227, 673-683.	1.5	19
944	Neuregulin-1 signalling and antipsychotic treatment. Psychopharmacology, 2013, 226, 201-215.	1.5	50

#	Article	IF	CITATIONS
945	Sleep and Circadian Rhythm Disruption in Social Jetlag and Mental Illness. Progress in Molecular Biology and Translational Science, 2013, 119, 325-346.	0.9	168
946	Mouse models of gene–environment interactions in schizophrenia. Neurobiology of Disease, 2013, 57, 5-11.	2.1	50
947	Personalized medicine in psychiatry: problems and promises. BMC Medicine, 2013, 11, 132.	2.3	192
948	A neuregulin 1 transmembrane domain mutation causes imbalanced glutamatergic and dopaminergic receptor expression in mice. Neuroscience, 2013, 248, 670-680.	1.1	34
949	Signaling mechanisms regulating myelination in the central nervous system. Neuroscience Bulletin, 2013, 29, 199-215.	1.5	29
951	A common missense variant in the neuregulin 1 gene is associated with both schizophrenia and sudden cardiac death. Heart Rhythm, 2013, 10, 994-998.	0.3	29
952	A new single gene deletion on 2q34: <i>ERBB4</i> is associated with intellectual disability. American Journal of Medical Genetics, Part A, 2013, 161, 1487-1490.	0.7	26
953	Neuregulin 1-Î <sup>2</sup> regulates cell adhesion molecule L1 expression in the cortex and hippocampus of mice. Biochemical and Biophysical Research Communications, 2013, 441, 7-12.	1.0	8
954	Evaluating the role of the alpha-7 nicotinic acetylcholine receptor in the pathophysiology and treatment of schizophrenia. Biochemical Pharmacology, 2013, 86, 1122-1132.	2.0	112
955	Modeling Schizophrenia in Animals. , 2013, , 727-755.		6
955 956	Modeling Schizophrenia in Animals. , 2013, , 727-755. Postmortem analysis of cardiovascular deaths in schizophrenia: A 10-year review. Schizophrenia Research, 2013, 150, 398-403.	1.1	6 40
955 956 957	Modeling Schizophrenia in Animals. , 2013, , 727-755.         Postmortem analysis of cardiovascular deaths in schizophrenia: A 10-year review. Schizophrenia Research, 2013, 150, 398-403.         Erbb4 Deletion from Fast-Spiking Interneurons Causes Schizophrenia-like Phenotypes. Neuron, 2013, 79, 1152-1168.	1.1 3.8	6 40 254
955 956 957 958	Modeling Schizophrenia in Animals., 2013,, 727-755.         Postmortem analysis of cardiovascular deaths in schizophrenia: A 10-year review. Schizophrenia Research, 2013, 150, 398-403.         Erbb4 Deletion from Fast-Spiking Interneurons Causes Schizophrenia-like Phenotypes. Neuron, 2013, 79, 1152-1168.         Reversing hypomyelination in BACE1â€null mice with Aktâ€DD overexpression. FASEB Journal, 2013, 27, 1868-1873.	1.1 3.8 0.2	6 40 254 14
955 956 957 958	Modeling Schizophrenia in Animals. , 2013, , 727-755.         Postmortem analysis of cardiovascular deaths in schizophrenia: A 10-year review. Schizophrenia Research, 2013, 150, 398-403.         Erbb4 Deletion from Fast-Spiking Interneurons Causes Schizophrenia-like Phenotypes. Neuron, 2013, 79, 1152-1168.         Reversing hypomyelination in BACE1â€null mice with Aktâ€DD overexpression. FASEB Journal, 2013, 27, 1868-1873.         Neuregulin1 signaling promotes dendritic spine growth through kalirin. Journal of Neurochemistry, 2013, 126, 625-635.	1.1 3.8 0.2 2.1	6 40 254 14 33
955 956 957 958 959	Modeling Schizophrenia in Animals., 2013,, 727-755.         Postmortem analysis of cardiovascular deaths in schizophrenia: A 10-year review. Schizophrenia Research, 2013, 150, 398-403.         Erbb4 Deletion from Fast-Spiking Interneurons Causes Schizophrenia-like Phenotypes. Neuron, 2013, 79, 1152-1168.         Reversing hypomyelination in BACE1â€null mice with Aktâ€DD overexpression. FASEB Journal, 2013, 27, 1868-1873.         Neuregulin1 signaling promotes dendritic spine growth through kalirin. Journal of Neurochemistry, 2013, 126, 625-635.         A New Beginning for a Broken Mind: Balancing Neuregulin 1 Reverses Synaptic Dysfunction. Neuron, 2013, 78, 577-579.	1.1 3.8 0.2 2.1 3.8	6 40 254 14 33
955 956 957 958 959 960	Modeling Schizophrenia in Animals. , 2013, , 727-755.         Postmortem analysis of cardiovascular deaths in schizophrenia: A 10-year review. Schizophrenia Research, 2013, 150, 398-403.         Erbb4 Deletion from Fast-Spiking Interneurons Causes Schizophrenia-like Phenotypes. Neuron, 2013, 79, 1152-1168.         Reversing hypomyelination in BACE1â€null mice with Aktâ€DD overexpression. FASEB Journal, 2013, 27, 1868-1873.         Neuregulin1 signaling promotes dendritic spine growth through kalirin. Journal of Neurochemistry, 2013, 126, 625-635.         A New Beginning for a Broken Mind: Balancing Neuregulin 1 Reverses Synaptic Dysfunction. Neuron, 2013, 78, 577-579.         Gene expression of glutamate transporters SLC1A1, SLC1A3 and SLC1A6 in the cerebellar subregions of elderly schizophrenia patients and effects of antipsychotic treatment. World Journal of Biological Psychiatry, 2013, 14, 490-499.	1.1 3.8 0.2 2.1 3.8 1.3	6 40 254 14 33 5
955 956 957 958 959 960 961	Modeling Schizophrenia in Animals. , 2013, , 727-755.         Postmortem analysis of cardiovascular deaths in schizophrenia: A 10-year review. Schizophrenia         Research, 2013, 150, 398-403.         Erbb4 Deletion from Fast-Spiking Interneurons Causes Schizophrenia-like Phenotypes. Neuron, 2013, 79, 1152-1168.         Reversing hypomyelination in BACE1â€null mice with Aktâ€DD overexpression. FASEB Journal, 2013, 27, 1868-1873.         Neuregulin1 signaling promotes dendritic spine growth through kalirin. Journal of Neurochemistry, 2013, 126, 625-635.         A New Beginning for a Broken Mind: Balancing Neuregulin 1 Reverses Synaptic Dysfunction. Neuron, 2013, 78, 577-579.         Gene expression of glutamate transporters SLC1A1, SLC1A3 and SLC1A6 in the cerebellar subregions of elderly schizophrenia patients and effects of antipsychotic treatment. World Journal of Biological Psychiatry, 2013, 14, 490-499.         Losing your inhibition: Linking cortical GABAergic interneurons to schizophrenia. Neurobiology of Disease, 2013, 53, 36-48.	1.1 3.8 0.2 2.1 3.8 1.3 2.1	6 40 254 14 33 5 5 15 97

#	Article	IF	CITATIONS
964	Coupling of gene expression in medial prefrontal cortex and nucleus accumbens after neonatal ventral hippocampal lesions accompanies deficits in sensorimotor gating and auditory processing in rats. Neuropharmacology, 2013, 75, 38-46.	2.0	16
965	White matter integrity as an intermediate phenotype: Exploratory genome-wide association analysis in individuals at high risk of bipolar disorder. Psychiatry Research, 2013, 206, 223-231.	1.7	54
966	Association study of Neuregulin-1 gene polymorphisms in a north Indian schizophrenia sample. Schizophrenia Research, 2013, 144, 24-30.	1.1	36
967	Forebrain gene expression predicts deficits in sensorimotor gating after isolation rearing in male rats. Behavioural Brain Research, 2013, 257, 118-128.	1.2	16
969	The interaction of disrupted Type II Neuregulin 1 and chronic adolescent stress on adult anxiety- and fear-related behaviors. Neuroscience, 2013, 249, 31-42.	1.1	32
970	Hypomethylation of neuregulin in rats selectively bred for reduced sensorimotor gating. Schizophrenia Research, 2013, 150, 262-265.	1.1	14
971	P.6.d.001 Inhibition-specific prefrontal connectivity after an acute dose of heroin. European Neuropsychopharmacology, 2013, 23, S573-S574.	0.3	0
972	Neuregulin-1 (NRC-1) and its susceptibility to schizophrenia: a case–control study and meta-analysis. Psychiatry Research, 2013, 208, 186-188.	1.7	12
973	An updated overview of animal models in neuropsychiatry. Neuroscience, 2013, 240, 204-218.	1.1	36
974	Psychiatric disorderâ€related abnormal behavior and habenulointerpeduncular pathway defects in Wnt1â€cre and Wnt1â€GAL4 double transgenic mice. Journal of Neurochemistry, 2013, 124, 241-249.	2.1	10
975	GABAergic Interneurons Shape the Functional Maturation of the Cortex. Neuron, 2013, 77, 388-405.	3.8	367
976	Roles of glial cells in schizophrenia: Possible targets for therapeutic approaches. Neurobiology of Disease, 2013, 53, 49-60.	2.1	59
977	Progress in imaging the effects of psychosis susceptibility gene variants. Expert Review of Neurotherapeutics, 2013, 13, 37-47.	1.4	7
978	Animal models of schizophrenia for molecular and pharmacological intervention and potential candidate molecules. Neurobiology of Disease, 2013, 53, 61-74.	2.1	29
979	Genetic models of schizophrenia and related psychotic disorders: progress and pitfalls across the methodological "minefield― Cell and Tissue Research, 2013, 354, 247-257.	1.5	10
980	Reversal of Behavioral Deficits and Synaptic Dysfunction in Mice Overexpressing Neuregulin 1. Neuron, 2013, 78, 644-657.	3.8	111
981	ErbB1-4-dependent EGF/neuregulin signals and their cross talk in the central nervous system: pathological implications in schizophrenia and Parkinson's disease. Frontiers in Cellular Neuroscience, 2013, 7, 4.	1.8	101
982	New Animal Models of Progressive Neurodegeneration: Tools for Developing Predictive Diagnostics and Identifying Presymptomatic Therapeutic Targets. Advances in Predictive, Preventive and Personalised Medicine, 2013, , 45-68.	0.6	1

		CITATION REPORT		
#	Article		IF	CITATIONS
983	Editorsâ $\in$ <sup>TM</sup> Pick: mad and genius in the same gene?. Investigative Genetics, 2013, 4, 1	4.	3.3	1
984	Multiple variants aggregate in the neuregulin signaling pathway in a subset of schizopl Translational Psychiatry, 2013, 3, e264-e264.	nrenia patients.	2.4	37
985	Oligodendrocyte Genes, White Matter Tract Integrity, and Cognition in Schizophrenia. Cortex, 2013, 23, 2044-2057.	Cerebral	1.6	69
986	Schizophrenia Candidate Gene ERBB4: Covert Routes of Vulnerability to Psychosis Det Population Level. Schizophrenia Bulletin, 2013, 39, 349-357.	ected at the	2.3	15
987	Type III Neuregulin 1 Is Required for Multiple Forms of Excitatory Synaptic Plasticity of Cortico-Amygdala Circuits. Journal of Neuroscience, 2013, 33, 9655-9666.	Mouse	1.7	38
989	Brain vs Behavior: An Effect Size Comparison of Neuroimaging and Cognitive Studies o for Schizophrenia. Schizophrenia Bulletin, 2013, 39, 518-526.	f Genetic Risk	2.3	83
990	Neuregulin and BDNF Induce a Switch to NMDA Receptor-Dependent Myelination by O PLoS Biology, 2013, 11, e1001743.	lligodendrocytes.	2.6	264
991	Female Neuregulin 1 Heterozygous Mice Require Repeated Exposure to Δ9-Tetrahydro Sensorimotor Gating Function. Pharmacopsychiatry, 2013, 46, 286-291.	cannabinol to Alter	1.7	4
992	Bace1 and Neuregulin-1 cooperate to control formation and maintenance of muscle sp Journal, 2013, 32, 2015-2028.	pindles. EMBO	3.5	122
994	DISC1. Neuroscientist, 2013, 19, 451-464.		2.6	35
995	Developmental vulnerability of synapses and circuits associated with neuropsychiatric Journal of Neurochemistry, 2013, 126, 165-182.	disorders.	2.1	106
996	Deletion at the SLC1A1 glutamate transporter gene coâ€segregates with schizophreni schizoaffective disorder in a 5â€generation family. American Journal of Medical Genetic Neuropsychiatric Genetics, 2013, 162, 87-95.	a and bipolar cs Part B:	1.1	36
997	Regulation of Spine Formation by ErbB4 in PV-Positive Interneurons. Journal of Neuroso 19295-19303.	sience, 2013, 33,	1.7	58
998	Effects of NRG1 and DAOA genetic variation on transition to psychosis in individuals at for psychosis. Translational Psychiatry, 2013, 3, e251-e251.	t ultra-high risk	2.4	31
999	ErbB inhibitors ameliorate behavioral impairments of an animal model for schizophrenia of their dopamine-modulatory actions. Translational Psychiatry, 2013, 3, e252-e252.	a: implication	2.4	23
1000	Transmembrane domain Nrg1 mutant mice show altered susceptibility to the neurobel of repeated THC exposure in adolescence. International Journal of Neuropsychopharma 16, 163-175.	navioural actions acology, 2013,	1.0	69
1001	Genetics of Schizophrenia. International Journal of Mental Health, 2013, 42, 5-22.		0.5	4
1002	Neuregulins 2013 1633-1638.			3

#	Article	IF	CITATIONS
1003	Spine Homeostasis as a Novel Therapeutic Target for Schizophrenia. Clinical Pharmacology & Biopharmaceutics, 2013, S1, .	0.2	1
1004	Estudos traducionais de neuropsiquiatria e esquizofrenia: modelos animais genéticos e de neurodesenvolvimento. Revista De Psiquiatria Clinica, 2013, 40, 41-50.	0.6	5
1005	The Neuroimmunology of Schizophrenia. Clinical Psychopharmacology and Neuroscience, 2013, 11, 107-117.	0.9	58
1006	Discovery, Validation and Characterization of Erbb4 and Nrg1 Haplotypes Using Data from Three Genome-Wide Association Studies of Schizophrenia. PLoS ONE, 2013, 8, e53042.	1.1	42
1007	Cortical Surface Area Correlates with STON2 Gene Ser307Pro Polymorphism in First-Episode Treatment-NaÃ <sup>-</sup> ve Patients with Schizophrenia. PLoS ONE, 2013, 8, e64090.	1.1	6
1008	Neuregulin 1: a prime candidate for research into gene-environment interactions in schizophrenia? Insights from genetic rodent models. Frontiers in Behavioral Neuroscience, 2013, 7, 106.	1.0	33
1009	Novel molecular changes induced by Nrg1 hypomorphism and Nrg1-cannabinoid interaction in adolescence: a hippocampal proteomic study in mice. Frontiers in Cellular Neuroscience, 2013, 7, 15.	1.8	31
1010	What does a mouse tell us about neuregulin 1—cannabis interactions?. Frontiers in Cellular Neuroscience, 2013, 7, 18.	1.8	15
1011	Impact of structural aberrancy of polysialic acid and its synthetic enzyme ST8SIA2 in schizophrenia. Frontiers in Cellular Neuroscience, 2013, 7, 61.	1.8	46
1012	Production and organization of neocortical interneurons. Frontiers in Cellular Neuroscience, 2013, 7, 221.	1.8	71
1013	Reward learning as a potential target for pharmacological augmentation of cognitive remediation for schizophrenia: a roadmap for preclinical development. Frontiers in Neuroscience, 2013, 7, 103.	1.4	23
1014	Perinatal complications and schizophrenia: involvement of the immune system. Frontiers in Neuroscience, 2013, 7, 110.	1.4	27
1015	Autoimmune Disorders. , 2013, , 822-838.		5
1016	Neuropathologic Implication of Peripheral Neuregulin-1 and EGF Signals in Dopaminergic Dysfunction and Behavioral Deficits Relevant to Schizophrenia: Their Target Cells and Time Window. BioMed Research International, 2014, 2014, 1-12.	0.9	28
1017	Distinct phenotypes of new transmembrane-domain neuregulin 1 mutant mice and the rescue effects of valproate on the observed schizophrenia-related cognitive deficits. Frontiers in Behavioral Neuroscience, 2014, 8, 126.	1.0	21
1018	Partial genetic deletion of neuregulin 1 and adolescent stress interact to alter NMDA receptor binding in the medial prefrontal cortex. Frontiers in Behavioral Neuroscience, 2014, 8, 298.	1.0	15
1019	Schizophrenia: susceptibility genes and oligodendroglial and myelin related abnormalities. Frontiers in Cellular Neuroscience, 2014, 8, 5.	1.8	78
1020	Neuron-specific regulation of class I PI3K catalytic subunits and their dysfunction in brain disorders. Frontiers in Molecular Neuroscience, 2014, 7, 12.	1.4	47

	CITATION	REPORT	
#	Article	IF	CITATIONS
1021	Synaptic plasticity, neural circuits, and the emerging role of altered short-term information processing in schizophrenia. Frontiers in Synaptic Neuroscience, 2014, 6, 28.	1.3	85
1022	Schizophrenia-risk variant rs6994992 in the neuregulin-1 gene on brain developmental trajectories in typically developing children. Translational Psychiatry, 2014, 4, e392-e392.	2.4	9
1023	Classic Selective Sweeps Revealed by Massive Sequencing in Cattle. PLoS Genetics, 2014, 10, e1004148.	1.5	254
1025	Gone to Pot ââ,¬â€œ A Review of the Association between Cannabis and Psychosis. Frontiers in Psychiatry, 2014, 5, 54.	1.3	235
1026	Signalling between microvascular endothelium and cardiomyocytes through neuregulin. Cardiovascular Research, 2014, 102, 194-204.	1.8	62
1027	Striatal Response to Reward Anticipation. JAMA Psychiatry, 2014, 71, 531.	6.0	96
1028	Effects of neuregulinâ€1 genetic variation and depression symptom severity on longitudinal patterns of psychotic symptoms in primary care attendees. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2014, 165, 62-67.	1.1	8
1029	Ablation of ErbB4 from excitatory neurons leads to reduced dendritic spine density in mouse prefrontal cortex. Journal of Comparative Neurology, 2014, 522, 3351-3362.	0.9	25
1030	A <scp>N</scp> euregulinâ€1 schizophrenia susceptibility variant causes perihippocampal fiber tract anomalies in healthy young subjects. Brain and Behavior, 2014, 4, 215-226.	1.0	13
1032	Do individually ventilated cage systems generate a problem for genetic mouse model research?. Genes, Brain and Behavior, 2014, 13, 713-720.	1.1	23
1033	New approaches to the management of schizophrenia: focus on aberrant hippocampal drive of dopamine pathways. Drug Design, Development and Therapy, 2014, 8, 887.	2.0	28
1034	No Association Between NRG1 and ErbB4 Genes and Psychopathological Symptoms of Schizophrenia. NeuroMolecular Medicine, 2014, 16, 742-751.	1.8	4
1035	The effect of epiregulin on epidermal growth factor receptor expression and proliferation of oral squamous cell carcinoma cell lines. Cancer Cell International, 2014, 14, 65.	1.8	3
1036	Developmentally vitamin D-deficient rats show enhanced prepulse inhibition after acute Δ9-tetrahydrocannabinol. Behavioural Pharmacology, 2014, 25, 236-244.	0.8	14
1037	Postmortem Brain: An Underutilized Substrate for Studying Severe Mental Illness. Neuropsychopharmacology, 2014, 39, 65-87.	2.8	96
1038	Mesencephalic GABA neuronal development: no more on the other side of oblivion. Biomolecular Concepts, 2014, 5, 371-382.	1.0	1
1039	Elevated ErbB4 mRNA is related to interneuron deficit in prefrontal cortex in schizophrenia. Journal of Psychiatric Research, 2014, 53, 125-132.	1.5	53
1040	The PSD protein ProSAP2/Shank3 displays synapto-nuclear shuttling which is deregulated in a schizophrenia-associated mutation. Experimental Neurology, 2014, 253, 126-137.	2.0	59

#	Article	IF	CITATIONS
1041	Convergent lines of evidence support CAMKK2 as a schizophrenia susceptibility gene. Molecular Psychiatry, 2014, 19, 774-783.	4.1	56
1042	The chandelier cell, form and function. Current Opinion in Neurobiology, 2014, 26, 142-148.	2.0	63
1043	Genetics of Psychosis in Alzheimer Disease. Current Genetic Medicine Reports, 2014, 2, 30-38.	1.9	11
1044	Neuregulin as a Heart Failure Therapy and Mediator of Reverse Remodeling. Current Heart Failure Reports, 2014, 11, 40-49.	1.3	56
1045	Genetics and Smoking. Current Addiction Reports, 2014, 1, 75-82.	1.6	47
1046	The emerging molecular architecture of schizophrenia, polygenic risk scores and the clinical implications for GxE research. Social Psychiatry and Psychiatric Epidemiology, 2014, 49, 169-182.	1.6	68
1047	Genetic dissection of the psychotomimetic effects of cannabinoid exposure. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2014, 52, 33-40.	2.5	8
1048	Reversible Overexpression of Bace1-Cleaved Neuregulin-1 N-Terminal Fragment Induces Schizophrenia-Like Phenotypes in Mice. Biological Psychiatry, 2014, 76, 120-127.	0.7	49
1050	A blueprint for research on Shankopathies: A view from research on autism spectrum disorder. Developmental Neurobiology, 2014, 74, 85-112.	1.5	12
1051	Neuregulin 1/ErbB4 enhances synchronized oscillations of prefrontal cortex neurons via inhibitory synapses. Neuroscience, 2014, 261, 107-117.	1.1	26
1052	The WAVE Regulatory Complex Links Diverse Receptors to the Actin Cytoskeleton. Cell, 2014, 156, 195-207.	13.5	260
1053	Novel association of Neuregulin 1 gene with bipolar disorder but not with schizophrenia. Schizophrenia Research, 2014, 159, 552-553.	1.1	8
1054	Dysbindin-1, a schizophrenia-related protein, interacts with HDAC3. Neuroscience Letters, 2014, 582, 120-124.	1.0	5
1055	Genetic Labeling Reveals Novel Cellular Targets of Schizophrenia Susceptibility Gene: Distribution of GABA and Non-GABA ErbB4-Positive Cells in Adult Mouse Brain. Journal of Neuroscience, 2014, 34, 13549-13566.	1.7	84
1056	Neuregulin-ERBB Signaling in the Nervous System and Neuropsychiatric Diseases. Neuron, 2014, 83, 27-49.	3.8	465
1057	Partial Genetic Deletion of Neuregulin 1 Modulates the Effects of Stress on Sensorimotor Gating, Dendritic Morphology, and HPA Axis Activity in Adolescent Mice. Schizophrenia Bulletin, 2014, 40, 1272-1284.	2.3	27
1058	Cognitive outcome and gamma noise power unrelated to neuregulin 1 and 3 variation in schizophrenia. Annals of General Psychiatry, 2014, 13, 18.	1.2	5
1059	Effects of Schizophrenia Risk Variation in the NRG1 Gene on NRG1-IV Splicing During Fetal and Early Postnatal Human Neocortical Development. American Journal of Psychiatry, 2014, 171, 979-989.	4.0	26

	CITA	ation Report	
#	Article	IF	CITATIONS
1060	A Bayesian clustering approach for detecting gene-gene interactions in high-dimensional genotype data. Statistical Applications in Genetics and Molecular Biology, 2014, 13, 275-97.	0.2	0
1061	Global signaling effects of a schizophrenia-associated missense mutation in neuregulin 1: an exploratory study using whole genome and novel kinome approaches. Journal of Neural Transmission, 2014, 121, 479-490.	1.4	3
1062	Replication of linkage at chromosome 20p13 and identification of suggestive sex-differential risk loci for autism spectrum disorder. Molecular Autism, 2014, 5, 13.	2.6	29
1063	Dopaminergic function in relation to genes associated with risk for schizophrenia. Progress in Brain Research, 2014, 211, 79-112.	0.9	18
1064	Development and Developmental Disorders of the Cerebral Cortex. , 2014, , 523-642.		5
1065	Dysregulated Expression of Neuregulin-1 by Cortical Pyramidal Neurons Disrupts Synaptic Plasticity. Cell Reports, 2014, 8, 1130-1145.	2.9	81
1066	Genetic Mouse Models of Neuregulin 1: Gene Dosage Effects, Isoform-Specific Functions, and Relevance to Schizophrenia. Biological Psychiatry, 2014, 76, 89-90.	0.7	8
1067	High White Matter Neuron Density with Elevated Cortical Cytokine Expression in Schizophrenia. Biological Psychiatry, 2014, 75, e5-e7.	0.7	36
1068	Association of decreased prefrontal hemodynamic response during a verbal fluency task with EGR3 gene polymorphism in patients with schizophrenia and in healthy individuals. NeuroImage, 2014, 85, 527-534.	2.1	26
1069	Altered Expression of Oligodendrocyte and Neuronal Marker Genes Predicts the Clinical Onset of Autoimmune Encephalomyelitis and Indicates the Effectiveness of Multiple Sclerosis–Directed Therapeutics. Journal of Immunology, 2014, 192, 4122-4133.	0.4	18
1070	Genetics of Schizophrenia. , 2014, , 59-70.		1
1071	Association of the 3′ region of the neuregulin 1 gene with bipolar I disorder in the Chinese Han population. Journal of Affective Disorders, 2014, 162, 81-88.	2.0	8
1072	Phenotypic effects of maternal immune activation and early postnatal milieu in mice mutant for the schizophrenia risk gene neuregulin-1. Neuroscience, 2014, 277, 294-305.	1.1	56
1073	Risk genes for schizophrenia: Translational opportunities for drug discovery. , 2014, 143, 34-50.		26
1074	Behavioral Phenotypes for Negative Symptoms in Animal Models of Schizophrenia. Journal of Pharmacological Sciences, 2014, 126, 310-320.	1.1	23
1077	Synergistic association of <i>PI4KA</i> and <i>GRM3</i> genetic polymorphisms with poor antipsychotic response in south Indian schizophrenia patients with low severity of illness. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2014, 165, 635-646.	1.1	14
1080	Interneuronal DISC1 regulates NRG1-ErbB4 signalling and excitatory–inhibitory synapse formation in the mature cortex. Nature Communications, 2015, 6, 10118.	5.8	62
1081	Polymorphisms of dopamine pathway genes <i><scp>NRG</scp>1</i> and <i><scp>LMX</scp>1A</i> associated with cognitive performance in bipolar disorder. Bipolar Disorders, 2015, 17, 859-868.	are 1.1	23

#	Article	IF	CITATIONS
1082	Effects of genetic variations in NRG1 on cognitive domains in patients with schizophrenia and healthy individuals. Psychiatric Genetics, 2015, 25, 147-154.	0.6	12
1083	7. General Discussion. , 2015, , 222-260.		0
1084	Neuregulin 1 Type II-ErbB Signaling Promotes Cell Divisions Generating Neurons from Neural Progenitor Cells in the Developing Zebrafish Brain. PLoS ONE, 2015, 10, e0127360.	1.1	20
1085	Dendritic spine morphology and dynamics in health and disease. Cell Health and Cytoskeleton, 0, , 121.	0.7	6
1086	Family Support and Adherence to Treatment in Patients Diagnosed with Schizophrenia in Tabasco, Mexico: A Case- Series Study. Journal of Psychiatry, 2015, 18, .	0.1	3
1087	Screening of three ERBB4 gene polymorphisms in a group of Turkish schizophrenia patients and controls / ERBB4 genindeki üÁ§ polimorfizmin bir Tü4rk ÅŸizofreni hasta grubunda ve kontrollerde taranması. Turkish Journal of Biochemistry, 2015, 40, .	0.3	1
1088	Investigation of gene effects and epistatic interactions between Akt1 and neuregulin 1 in the regulation of behavioral phenotypes and social functions in genetic mouse models of schizophrenia. Frontiers in Behavioral Neuroscience, 2014, 8, 455.	1.0	20
1089	ErbB4 in Laminated Brain Structures: A Neurodevelopmental Approach to Schizophrenia. Frontiers in Cellular Neuroscience, 2015, 9, 472.	1.8	13
1090	Neuronal migration abnormalities and its possible implications for schizophrenia. Frontiers in Neuroscience, 2015, 9, 74.	1.4	68
1091	Neurobehavioral Differences Between Mice Receiving Distinct Neuregulin Variants as Neonates; Impact on Sensitivity to MK-801. Current Molecular Medicine, 2015, 15, 222-236.	0.6	10
1092	Evaluating historical candidate genes for schizophrenia. Molecular Psychiatry, 2015, 20, 555-562.	4.1	281
1093	Schizophrenia and Depression Co-Morbidity: What We have Learned from Animal Models. Frontiers in Psychiatry, 2015, 6, 13.	1.3	55
1094	Functional Variants in <i>DPYSL2</i> Sequence Increase Risk of Schizophrenia and Suggest a Link to mTOR Signaling. G3: Genes, Genomes, Genetics, 2015, 5, 61-72.	0.8	39
1095	Hierarchical Classes Analysis (HICLAS): A novel data reduction method to examine associations between biallelic SNPs and perceptual organization phenotypes in schizophrenia. Schizophrenia Research: Cognition, 2015, 2, 56-63.	0.7	0
1096	A systematic review of the effect of genes mediating neurodevelopment and neurotransmission on brain morphology: Focus on schizophrenia. Neurology Psychiatry and Brain Research, 2015, 21, 1-26.	2.0	3
1097	Differential effects of short- and long-term antipsychotic treatment on the expression of neuregulin-1 and ErbB4 receptors in the rat brain. Psychiatry Research, 2015, 225, 347-354.	1.7	12
1098	Genetic variants in Nogo receptor signaling pathways may be associated with early life adversity in schizophrenia susceptibility. BBA Clinical, 2015, 3, 36-43.	4.1	2
1099	S-SCAM, A Rare Copy Number Variation Gene, Induces Schizophrenia-Related Endophenotypes in Transgenic Mouse Model. Journal of Neuroscience, 2015, 35, 1892-1904.	1.7	19

ARTICLE IF CITATIONS Diffusion tensor imaging in first degree relatives of schizophrenia and bipolar disorder patients. 1100 1.1 29 Schizophrenia Research, 2015, 161, 329-339. Evidence for schizophrenia susceptibility alleles in the Indian population: An association of neurodevelopmental genes in case–control and familial samples. Schizophrenia Research, 2015, 162, 1.1 24 112-117. The impact of NMDA receptor hypofunction on GABAergic neurons in the pathophysiology of 1102 1.1 184 schizophrenia. Schizophrenia Research, 2015, 167, 98-107. Sleep and Circadian Rhythm Disruption and Recognition Memory in Schizophrenia. Methods in Enzymology, 2015, 552, 325-349. Gliaâ€related genes and their contribution to schizophrenia. Psychiatry and Clinical Neurosciences, 1104 1.0 28 2015, 69, 448-461. The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response. Translational Psychiatry, 2015, 5, e553-e553. 2.4 ERBB4 polymorphism and family history of psychiatric disorders on age-related cortical changes in 1106 1.1 4 healthy children. Brain Imaging and Behavior, 2015, 9, 128-140. Large-scale candidate gene study to identify genetic risk factors predictive of paliperidone treatment 14 response in patients with schizophrenia. Pharmacogenetics and Genomics, 2015, 25, 173-185. Decreased plasma levels of neureglin-1 in drug naà ve patients and chronic patients with schizophrenia. 1108 1.0 18 Neuroscience Letters, 2015, 606, 220-224. New discoveries in schizophrenia genetics reveal neurobiological pathways: A review of recent 1109 39 findings. European Journal of Medical Genetics, 2015, 58, 704-714. Progressive Structural Brain Changes and NRG1 Gene Variants in First-Episode Nonaffective Psychosis. 1110 0.9 9 Neuropsychobiology, 2015, 71, 103-111. Involvement of Protein Kinase D1 in Signal Transduction from the Protein Kinase C Pathway to the Tyrosine Kinase Pathway in Response to Gonadotropin-releasing Hormone. Journal of Biological Chemistry, 2015, 290, 25974-25985. 1.6 Neuregulin 1 Prevents Phencyclidine-Induced Behavioral Impairments and Disruptions to GABAergic 1112 1.0 16 Signaling in Mice. International Journal of Neuropsychopharmacology, 2015, 18, pyu114-pyu114. Expression analysis in a rat psychosis model identifies novel candidate genes validated in a large 2.4 36 case–control sample of schizophrenia. Translational Psychiatry, 2015, 5, e656-e656. Modulation of schizophrenia-related genes in the forebrain of adolescent and adult rats exposed to 1114 1.1 29 maternal immune activation. Schizophrenia Research, 2015, 168, 411-420. Neuregulin 1 Controls Glutamate Uptake by Up-regulating Excitatory Amino Acid Carrier 1 (EAAC1). Journal of Biological Chemistry, 2015, 290, 20233-20244. Rapid transient isoform-specific neuregulin1 transcription in motor neurons is regulated by neurotrophic factors and axonâ€"target interactions. Molecular and Cellular Neurosciences, 2015, 68, 1116 1.0 11 73-81. Myelin, myelin-related disorders, and psychosis. Schizophrenia Research, 2015, 161, 85-93. 1.1 124

#	Article	IF	CITATIONS
1118	The current and potential impact of genetics and genomics on neuropsychopharmacology. European Neuropsychopharmacology, 2015, 25, 671-681.	0.3	11
1119	Development of Cortical Interneurons. Neuropsychopharmacology, 2015, 40, 16-23.	2.8	69
1120	Common Variants in the MKL1 Gene Confer Risk of Schizophrenia. Schizophrenia Bulletin, 2015, 41, 715-727.	2.3	15
1121	Calcyon stimulates neuregulin 1 maturation and signaling. Molecular Psychiatry, 2015, 20, 1251-1260.	4.1	16
1122	Neuregulin 1 signalling modulates mGluR1 function in mesencephalic dopaminergic neurons. Molecular Psychiatry, 2015, 20, 959-973.	4.1	36
1123	A joint history of the nature of genetic variation and the nature of schizophrenia. Molecular Psychiatry, 2015, 20, 77-83.	4.1	35
1124	Modeling Gene–Gene Interactions in Schizophrenia. Handbook of Behavioral Neuroscience, 2016, 23, 327-343.	0.7	0
1125	Modeling Schizophrenia in Animals. , 2016, , 353-381.		0
1126	Schizophrenia and Functional Imaging. , 2016, , 297-312.		0
1127	Dimensions of GSK3 Monoamine-Related Intracellular Signaling in Schizophrenia. Handbook of Behavioral Neuroscience, 2016, 23, 447-462.	0.7	0
1128	Role of NMDA Receptor-Mediated Glutamatergic Signaling in Chronic and Acute Neuropathologies. Neural Plasticity, 2016, 2016, 1-20.	1.0	111
1129	Neuregulin-1 Regulates Cortical Inhibitory Neuron Dendrite and Synapse Growth through DISC1. Neural Plasticity, 2016, 2016, 1-15.	1.0	15
1130	Neuregulin 1 Promotes Glutathione-Dependent Neuronal Cobalamin Metabolism by Stimulating Cysteine Uptake. Oxidative Medicine and Cellular Longevity, 2016, 2016, 1-13.	1.9	10
1131	Modeling Affective Symptoms of Schizophrenia. Handbook of Behavioral Neuroscience, 2016, 23, 85-102.	0.7	2
1132	Mouse Models of Schizophrenia. Handbook of Behavioral Neuroscience, 2016, 23, 267-284.	0.7	0
1133	Mouse Genetic Models of Human Brain Disorders. Frontiers in Genetics, 2016, 7, 40.	1.1	46
1134	From Linkage Studies to Epigenetics: What We Know and What We Need to Know in the Neurobiology of Schizophrenia. Frontiers in Neuroscience, 2016, 10, 202.	1.4	34
1135	Cannabidiol as a Potential New Type of an Antipsychotic. A Critical Review of the Evidence. Frontiers in Pharmacology, 2016, 7, 422.	1.6	75

#	Article	IF	CITATIONS
1136	Gene × Environment Interactions in Schizophrenia: Evidence from Genetic Mouse Models. Neural Plasticity, 2016, 2016, 1-23.	1.0	265
1137	Modeling Gene–Environment Interaction in Schizophrenia. Handbook of Behavioral Neuroscience, 2016, 23, 345-360.	0.7	2
1138	Use of conducting polymers to facilitate neurite branching in schizophrenia-related neuronal development. Biomaterials Science, 2016, 4, 1244-1251.	2.6	8
1139	Behavioural effects of high fat diet in a mutant mouse model for the schizophrenia risk gene <i>neuregulin 1</i> . Genes, Brain and Behavior, 2016, 15, 295-304.	1.1	7
1140	Effects of <scp> <i>NRG1</i> </scp> genotypes on orbitofrontal sulcogyral patterns in Japanese patients diagnosed with schizophrenia. Psychiatry and Clinical Neurosciences, 2016, 70, 261-268.	1.0	10
1141	Genetic association between <i>NRG1</i> and schizophrenia, major depressive disorder, bipolar disorder in Han Chinese population. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2016, 171, 468-478.	1.1	26
1142	Brain-specific Crmp2 deletion leads to neuronal development deficits and behavioural impairments in mice. Nature Communications, 2016, 7, .	5.8	84
1143	Genome-wide Association Study of Cannabis Dependence Severity, Novel Risk Variants, and Shared Genetic Risks. JAMA Psychiatry, 2016, 73, 472.	6.0	148
1144	Association of the DISC1 and NRG1 genetic polymorphisms with schizophrenia in a Chinese population. Gene, 2016, 590, 293-297.	1.0	18
1145	Genetics of Substance Use Disorders. Child and Adolescent Psychiatric Clinics of North America, 2016, 25, 377-385.	1.0	14
1146	mGluR2/3 agonist LY379268 rescues NMDA and GABAA receptor level deficits induced in a two-hit mouse model of schizophrenia. Psychopharmacology, 2016, 233, 1349-1359.	1.5	7
1147	Alzheimer's therapy targeting the β-secretase enzyme BACE1: Benefits and potential limitations from the perspective of animal model studies. Brain Research Bulletin, 2016, 126, 183-198.	1.4	42
1148	Behavioral, Neurophysiological, and Synaptic Impairment in a Transgenic Neuregulin1 (NRG1-IV) Murine Schizophrenia Model. Journal of Neuroscience, 2016, 36, 4859-4875.	1.7	47
1149	Loss of Nicastrin from Oligodendrocytes Results in Hypomyelination and Schizophrenia with Compulsive Behavior. Journal of Biological Chemistry, 2016, 291, 11647-11656.	1.6	16
1150	Mutation of the 3-Phosphoinositide-Dependent Protein Kinase 1 (PDK1) Substrate-Docking Site in the Developing Brain Causes Microcephaly with Abnormal Brain Morphogenesis Independently of Akt, Leading to Impaired Cognition and Disruptive Behaviors. Molecular and Cellular Biology, 2016, 36, 2967-2982.	1.1	27
1151	A reverse genetic approach identifies an ancestral frameshift mutation in RP1 causing recessive progressive retinal degeneration in European cattle breeds. Genetics Selection Evolution, 2016, 48, 56.	1.2	25
1152	Functions of the Alzheimer's Disease Protease BACE1 at the Synapse in the Central Nervous System. Journal of Molecular Neuroscience, 2016, 60, 305-315.	1.1	48
1153	Neurological dysfunctions associated with altered <scp>BACE</scp> 1â€dependent Neuregulinâ€1 signaling. Journal of Neurochemistry, 2016, 136, 234-249.	2.1	40

#	Article	IF	CITATIONS
1154	Neuregulin-1 (Nrg1) signaling has a preventive role and is altered in the frontal cortex under the pathological conditions of Alzheimer's disease. Molecular Medicine Reports, 2016, 14, 2614-2624.	1.1	39
1155	Effects of neuregulin-1 administration on neurogenesis in the adult mouse hippocampus and characterization of immature neurons along the septotemporal axis. Scientific Reports, 2016, 6, 30467.	1.6	24
1156	Dynamic brain network reconfiguration as a potential schizophrenia genetic risk mechanism modulated by NMDA receptor function. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 12568-12573.	3.3	161
1157	Genetic factors in the etiology of bipolar disorder. , 0, , 144-168.		0
1158	Neuregulin 3 Knockout Mice Exhibit Behaviors Consistent with Psychotic Disorders. Molecular Neuropsychiatry, 2016, 2, 79-87.	3.0	27
1159	Sub-chronic Antipsychotic Drug Administration Reverses the Expression of Neuregulin 1 and ErbB4 in a Cultured MK801-Induced Mouse Primary Hippocampal Neuron or a Neurodevelopmental Schizophrenia Model. Neurochemical Research, 2016, 41, 2049-2064.	1.6	20
1160	Neuregulin-1 and schizophrenia in the genome-wide association study era. Neuroscience and Biobehavioral Reviews, 2016, 68, 387-409.	2.9	68
1161	The importance of the excitatory amino acid transporter 3 (EAAT3). Neurochemistry International, 2016, 98, 4-18.	1.9	53
1162	Striatal but not frontal cortical up-regulation of the epidermal growth factor receptor in rats exposed to immune activation in utero and cannabinoid treatment in adolescence. Psychiatry Research, 2016, 240, 260-264.	1.7	8
1163	Genetic assessment of additional endophenotypes from the Consortium on the Genetics of Schizophrenia Family Study. Schizophrenia Research, 2016, 170, 30-40.	1.1	65
1164	Changes in BQCA Allosteric Modulation of [3H]NMS Binding to Human Cortex within Schizophrenia and by Divalent Cations. Neuropsychopharmacology, 2016, 41, 1620-1628.	2.8	26
1165	Primary phospholipase C and brain disorders. Advances in Biological Regulation, 2016, 61, 80-85.	1.4	86
1166	Molecular substrates of schizophrenia: homeostatic signaling to connectivity. Molecular Psychiatry, 2016, 21, 10-28.	4.1	85
1167	Animal models of gene–environment interaction in schizophrenia: A dimensional perspective. Progress in Neurobiology, 2016, 136, 1-27.	2.8	67
1168	Meta-analysis of Positive and Negative Symptoms Reveals Schizophrenia Modifier Genes: Table 1 Schizophrenia Bulletin, 2016, 42, 279-287.	2.3	40
1169	Neural circuit dysfunction in schizophrenia: Insights from animal models. Neuroscience, 2016, 321, 42-65.	1.1	56
1170	Variation at NRG1 genotype related to modulation of small-world properties of the functional cortical network. European Archives of Psychiatry and Clinical Neuroscience, 2017, 267, 25-32.	1.8	4
1171	Genetics of psychosis of Alzheimer disease. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2017, 174, 27-35.	1.1	22

#	Article	IF	CITATIONS
1172	Diagnostic and therapeutic potential of microRNAs in neuropsychiatric disorders: Past, present, and future. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 73, 87-103.	2.5	72
1173	Neuregulin-1 mutant mice indicate motor and sensory deficits, indeed few references for schizophrenia endophenotype model. Behavioural Brain Research, 2017, 322, 177-185.	1.2	5
1174	Meta-analysis reveals associations between genetic variation in the 5′ and 3′ regions of Neuregulin-1 and schizophrenia. Translational Psychiatry, 2017, 7, e1004-e1004.	2.4	32
1175	Microglia-derived neuregulin expression in psychiatric disorders. Brain, Behavior, and Immunity, 2017, 61, 375-385.	2.0	28
1176	Effects of RET, NRG1 and NRG3 Polymorphisms in a Chinese Population with Hirschsprung Disease. Scientific Reports, 2017, 7, 43222.	1.6	22
1177	Cannabinoids as hippocampal network administrators. Neuropharmacology, 2017, 124, 25-37.	2.0	46
1178	Understanding principles of integration and segregation using whole-brain computational connectomics: implications for neuropsychiatric disorders. Philosophical Transactions Series A, Mathematical, Physical, and Engineering Sciences, 2017, 375, 20160283.	1.6	95
1179	A brief history of the study of nerve dependent regeneration. Neurogenesis (Austin, Tex ), 2017, 4, e1302216.	1.5	49
1180	A functional neuregulin-1 gene variant and stressful life events: Effect on drug use in a longitudinal population-representative cohort study. Journal of Psychopharmacology, 2017, 31, 54-61.	2.0	9
1181	Schizophrenia and neurogenesis: A stem cell approach. Neuroscience and Biobehavioral Reviews, 2017, 80, 414-442.	2.9	36
1182	Electrical Stimulation Using Conductive Polymer Polypyrrole Counters Reduced Neurite Outgrowth of Primary Prefrontal Cortical Neurons from NRG1-KO and DISC1-LI Mice. Scientific Reports, 2017, 7, 42525.	1.6	27
1183	Hippocampal GABAergic Inhibitory Interneurons. Physiological Reviews, 2017, 97, 1619-1747.	13.1	601
1184	Spironolactone is an antagonist of <scp>NRG</scp> 1― <scp>ERBB</scp> 4 signaling and schizophreniaâ€relevant endophenotypes in mice. EMBO Molecular Medicine, 2017, 9, 1448-1462.	3.3	34
1185	Association of Established Thyroid-stimulating Hormone and Free Thyroxine Genetic Variants with Hashimoto's Thyroiditis. Immunological Investigations, 2017, 46, 625-638.	1.0	5
1186	ErbB4 protects against neuronal apoptosis via activation of YAP/PIK3CB signaling pathway in a rat model of subarachnoid hemorrhage. Experimental Neurology, 2017, 297, 92-100.	2.0	26
1187	Association between ErbB4 single nucleotide polymorphisms and susceptibility to schizophrenia. Medicine (United States), 2017, 96, e5920.	0.4	5
1188	The association between gene variants and longitudinal structural brain changes in psychosis: a systematic review of longitudinal neuroimaging genetics studies. NPJ Schizophrenia, 2017, 3, 40.	2.0	7
1189	Endocannabinoid dysregulation in cognitive and stress-related brain regions in the Nrg1 mouse model of schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 72, 9-15.	2.5	21

#	Article	IF	CITATIONS
1190	Epistatic and Independent Effects on Schizophrenia-Related Phenotypes Following Co-disruption of the Risk Factors Neuregulin-1 × DISC1. Schizophrenia Bulletin, 2017, 43, 214-225.	2.3	15
1191	A Novel Relationship for Schizophrenia, Bipolar, and Major Depressive Disorder. Part 8: a Hint from Chromosome 8 High Density Association Screen. Molecular Neurobiology, 2017, 54, 5868-5882.	1.9	20
1192	Genome-wide association study of working memory brain activation. International Journal of Psychophysiology, 2017, 115, 98-111.	0.5	17
1194	A Gene-Based Analysis of Acoustic Startle Latency. Frontiers in Psychiatry, 2017, 8, 117.	1.3	7
1195	Drug Abuse and Psychosis: New Insights into Drug-induced Psychosis. Experimental Neurobiology, 2017, 26, 11-24.	0.7	36
1196	Emerging Synaptic Molecules as Candidates in the Etiology of Neurological Disorders. Neural Plasticity, 2017, 2017, 1-25.	1.0	57
1197	Physiological Functions of the β-Site Amyloid Precursor Protein Cleaving Enzyme 1 and 2. Frontiers in Molecular Neuroscience, 2017, 10, 97.	1.4	84
1198	BACE1-Dependent Neuregulin-1 Signaling: An Implication for Schizophrenia. Frontiers in Molecular Neuroscience, 2017, 10, 302.	1.4	17
1199	Modeling Schizophrenia in Animals. , 2017, , 587-617.		0
1200	Glutamate-dependent ectodomain shedding of neuregulin-1 type II precursors in rat forebrain neurons. PLoS ONE, 2017, 12, e0174780.	1.1	20
1201	Role of BACE1 in Alzheimer's synaptic function. Translational Neurodegeneration, 2017, 6, 23.	3.6	80
1202	The Interactive Nature of Cannabis andÂSchizophrenia Risk Genes. , 2017, , 335-344.		2
1203	Specialized Information Processing Deficits and Distinct Metabolomic Profiles Following TM-Domain Disruption of Nrg1. Schizophrenia Bulletin, 2017, 43, 1100-1113.	2.3	2
1204	Chlorpromazine Increases the Expression of Polysialic Acid (PolySia) in Human Neuroblastoma Cells and Mouse Prefrontal Cortex. International Journal of Molecular Sciences, 2017, 18, 1123.	1.8	15
1205	A Genetic Study of Psychosis in Huntington's Disease: Evidence for the Involvement of Glutamate Signaling Pathways. Journal of Huntington's Disease, 2018, 7, 51-59.	0.9	9
1206	Brain, blood, cerebrospinal fluid, and serum biomarkers in schizophrenia. Psychiatry Research, 2018, 265, 25-38.	1.7	79
1207	Neuregulin 1/ErbB signalling modulates hippocampal mGluRI-dependent LTD and object recognition memory. Pharmacological Research, 2018, 130, 12-24.	3.1	21
1208	A Novel Ultrasensitive In Situ Hybridization Approach to Detect Short Sequences and Splice Variants with Cellular Resolution. Molecular Neurobiology, 2018, 55, 6169-6181.	1.9	53

#	Article	IF	CITATIONS
1209	Sensorimotor gating deficits and effects of antipsychotics on the hyperactivity in VGF-overexpressing mice. Pharmacological Reports, 2018, 70, 476-480.	1.5	5
1210	Trophic modulation of gamma oscillations: The key role of processing protease for Neuregulin-1 and BDNF precursors. Neurochemistry International, 2018, 119, 2-10.	1.9	12
1211	Association of Neuregulin-1 gene polymorphisms with neuro-cognitive features of schizophrenia patients from South India: A pilot study. Meta Gene, 2018, 16, 5-9.	0.3	0
1212	Schizophrenia-relevant behaviours of female mice overexpressing neuregulin 1 type III. Behavioural Brain Research, 2018, 353, 227-235.	1.2	21
1213	Inhibition of STEP61 ameliorates deficits in mouse and hiPSC-based schizophrenia models. Molecular Psychiatry, 2018, 23, 271-281.	4.1	37
1214	Neuregulin-2 ablation results in dopamine dysregulation and severe behavioral phenotypes relevant to psychiatric disorders. Molecular Psychiatry, 2018, 23, 1233-1243.	4.1	45
1215	Neuregulin 3 and its roles in schizophrenia risk and presentation. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2018, 177, 257-266.	1.1	28
1216	Genetic Background of Hirschsprung Disease: A Bridge Between Basic Science and Clinical Application. Journal of Cellular Biochemistry, 2018, 119, 28-33.	1.2	29
1217	Overexpression of Neuregulin 1 Type III Confers Hippocampal mRNA Alterations and Schizophrenia-Like Behaviors in Mice. Schizophrenia Bulletin, 2018, 44, 865-875.	2.3	28
1218	Defects in Bioenergetic Coupling in Schizophrenia. Biological Psychiatry, 2018, 83, 739-750.	0.7	67
1219	Constitutive loss and acute pharmacological manipulation of ErbB4 signaling do not affect attention and inhibitory control in mice. Genes, Brain and Behavior, 2018, 17, 56-69.	1.1	4
1220	Stress, Trauma and Synaptic Plasticity. , 2018, , .		2
1221	Neuregulin1 types mRNA level changes in autism spectrum disorder, and is associated with deficit in executive functions. EBioMedicine, 2018, 37, 483-488.	2.7	16
1222	Inhibitory control of the excitatory/inhibitory balance in psychiatric disorders. F1000Research, 2018, 7, 23.	0.8	149
1223	Excitotoxicity. , 2018, , 70-100.		0
1224	Genetic recovery of ErbB4 in adulthood partially restores brain functions in null mice. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 13105-13110.	3.3	33
1225	mGluR1-Dependent Long Term Depression in Rodent Midbrain Dopamine Neurons Is Regulated by Neuregulin 1/ErbB Signaling. Frontiers in Molecular Neuroscience, 2018, 11, 346.	1.4	15
1226	Restoring wild-type-like CA1 network dynamics and behavior during adulthood in a mouse model of schizophrenia. Nature Neuroscience, 2018, 21, 1412-1420.	7.1	53

#	Article	IF	CITATIONS
1227	Levels of peripheral Neuregulin 1 are increased in non-medicated autism spectrum disorder patients. Journal of Clinical Neuroscience, 2018, 57, 43-45.	0.8	10
1228	Electrical Stimulation with a Conductive Polymer Promotes Neurite Outgrowth and Synaptogenesis in Primary Cortical Neurons in 3D. Scientific Reports, 2018, 8, 9855.	1.6	34
1229	Neuregulin 3 promotes excitatory synapse formation on hippocampal interneurons. EMBO Journal, 2018, 37, .	3.5	45
1230	Mental disorders and an acidic glycan-from the perspective of polysialic acid (PSA/polySia) and the synthesizing enzyme, ST8SIA2. Glycoconjugate Journal, 2018, 35, 353-373.	1.4	13
1231	The Endocannabinoid System across Postnatal Development in Transmembrane Domain Neuregulin 1 Mutant Mice. Frontiers in Psychiatry, 2018, 9, 11.	1.3	5
1232	Immediate Early Genes Anchor a Biological Pathway of Proteins Required for Memory Formation, Long-Term Depression and Risk for Schizophrenia. Frontiers in Behavioral Neuroscience, 2018, 12, 23.	1.0	29
1233	Sex Differences in Psychiatric Disease: A Focus on the Glutamate System. Frontiers in Molecular Neuroscience, 2018, 11, 197.	1.4	82
1234	Hippocampal protein kinase D1 is necessary for DHPG-induced learning and memory impairments in rats. PLoS ONE, 2018, 13, e0195095.	1.1	3
1235	Assessment of genotyping tools applied in genetic susceptibility studies of periodontal disease: A systematic review. Archives of Oral Biology, 2018, 92, 38-50.	0.8	9
1236	Reduced type III neuregulin 1 expression does not modulate the behavioural sensitivity of mice to acute Δ 9 -tetrahydrocannabinol (D 9 -THC). Pharmacology Biochemistry and Behavior, 2018, 170, 64-70.	1.3	5
1237	Antibody-mediated stabilization of NRG1 induces behavioral and electrophysiological alterations in adult mice. Scientific Reports, 2018, 8, 8239.	1.6	9
1238	Effects of antipsychotic drugs on neurites relevant to schizophrenia treatment. Medicinal Research Reviews, 2019, 39, 386-403.	5.0	36
1239	Nrg1 deficiency modulates the behavioural effects of prenatal stress in mice. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 88, 86-95.	2.5	8
1240	Effect of age onset on schizophrenia-like phenotypes and underlying mechanisms in model mice. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 89, 465-474.	2.5	5
1241	An Overview of Animal Models Related to Schizophrenia. Canadian Journal of Psychiatry, 2019, 64, 5-17.	0.9	138
1242	NMDAR Hypofunction Animal Models of Schizophrenia. Frontiers in Molecular Neuroscience, 2019, 12, 185.	1.4	95
1243	Plasma neuropeptides as circulating biomarkers of multifactorial schizophrenia. Comprehensive Psychiatry, 2019, 94, 152114.	1.5	4
1244	A critical review of zebrafish schizophrenia models: Time for validation?. Neuroscience and Biobehavioral Reviews, 2019, 107, 6-22.	2.9	29

# 1245	ARTICLE Hippocampal Dysfunction in Schizophrenia and Aberrant Hippocampal Synaptic Plasticity in Rodent Model Prychosia: a Selective Provide Dearmaconcyclaiotry, 2023, 56, 57, 63	IF 1.7	CITATIONS 3
1246	Neuroprotection by Exogenous and Endogenous Neuregulin-1 in Mouse Models of Focal Ischemic Stroke. Journal of Molecular Neuroscience, 2019, 69, 333-342.	1.1	17
1247	Behavioural effects of high fat diet exposure starting in late adolescence in neuregulin 1 transmembrane domain mutant mice. Behavioural Brain Research, 2019, 373, 112074.	1.2	3
1248	Acute stress-induced change in polysialic acid levels mediated by sialidase in mouse brain. Scientific Reports, 2019, 9, 9950.	1.6	18
1249	Developing zebrafish experimental animal models relevant to schizophrenia. Neuroscience and Biobehavioral Reviews, 2019, 105, 126-133.	2.9	19
1250	Genome-wide Association of Endophenotypes for Schizophrenia From the Consortium on the Genetics of Schizophrenia (COGS) Study. JAMA Psychiatry, 2019, 76, 1274.	6.0	78
1251	The impact of D-cycloserine and sarcosine on in vivo frontal neural activity in a schizophrenia-like model. BMC Psychiatry, 2019, 19, 314.	1.1	5
1252	The Association Between Schizophrenia Risk Variants and Creativity in Healthy Han Chinese Subjects. Frontiers in Psychology, 2019, 10, 2218.	1.1	4
1253	Therapeutic efficacy of neuregulin 1-expressing human adipose-derived mesenchymal stem cells for ischemic stroke. PLoS ONE, 2019, 14, e0222587.	1.1	17
1254	Neuregulin1β improves both spatial and associative learning and memory in Alzheimer model of rats possibly through signaling pathways other than Erk1/2. Neuropeptides, 2019, 78, 101963.	0.9	18
1255	Association between schizophrenia risk allele dosage of rs6994992 and whole-brain structural and functional characteristics. Psychiatry Research - Neuroimaging, 2019, 294, 110956.	0.9	3
1256	Sex differences in gene expression related to antipsychotic induced weight gain. PLoS ONE, 2019, 14, e0215477.	1.1	13
1257	Molecular Genetics Meets Sociology: Birth Cohort Effects on Alcohol Use and Relationship With Candidate Genes. , 2019, , 13-20.		1
1258	Exome Sequencing Identifies TENM4 as a Novel Candidate Gene for Schizophrenia in the SCZD2 Locus at 11q14-21. Frontiers in Genetics, 2018, 9, 725.	1.1	33
1259	Causes of Sudden Unexpected Death in Schizophrenia Patients. American Journal of Forensic Medicine and Pathology, 2019, 40, 312-317.	0.4	19
1260	erbb4 Deficits in Chandelier Cells of the Medial Prefrontal Cortex Confer Cognitive Dysfunctions: Implications for Schizophrenia. Cerebral Cortex, 2019, 29, 4334-4346.	1.6	22
1261	Current Practice and New Developments in the Use of In Vivo Magnetic Resonance Spectroscopy for the Assessment of Key Metabolites Implicated in the Pathophysiology of Schizophrenia. Current Topics in Medicinal Chemistry, 2019, 18, 1908-1924.	1.0	4
1262	Elevated cleavage of neuregulin-1 by beta-secretase 1 in plasma of schizophrenia patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 90, 161-168.	2.5	10

#	Article	IF	CITATIONS
1263	Genetic study of neuregulin 1 and receptor tyrosine-protein kinase erbB-4 in tardive dyskinesia. World Journal of Biological Psychiatry, 2019, 20, 91-95.	1.3	8
1264	GABAergic Abnormalities Associated with Sensorimotor Cortico-striatal Community Structural Deficits in ErbB4 Knockout Mice and First-Episode Treatment-NaÃ⁻ve Patients with Schizophrenia. Neuroscience Bulletin, 2020, 36, 97-109.	1.5	6
1265	On the Modulatory Roles of Neuregulins/ErbB Signaling on Synaptic Plasticity. International Journal of Molecular Sciences, 2020, 21, 275.	1.8	36
1266	Schizophrenia in a genomic era: a review from the pathogenesis, genetic and environmental etiology to diagnosis and treatment insights. Psychiatric Genetics, 2020, 30, 1-9.	0.6	48
1267	Vitamin D and Neurotrophin Levels and Their Impact on the Symptoms of Schizophrenia. Neuropsychobiology, 2020, 79, 179-185.	0.9	9
1268	CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimer's disease. Alzheimer's Research and Therapy, 2020, 12, 88.	3.0	20
1269	Solute Carrier Family 1 (SLC1A1) Contributes to Susceptibility and Psychopathology Symptoms of Schizophrenia in the Han Chinese Population. Frontiers in Psychiatry, 2020, 11, 559210.	1.3	3
1270	A meta-analysis of ultra-high field glutamate, glutamine, GABA and glutathione 1HMRS in psychosis: Implications for studies of psychosis risk. Schizophrenia Research, 2020, 226, 61-69.	1.1	46
1271	Insights on the Functional Interaction between Group 1 Metabotropic Glutamate Receptors (mGluRI) and ErbB Receptors. International Journal of Molecular Sciences, 2020, 21, 7913.	1.8	9
1272	Plasticity in oligodendrocyte lineage progression: An OPC puzzle on our nerves. European Journal of Neuroscience, 2021, 54, 5747-5761.	1.2	4
1273	Neuregulins 1, 2, and 3 Promote Early Neurite Outgrowth in ErbB4-Expressing Cortical GABAergic Interneurons. Molecular Neurobiology, 2020, 57, 3568-3588.	1.9	7
1274	Prefrontal cortical alterations of glutamate and GABA neurotransmission in schizophrenia: Insights for rational biomarker development. Biomarkers in Neuropsychiatry, 2020, 3, 100015.	0.7	22
1275	Neuregulin 1: an intriguing therapeutic target for neurodevelopmental disorders. Translational Psychiatry, 2020, 10, 190.	2.4	33
1276	Developmental alterations in the transcriptome of three distinct rodent models of schizophrenia. PLoS ONE, 2020, 15, e0232200.	1.1	9
1277	Neuronal Plasticity: Neuronal Organization is Associated with Neurological Disorders. Journal of Molecular Neuroscience, 2020, 70, 1684-1701.	1.1	11
1278	Differential methylation of imprinting genes and MHC locus in 22q11.2 deletion syndrome-related schizophrenia spectrum disorders. World Journal of Biological Psychiatry, 2021, 22, 46-57.	1.3	10
1279	Sex-specific and shared expression profiles of vulnerability and resilience to trauma in brain and blood. Biology of Sex Differences, 2020, 11, 13.	1.8	11
1280	White matter alterations and the conversion to psychosis: A combined diffusion tensor imaging and glutamate 1H MRS study. Schizophrenia Research, 2022, 249, 85-92.	1.1	8

#	Article	IF	CITATIONS
1281	Adolescent cannabinoid exposure interacts with other risk factors in schizophrenia: A review of the evidence from animal models. Neuroscience and Biobehavioral Reviews, 2020, 116, 202-220.	2.9	11
1282	Parvalbumin Interneuron Activation-Dependent Adult Hippocampal Neurogenesis Is Required for Treadmill Running to Reverse Schizophrenia-Like Phenotypes. Frontiers in Cell and Developmental Biology, 2020, 8, 24.	1.8	13
1283	Novel Treatment Strategies Targeting Myelin and Oligodendrocyte Dysfunction in Schizophrenia. Frontiers in Psychiatry, 2020, 11, 379.	1.3	37
1284	Sex differences in circulating neuregulin1-β1 and β-secretase 1 expression in childhood-onset schizophrenia. Comprehensive Psychiatry, 2020, 100, 152176.	1.5	8
1285	Beneficial Effects of Fingolimod on Social Interaction, CNS and Peripheral Immune Response in the BTBR Mouse Model of Autism. Neuroscience, 2020, 435, 22-32.	1.1	10
1286	Adiponectin receptor2 and HCLS1 associated proteinX-1 levels are altered in postmortem schizophrenic brain. Meta Gene, 2021, 27, 100834.	0.3	1
1287	Brain Network Simulations Indicate Effects of Neuregulin-1 Genotype on Excitation-Inhibition Balance in Cortical Dynamics. Cerebral Cortex, 2021, 31, 2013-2025.	1.6	4
1288	Brain changes in NF-κB1 and epidermal growth factor system markers at peri-pubescence in the spiny mouse following maternal immune activation. Psychiatry Research, 2021, 295, 113564.	1.7	5
1289	Sex-specific sensitivity to methamphetamine-induced schizophrenia-relevant behaviours in <i>neuregulin 1 type III</i> overexpressing mice. Journal of Psychopharmacology, 2021, 35, 50-64.	2.0	10
1290	Autism and severe clinical phenotype in a patient with 8p21.2p11.21 deletion: Case report and literature review. Clinical Case Reports (discontinued), 2021, 9, 314-321.	0.2	1
1291	Polysialylation and disease. Molecular Aspects of Medicine, 2021, 79, 100892.	2.7	42
1292	Association of Neuregulin 1 rs7835688 G > C, rs16879552 T > C and rs2439302â€ with Susceptibility to Non-Syndromic Hirschsprung's Disease. Fetal and Pediatric Pathology, 2021, 40, 198-205.	‰G 8 0.4	> C P 2
1293	Overexpression of neuregulin 1 in GABAergic interneurons results in reversible cortical disinhibition. Nature Communications, 2021, 12, 278.	5.8	16
1294	Increased thin-spine density in frontal cortex pyramidal neurons in a genetic rat model of schizophrenia-relevant features. European Neuropsychopharmacology, 2021, 44, 79-91.	0.3	18
1295	Striatal transcriptome changes linked to drugâ€induced repetitive behaviors. European Journal of Neuroscience, 2021, 53, 2450-2468.	1.2	9
1296	An alternative splicing hypothesis for neuropathology of schizophrenia: evidence from studies on historical candidate genes and multi-omics data. Molecular Psychiatry, 2022, 27, 95-112.	4.1	19
1297	Neuregulins in Neurodegenerative Diseases. Frontiers in Aging Neuroscience, 2021, 13, 662474.	1.7	37
1298	Hyperactivity is a Core Endophenotype of Elevated Neuregulin-1 Signaling in Embryonic Glutamatergic Networks. Schizophrenia Bulletin, 2021, 47, 1409-1420.	2.3	3

#	Article	IF	CITATIONS
1299	Spine impairment in mice high-expressing neuregulin 1 due to LIMK1 activation. Cell Death and Disease, 2021, 12, 403.	2.7	19
1302	The laterodorsal tegmentum-ventral tegmental area circuit controls depression-like behaviors by activating ErbB4 in DA neurons. Molecular Psychiatry, 2023, 28, 1027-1045.	4.1	10
1303	Pharmacogenetic associations of NRG1 polymorphisms with neurocognitive performance and clinical symptom response to risperidone in the untreated schizophrenia. Schizophrenia Research, 2021, 231, 67-69.	1.1	4
1304	Dopamine System, NMDA Receptor and EGF Family Expressions in Brain Structures of Bl6 and 129Sv Strains Displaying Different Behavioral Adaptation. Brain Sciences, 2021, 11, 725.	1.1	2
1305	Investigating Post-translational Modifications in Neuropsychiatric Disease: The Next Frontier in Human Post-mortem Brain Research. Frontiers in Molecular Neuroscience, 2021, 14, 689495.	1.4	4
1306	Global Scientific Outputs of Schizophrenia Publications From 1975 to 2020: a Bibliometric Analysis. Psychiatric Quarterly, 2021, 92, 1725-1744.	1.1	36
1307	Association and epistatic analysis of white matter related genes across the continuum schizophrenia and autism spectrum disorders: The joint effect of NRG1-ErbB genes. World Journal of Biological Psychiatry, 2022, 23, 208-218.	1.3	1
1308	Neurobiological substrates of major psychiatry disorders: transdiagnostic associations between white matter abnormalities, neuregulin 1 and clinical manifestation. Journal of Psychiatry and Neuroscience, 2021, 46, E506-E515.	1.4	7
1309	Nrg1 haploinsufficiency alters inhibitory cortical circuits. Neurobiology of Disease, 2021, 157, 105442.	2.1	10
1310	The importance of non-coding RNAs in environmental stress-related developmental brain disorders: A systematic review of evidence associated with exposure to alcohol, anesthetic drugs, nicotine, and viral infections. Neuroscience and Biobehavioral Reviews, 2021, 128, 633-647.	2.9	14
1311	Role of Polysialic Acid in Schizophrenia. , 2021, , 276-286.		0
1312	Disease models in neurodevelopmental disorders. , 2021, , 511-520.		0
1316	Neuregulin 1 and Schizophrenia. , 2009, , 243-265.		2
1318	Animal Models for Schizophrenia: A Brief Overview. , 2008, , 163-184.		1
1319	The Neuropathology of Schizophrenia: Central Role for the Hippocampus?. , 2010, , 149-165.		3
1320	The Organization and Integrative Function of the Post-Synaptic Proteome. , 2003, , 13-44.		2
1321	Genetics of Psychiatric Disorders. , 2016, , 553-600.		1
1322	Positional Cloning. Methods in Molecular Medicine, 2006, , 137-152.	0.8	2

#	Article	IF	CITATIONS
1323	Genetics of Psychiatric Disorders. , 2008, , 487-518.		5
1324	Genetic Regulation of the Variation in Pubertal Timing. , 2007, , 83-102.		3
1325	The influence of genetics on intracranial aneurysm formation and rupture: current knowledge and its possible impact on future treatment. Advances and Technical Standards in Neurosurgery, 2008, 33, 131-147.	0.2	14
1326	The Aberrant Connectivity Hypothesis in Schizophrenia. , 2009, , 301-323.		6
1327	Impaired Neurogenesis as a Risk Factor for Schizophrenia and Related Mental Diseases. , 2011, , 109-131.		2
1328	The Schizophrenia Construct After 100 Years of Challenges. , 2011, , 1-44.		3
1329	A systematic meta-analysis of the association of Neuregulin 1 (NRG1), d-amino acid oxidase (DAO), and DAO activator (DAOA)/G72 polymorphisms with schizophrenia. Journal of Neural Transmission, 2018, 125, 89-102.	1.4	21
1330	Schizophrenia and related disorders. , 2012, , 259-286.		1
1331	ErbB-4. , 2003, , 69-80.		2
1332	PSYCHOSIS AND SCHIZOPHRENIA. , 2009, , 797-815.		1
1333	Parent-of-origin effects on schizophrenia-relevant behaviours of type III neuregulin 1 mutant mice. Behavioural Brain Research, 2017, 332, 250-258.	1.2	5
1334	Can structural magnetic resonance imaging provide an alternative phenotype for genetic studies of schizophrenia?. , 2004, , 138-155.		1
1335	Allelic variation in GAD1 (GAD67) is associated with schizophrenia and influences cortical function and gene expression. , 0, .		1
1336	The Genetics of Schizophrenia. RSC Drug Discovery Series, 2015, , 1-27.	0.2	3
1337	Inflammatory disorders of the central nervous system. Current Opinion in Neurology, 2003, 16, 347-350.	1.8	10
1339	Genetics of Schizophrenia and Bipolar Affective Disorder: Strategies to Identify Candidate Genes. Cold Spring Harbor Symposia on Quantitative Biology, 2003, 68, 383-394.	2.0	7
1340	Finding schizophrenia genes. Journal of Clinical Investigation, 2005, 115, 1440-1448.	3.9	101
1341	Schizophrenia from a neural circuitry perspective: advancing toward rational pharmacological therapies, Journal of Clinical Investigation, 2009, 119, 706-716,	3.9	202
ARTICLE IF CITATIONS Genetics of Multifactorial Disorders., 2006, , 35-46. 1 1342 Neuregulin-1 Regulates Cell Adhesion via an ErbB2/Phosphoinositide-3 Kinase/Akt-Dependent Pathway: 1343 1.1 58 Potential Implications for Schizophrenia and Cancer. PLoS ONE, 2007, 2, e1369. Decreased Expression of Sprouty2 in the Dorsolateral Prefrontal Cortex in Schizophrenia and Bipolar 1344 1.1 27 Disorder: A Correlation with BDNF Expression. PLoS ONE, 2008, 3, e1784. Arachidonic Acid Drives Postnatal Neurogenesis and Elicits a Beneficial Effect on Prepulse Inhibition, 1345 1.1 98 a Biological Trait of Psychiatric Illnesses. PLoS ONE, 2009, 4, e5085. A Novel Analytical Framework for Dissecting the Genetic Architecture of Behavioral Symptoms in 1346 1.1 9 Neuropsychiatric Disorders. PLoS ONE, 2010, 5, e9714. 1347 Phenotypic Characterization of Transgenic Mice Overexpressing Neuregulin-1. PLoS ONE, 2010, 5, e14185. 1.1 Mutation of Semaphorin-6A Disrupts Limbic and Cortical Connectivity and Models 1348 1.1 40 Neurodevelopmental Psychopathology. PLoS ONE, 2011, 6, e26488. Subchronic Peripheral Neuregulin-1 Increases Ventral Hippocampal Neurogenesis and Induces 1349 1.1 Antidepressant-Like Effects. PLoS ONE, 2011, 6, e26610. Genetic Evidence for the Association between the Early Growth Response 3 (EGR3) Gene and 1350 1.1 24 Schizophrenia. PLoS ONE, 2012, 7, e30237. QT Is Longer in Drug-Free Patients with Schizophrenia Compared with Age-Matched Healthy Subjects. 1.1 PLoS ONE, 2014, 9, e98555. Temporal and Spatial Transcriptional Fingerprints by Antipsychotic or Propsychotic Drugs in Mouse 1352 1.1 23 Brain. PLoS ONE, 2015, 10, e0118510. Neuregulin 1 Expression and Electrophysiological Abnormalities in the Neuregulin 1 Transmembrane Domain Heterozygous Mutant Mouse. PLoS ONE, 2015, 10, e0124114. 1.1 Association of SNPs in EGR3 and ARC with Schizophrenia Supports a Biological Pathway for 1354 1.1 42 Schizophrenia Risk. PLoS ONE, 2015, 10, e0135076. Genetic factors affecting EBV copy number in lymphoblastoid cell lines derived from the 1000 Genome Project samples. PLoS ONE, 2017, 12, e0179446. 1.1 1356 Theory and Practice in Quantitative Genetics., 0, . 19 Axonal Type III Nrg1 Controls Glutamate Synapse Formation and GluA2 Trafficking in Hippocampal-Accumbens Connections. ENeuro, 2017, 4, ENEURO.0232-16.2017 Neuregulin 1 Type I Overexpression Is Associated with Reduced NMDA Receptor–Mediated Synaptic 1358 0.9 27 Signaling in Hippocampal Interneurons Expressing PV or CCK. ENeuro, 2018, 5, ENEURO.0418-17.2018. Neuregulin-1 Gene and Schizophrenia, and its Negative Symptoms in an Iranian Population. Iranian 1359 0.1 Journal of Psychiatry and Behavioral Sciences, 2016, 11, .

#	Article	IF	CITATIONS
1360	Common Mechanisms of Excitatory and Inhibitory Imbalance in Schizophrenia and Autism Spectrum Disorders. Current Molecular Medicine, 2015, 15, 146-167.	0.6	404
1361	A Case of Schizophrenia with Chromosomal Microdeletion of 17p11.2 Containing a Myelin-Related Gene PMP22. The Open Psychiatry Journal, 2008, 2, 1-4.	0.2	3
1362	Clinical impact of recently detected susceptibility genes for schizophrenia. Dialogues in Clinical Neuroscience, 2006, 8, 79-84.	1.8	15
1363	Contributions of molecular biology to antipsychotic drug discovery: promises fulfilled or unfulfilled?. Dialogues in Clinical Neuroscience, 2006, 8, 303-309.	1.8	13
1364	Genetics of bipolar disorder. Dialogues in Clinical Neuroscience, 2008, 10, 141-152.	1.8	31
1365	Nature and nurture in neuropsychiatric genetics: where do we stand?. Dialogues in Clinical Neuroscience, 2010, 12, 7-23.	1.8	38
1366	New findings in the genetics of major psychoses. Dialogues in Clinical Neuroscience, 2010, 12, 85-93.	1.8	62
1367	Linkage to the 8p21.1 Region Including the CLU Gene in Age at Onset Stratified Alzheimer's Disease Families. Journal of Alzheimer's Disease, 2011, 23, 13-20.	1.2	5
1368	A Review of Diffusion Tensor Imaging in Schizophrenia. Clinical Schizophrenia and Related Psychoses, 2009, 3, 142-154.	1.4	2
1370	Genetic Correlates of the Nosology of Catatonia. Psychiatric Annals, 2007, 37, .	0.1	1
1371	Complementary and Alternative Medicine (CAM). Journal of Clinical Psychiatry, 2009, 70, 4-6.	1.1	102
1372	An Association Study of the Signal Transducer and Activator of Transcription 6 Gene With Periodic Psychosis. Psychiatry Investigation, 2008, 5, 41.	0.7	2
1373	Unlocking the molecular mechanisms of antipsychotics – a new frontier for discovery. Swiss Medical Weekly, 2016, 146, w14314.	0.8	10
1374	Quantitative Analysis of Nucleic Acids - the Last Few Years of Progress. BMB Reports, 2004, 37, 1-10.	1.1	90
1375	Global Genetic Analysis. BMB Reports, 2004, 37, 11-27.	1.1	11
1376	Cell autonomous regulation of hippocampal circuitry via Aph1b-γ-secretase/neuregulin 1 signalling. ELife, 2014, 3, .	2.8	23
1377	Disorganization of Oscillatory Activity in Animal Models of Schizophrenia. Frontiers in Neural Circuits, 2021, 15, 741767.	1.4	6
1379	The dual hit hypothesis of schizophrenia: Evidence from animal models. Neuroscience and Biobehavioral Reviews, 2021, 131, 1150-1168.	2.9	36

#	Article	IF	CITATIONS
1380	Genetically Altered Mice as Models for Understanding Brain Disorders. Research and Perspectives in Neurosciences, 2003, , 65-84.	0.4	0
1381	Human genome and the perspectives for schizophrenia. , 2004, , 278-296.		0
1382	Searching for inherited causes for schizophrenia: has progress been made?. , 2004, , 233-244.		0
1383	Neuentwicklungen in der Erforschung der Genetik der Schizophrenie. , 2004, , 63-72.		4
1384	Genetik affektiver Störungen – der quantitative Ansatz Syndrom-orientierter Modelle. , 2005, , 219-257.		0
1385	Genes for schizophrenia and beyond. , 2006, , 119-126.		0
1386	Are the genetic and environmental factors impacting on schizophrenia and bipolar disorder the same or different?. , 2006, , 185-192.		0
1387	çµ±å•åَ≣賿症ã®å^†åç—æ<ç"ç©¶ã«ã฿҉,ã┥ ―éºä¼åç"ç©¶ã,'äֻå¿fã«â€•. Okayama Igakkai Zasshi, 2007, 119,	1d. <b>@</b> -125.	0
1389	Molecular Genetic Study of Schizophrenia Based on Neurodevelopmental Hypothesis. Medical Psychiatry, 2007, , 101-116.	0.2	0
1390	Gene-Mapping Studies for Schizophrenia: How Useful Are They for the Clinician. Medical Psychiatry, 2007, , 35-54.	0.2	1
1391	Genetics of Bipolar Disorder. Medical Psychiatry, 2007, , 233-250.	0.2	0
1393	Genetic Association Studies: Concepts and Applications. , 2007, , 65-94.		0
1394	DNA Biomarkers for Pharmacogenomics and Personalized Medicine. , 2008, , 445-471.		0
1395	Biomarkers in Schizophrenia. , 2008, , 23-55.		1
1396	Bibliographie finale. Neurosciences & Cognition Série LMD, 2008, , 315-374.	0.0	0
1397	Bipolar Disorder in the Era of Genomic Psychiatry. , 2009, , 1299-1311.		0
1398	Molecular Genetics of Schizophrenia: Focus on Symptom Dimensions. , 2009, , 95-124.		4
1399	Genetic and epigenetic factors in schizophrenia. Medical Psychiatry, 2009, , 78-86.	0.2	0

	CHATION K	LPUKI	
#	Article	IF	CITATIONS
1400	Mutant and Transgenic Tools in Modeling Schizophrenia. Neuromethods, 2010, , 217-239.	0.2	0
1401	Gemeinsame Risikogene von affektiven und schizophrenen Erkrankungen. , 2010, , 93-103.		0
1402	Inhibition of Glycine Transporter-1 Improves the Functional Outcome of Schizophrenia. , 2010, , 577-610.		1
1403	Childhood Neuropsychiatric Risk. Issues in Clinical Child Psychology, 2010, , 369-405.	0.2	0
1404	Genetics in schizophrenia: where are we and what next?. Dialogues in Clinical Neuroscience, 2010, 12, 289-303.	1.8	44
1405	Genetic Studies of Schizophrenia. Advances in Neurobiology, 2011, , 333-380.	1.3	Ο
1406	Functional MRI Studies of Memory in Aging, Mild Cognitive Impairment, and Alzheimer's Disease. , 2011, , 419-453.		0
1407	Schizophrenia Has a High Heritability, but Where Are the Genes?. , 2011, , 219-236.		Ο
1409	Bases genéticas de la esquizofrenia: "Nurture vrs Nature― Actualidades En Psicologia: AP, 2011, 19, 131-138.	0.5	1
1411	A Class Representative Model for Pure Parsimony Haplotyping under Uncertain Data. PLoS ONE, 2011, 6, e17937.	1.1	1
1412	Schizophrene Störungen. , 2012, , 297-313.		0
1413	Cannabinoids, Monoamines, COMT and Schizophrenia: Pathobiological Mechanisms in Psychosis. , 2013, , 297-323.		0
1415	Schizophrenia and Bipolar Disorder. , 2014, , 153-183.		4
1416	Functional MRI Studies of Memory in Aging, Mild Cognitive Impairment, and Alzheimer's Disease. , 2015, , 179-225.		0
1417	Schizophrenia: implications of vitamin D deficit on brain development. International Journal of Clinical Neurosciences and Mental Health, 2014, , 16.	0.7	0
1418	Pursuit of the "truth" about mental illness: the significance of findings in neuropsychiatric research, and lessons from the past. Dialogues in Clinical Neuroscience, 2014, 16, 447-450.	1.8	1
1419	Verhaltens- und Neurogenetik. , 2015, , 667-735.		0
1420	CHAPTER 8. GSK3 Networks in Schizophrenia. RSC Drug Discovery Series, 2015, , 173-201.	0.2	0

#	Article	IF	CITATIONS
1421	CHAPTER 5. Modelling Schizophrenia: Strategies for Identifying Improved Platforms for Drug Discovery. RSC Drug Discovery Series, 2015, , 89-114.	0.2	0
1422	Animal Models of Schizophrenia with a Focus on Models Targeting NMDA Receptors. Cognitive Remediation Journal, 2015, 4, 3-18.	0.0	2
1423	The Link Between Psychosis and Creativity: A Myth or a Reality?. Psychology Research (Libertyville, III ), 2015, 05, .	0.0	0
1424	Synaptic Abnormalities and Neuroplasticity. Handbook of Behavioral Neuroscience, 2016, , 375-390.	0.7	0
1427	Neuregulin-1 Gene and Schizophrenia, and its Negative Symptoms in an Iranian Population. Iranian Journal of Psychiatry and Behavioral Sciences, 2016, 11, .	0.1	1
1428	Human Puberty: Physiology, Progression, and Genetic Regulation ofÂVariation in Onset. , 2017, , 357-371.		0
1429	Are There Schizophrenia Genetic Markers and Mutations? A Systematic Review and Meta-Analyses. Health, 2017, 09, 811-838.	0.1	0
1430	Glutamate as a Neural Stress Factor in Humans and Animals. Journal of Behavioral and Brain Science, 2019, 09, 13-25.	0.2	0
1431	Contributing Factors of Neurodegeneration in Alzheimer's Disease. , 0, , 69-84.		0
1434	Doctors' health & performance. , 2020, , 860-879.		0
1436	Ear, nose, and throat. , 2020, , 384-431.		0
1437	Verhaltens- und Neurogenetik. , 2020, , 813-895.		0
1439	Schizophrenie, Entzündung und glutamaterge Neurotransmission: ein pathophysiologisches Modell. , 2006, , 93-123.		0
1442	Postmortem investigations of the pathophysiology of schizophrenia: the role of susceptibility genes. Journal of Psychiatry and Neuroscience, 2004, 29, 287-93.	1.4	14
1443	Genetics of developmental psychiatric disorders: pathways to discovery. Journal of Psychiatry and Neuroscience, 2005, 30, 349-54.	1.4	4
1444	Schizophrenia: neural mechanisms for novel therapies. Molecular Medicine, 2003, 9, 3-9.	1.9	25
1445	Schizophrenia: an integrative approach to modelling a complex disorder. Journal of Psychiatry and Neuroscience, 2006, 31, 157-67.	1.4	22
1446	Bipolar disorder and schizophrenia: not so distant relatives?. World Psychiatry, 2003, 2, 68-72.	4.8	35

#	Article	IF	CITATIONS
1447	Rethinking psychosis: the disadvantages of a dichotomous classification now outweigh the advantages. World Psychiatry, 2007, 6, 84-91.	4.8	117
1449	Whole genome association studies of neuropsychiatric disease: An emerging era of collaborative genetic discovery. Neuropsychiatric Disease and Treatment, 2007, 3, 613-8.	1.0	2
1450	Neuregulin 1 genetic variation and anterior cingulum integrity in patients with schizophrenia and healthy controls. Journal of Psychiatry and Neuroscience, 2009, 34, 181-6.	1.4	37
1451	Beyond reliability: biomarkers and validity in psychiatry. Psychiatry, 2008, 5, 48-52.	0.3	5
1452	A Study of the Association between SNP8NRG241930 in the 5' End of Neuroglin 1 Gene with Schizophrenia in a Group of Iranian Patients. Cell Journal, 2011, 13, 91-6.	0.2	5
1454	Rare Pathogenic Variants in Genes Implicated in Glutamatergic Neurotransmission Pathway Segregate with Schizophrenia in Pakistani Families. Genes, 2021, 12, 1899.	1.0	2
1455	Cre-Activation in ErbB4-Positive Neurons of Floxed Grin1/NMDA Receptor Mice Is Not Associated With Major Behavioral Impairment. Frontiers in Psychiatry, 2021, 12, 750106.	1.3	2
1456	Biological Mechanism-based Neurology and Psychiatry: a BACE1/2 and Downstream Pathway Model. Current Neuropharmacology, 2021, 19, .	1.4	1
1458	Pre-hospital emergency medicine. , 2020, , 624-655.		0
1459	General practice. , 2020, , 774-841.		0
1463	Eponymous syndromes. , 2020, , 842-859.		0
1465	Orthopaedics. , 2020, , 462-519.		1
1469	Gynaecology. , 2020, , 104-177.		0
1470	New Insight into the human genetic diversity in North African populations by genotyping of <scp>SNPs</scp> in <scp><i>DRD3</i></scp> , <scp><i>CSMD1</i></scp> and <scp><i>NRG1</i></scp> genes. Molecular Genetics & Genomic Medicine, 2022, 10, e1871.	0.6	2
1471	Genetic predisposition of BDNF (rs6265) gene is susceptible to Schizophrenia: A prospective study and updated meta-analysis. NeurologÃa, 2022, , .	0.3	0
1472	Epistatic interactions of NRG1 and ERBB4 on antipsychotic treatment response in first-episode schizophrenia patients. Schizophrenia Research, 2022, 241, 197-200.	1.1	2
1473	Genetic animal models for psychiatric disorders. , 2022, , 241-267.		0
1474	The molecular genetic basis of creativity: a mini review and perspectives. Psychological Research, 2023, 87, 1-16.	1.0	1

	СПАНО	N REPORT	
#	Article	IF	CITATIONS
1475	Adult neural stem cells and schizophrenia. World Journal of Stem Cells, 2022, 14, 219-230.	1.3	4
1476	Prospects for Neurotrophic Factor-Based Early Intervention in Schizophrenia: Lessons Learned from the Effects of Antipsychotic Drugs on Cognition, Neurogenesis, and Neurotrophic Factors. CNS and Neurological Disorders - Drug Targets, 2022, 21, .	0.8	0
1477	Differential expression of miR-148b, miR-129-2 and miR-296 in animal models of schizophrenia-Relevance to NMDA receptor hypofunction. Neuropharmacology, 2022, 210, 109024.	2.0	14
1478	Caracterización de cultivos neuronales de hipocampo murino como modelo de estudio de la señalización NRGs/ErbB4. TecnologÃa En Marcha, 0, , .	0.1	0
1479	Early Detection and Prevention of Schizophrenic Psychosis—A Review. Brain Sciences, 2022, 12, 11.	1.1	7
1480	Plasticity-Related Gene 5 Is Expressed in a Late Phase of Neurodifferentiation After Neuronal Cell-Fate Determination. Frontiers in Cellular Neuroscience, 2022, 16, 797588.	1.8	2
1481	CHAPTER 13. Mechanism of Action of a GluN2C- and GluN2D-Selective NMDA Receptor Positive Allosteric Modulator. , 0, , 281-309.		0
1482	Neuregulin-erbB Signaling and the Pathogenesis of Schizophrenia. , 0, , 73-96.		0
1483	Alterations in Hippocampal Function in Schizophrenia: its Genetic Associations and Systems Implications. , 2008, , 157-190.		0
1489	Experimental Research. , 0, , 449-489.		0
1490	Developmental, neurochemical, and behavioral analyses of ErbB4 Cyt″ knockout mice. Journal of Neurochemistry, 2022, , .	2.1	3
1491	Plasma neuregulin 1 as a synaptic biomarker in Alzheimer's disease: a discovery cohort study. Alzheimer's Research and Therapy, 2022, 14, .	3.0	12
1492	Advantages and Limitations of Animal Schizophrenia Models. International Journal of Molecular Sciences, 2022, 23, 5968.	1.8	32
1493	Modelling the neurodevelopmental pathogenesis in neuropsychiatric disorders. Bioactive kynurenines and their analogues as neuroprotective agents—in celebration of 80th birthday of Professor Peter Riederer. Journal of Neural Transmission, 2022, 129, 627-642.	1.4	45
1494	Repeated Winning and Losing Experiences in Chronic Social Conflicts Are Linked to RNA Editing Pattern Difference. Frontiers in Psychiatry, 2022, 13, .	1.3	2
1498	The Long Non-Coding RNA GOMAFU in Schizophrenia: Function, Disease Risk, and Beyond. Cells, 2022, 11, 1949.	1.8	9
1499	Elevated peripheral Neuregulin-1 protein levels in non-medicated focal epilepsy patients. Journal of Clinical Neuroscience, 2022, 102, 1-4.	0.8	0
1501	FAM69C, a kinase critical for synaptic function and memory, is defective in neurodegenerative dementia. Cell Reports, 2022, 40, 111101.	2.9	3

#	Article	IF	CITATIONS
1502	Investigating the Role of GABA in Neural Development and Disease Using Mice Lacking GAD67 or VGAT Genes. International Journal of Molecular Sciences, 2022, 23, 7965.	1.8	12
1503	Role of the NRG1/ErbB4 and PI3K/AKT/mTOR signaling pathways in the anti-psychotic effects of aripiprazole and sertindole in ketamine-induced schizophrenia-like behaviors in rats. Inflammopharmacology, 2022, 30, 1891-1907.	1.9	10
1506	What Can We Learn from Animal Models to Study Schizophrenia?. Advances in Experimental Medicine and Biology, 2022, , 15-33.	0.8	0
1507	Genetic Influences on Cognitive Dysfunction in Schizophrenia. Current Topics in Behavioral Neurosciences, 2022, , 291-314.	0.8	1
1508	A Novel Gene Controls a New Structure: PiggyBac Transposable Element-Derived 1, Unique to Mammals, Controls Mammal-Specific Neuronal Paraspeckles. Molecular Biology and Evolution, 2022, 39, .	3.5	3
1509	ErbB4 in the brain: Focus on high grade glioma. Frontiers in Oncology, 0, 12, .	1.3	4
1510	Toxic and Phenotypic Effects of AAV_Cre Used to Transduce Mesencephalic Dopaminergic Neurons. International Journal of Molecular Sciences, 2022, 23, 9462.	1.8	7
1511	Effects of psychosis-associated genetic markers on brain volumetry: a systematic review of replicated findings and an independent validation. Psychological Medicine, 0, , 1-16.	2.7	1
1512	The effects of preventative cannabidiol in a male neuregulin 1 mouse model of schizophrenia. Frontiers in Cellular Neuroscience, 0, 16, .	1.8	1
1518	Alterations in prefrontal cortical neuregulin-1 levels in post-pubertal rats with neonatal ventral hippocampal lesions. Frontiers in Behavioral Neuroscience, 0, 16, .	1.0	1
1519	SELENBP1 overexpression in the prefrontal cortex underlies negative symptoms of schizophrenia. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	1
1520	A Missense Variant in CASKIN1's Proline-Rich Region Segregates with Psychosis in a Three-Generation Family. Genes, 2023, 14, 177.	1.0	3
1521	Schizophrenia Animal Modeling with Epidermal Growth Factor and Its Homologs: Their Connections to the Inflammatory Pathway and the Dopamine System. Biomolecules, 2023, 13, 372.	1.8	4
1522	Distinctive effects of NMDA receptor modulators on cerebral microcirculation in a schizophrenia mouse model. Biochemical and Biophysical Research Communications, 2023, 653, 62-68.	1.0	0
1523	Correlation of rs35753505 polymorphism in Neuregulin 1 gene with psychopathology and intelligence of people with schizophrenia. Gene, 2023, 867, 147285.	1.0	0
1526	Neuregulin-1/PI3K signaling effects on oligodendrocyte proliferation, remyelination and behaviors deficit in a male mouse model of ischemic stroke. Experimental Neurology, 2023, 362, 114323.	2.0	2
1535	LIM Kinases, LIMK1 and LIMK2, Are Crucial Node Actors of the Cell Fate: Molecular to Pathological Features. Cells, 2023, 12, 805.	1.8	3
1537	Rats, Neuregulins and Radical Prostatectomy: A Conceptual Overview. Journal of Clinical Medicine, 2023, 12, 2208.	1.0	2

		HATION REPORT	
#	Article	IF	CITATIONS
1538	GluN2D subunit in parvalbumin interneurons regulates prefrontal cortex feed-forward inhibitory circuit and molecular networks relevant to schizophrenia. Biological Psychiatry, 2023, , .	0.7	4
1546	Schizophrenia in the genetic era: a review from development history, clinical features and genomic research approaches toÂinsights of susceptibility genes. Metabolic Brain Disease, 0, , .	1.4	0
1547	Development and Developmental Disorders of the Cerebral Cortex. , 2023, , 725-891.		0